Synthetic Polypeptide Libraries and Methods for Generating Naturally Diversified Polypeptide Variants

ABSTRACT

The invention provides compositions and methods for generating libraries of DNA sequences encoding homologous polypeptides, and uses of the libraries to identify naturally diversified polypeptide variants. The invention also provides compositions and methods for generating collections of synthetic antibody fragments in which one or several complementary determining regions (CDR) are replaced by a collection of the corresponding CDR captured from a natural source. The invention further provides compositions and methods for diversifying a portion of a polypeptide by inserting a diversified sequence of synthetic or natural origin without the need for modification of the original polypeptide coding sequence.

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application Nos.61/179,850, filed May 20, 2009, 61/287,336, filed Dec. 17, 2009 and61/314,794, filed Mar. 17, 2010, the contents of each of which arehereby incorporated by reference in their entirety.

INCORPORATION BY REFERENCE OF SEQUENCE LISTING

The contents of the text file named “418USSeqList.txt,” which wascreated on May 20, 2010 and is 141 KB in size, are hereby incorporatedby reference in their entirety.

FIELD OF THE INVENTION

The invention relates to the generation of libraries of DNA sequencesencoding homologous polypeptides and to the use of such libraries. Thisinvention in particular relates to the generation of collections ofsynthetic antibody fragments in which one or several complementarydetermining regions (CDR) are replaced by a collection of thecorresponding CDR captured from a natural source. The invention furtherrelates to the generation of collections of antibody fragmentscontaining CDR derived from an immunized animal and their use as abetter source to derive high affinity antibody fragments. The inventionfurther relates to the diversification of a portion of a polypeptide byinserting a diversified sequence of synthetic or natural origin withoutthe need for modification of the original polypeptide coding sequence.

BACKGROUND OF THE INVENTION

An antibody is composed of four polypeptides: two heavy chains and twolight chains. The antigen binding portion of an antibody is formed bythe light chain variable domain (VL) and the heavy chain variable domain(VH). At one extremity of these domains six loops form the antigenbinding site and also referred to as the complementarity determiningregions (CDR). Three CDRs are located on the VH domain (H1, H2 and H3)and the three others are on the VL domain (L1, L2 and L3). During B celldevelopment a unique immunoglobulin region is formed by somaticrecombination known as V(D)J recombination. The variable region of theimmunoglobulin heavy or light chain is encoded by different genesegments. The heavy chain is encoded by three segments called variable(V), diversity (D) and joining (J) segments whereas the light chainvariable is formed by the recombination of only two segments V and J. Alarge number of antibody paratopes can be generated by recombinationbetween one of the multiple copies of the V, D and J segments that arepresent in the genome. The V segment encodes the CDR1 and CDR2 whereasthe CDR3 is generated by the recombination events. During the course ofthe immune response further diversity is introduced into the antigenbinding site by a process called somatic hypermutation (SHM). Duringthis process point mutations are introduced in the variable genes of theheavy and light chains and in particular into the regions encoding theCDRs. This additional variability allows for the selection and expansionof B cells expressing antibody variants with improved affinity for theircognate antigen.

In recent years several display technologies have emerged and allow forthe screening of large collections of proteins or peptides. Theseinclude phage display, bacterial display, yeast display and ribosomedisplay (Smith G P. Science. 1985 Jun. 14; 228(4705):1315-7; Hanes J andPlückthun A. Proc Natl Acad Sci USA. 1997 May 13; 94(10):4937-42;Daugherty P S et al., Protein Eng. 1998 September; 11(9):825-32; Boder ET and Wittrup K D. Nat. Biotechnol. 1997 June; 15(6):553-7). Inparticular these methods have been applied extensively to antibodies andfragments thereof. A number of methods have been described to generatelibraries of polypeptides and to screen for members with desired bindingproperties.

A first approach is to capture by gene amplification rearrangedimmunoglobulin genes from natural repertoires using either tissues orcells from humans or other mammals as a source of genetic diversity.These collections of rearranged heavy and light chains (VH and VL) arethen combined to generate libraries of binding pairs that can bedisplayed on bacteriophage or on other display packages such asbacteria, yeast or mammalian cells. In this case a large fraction of theimmunoglobulin repertoire found in the donor is captured. Thus all ofthe frameworks encoded by the donor germline genes can be found in suchrepertoires as well as diversity generated both by V(D)J recombinationand by somatic hypermutation (Marks J D et al., J Mol. Biol. 1991 Dec.5; 222(3):581-97; McCaffety U.S. Pat. No. 5,969,108).

A limitation of natural repertoires is that naturally occurringantibodies can be based on frameworks with low intrinsic stability thatlimit their expression levels, shelf life and their usefulness asreagents or therapeutic molecules. In order to overcome theselimitations a number of methods have been developed to generatesynthetic antibody libraries. In these approaches, a unique or a limitednumber of selected antibody framework encoded by their correspondinggermline genes are selected. The selection of these frameworks iscommonly based on their biochemical stability and/or their frequency ofexpression in natural antibody repertoires. In order to generate acollection of binding proteins, synthetic diversity is then introducedin all or a subset of CDRs. Typically either the whole or part of theCDR is diversified using different strategies. In some cases diversitywas introduced at selected positions within the CDRs (Knappik A et al.,J Mol. Biol. 2000 Feb. 11; 296(1):57-86). Targeted residues can be thosefrequently involved in antigen contact, those displaying maximaldiversity in natural antibody repertoires or even residues that would bepreferentially targeted by the cellular machinery involved in generatingsomatic hypermutations during the natural affinity maturation process(Balint R F, Larrick J W. Gene. 1993 Dec. 27; 137(1):109-18.).

Several methods have been used to diversify the antibody CDRs.Overlapping PCR using degenerate oligonucleotides have been extensivelyused to assemble framework and CDR elements to reconstitute antibodygenes. In another approach, unique restriction enzyme sites have beenengineered into the framework regions at the boundary of each CDRallowing for the introduction of diversified CDRs by restriction enzymemediated cloning. In any case, as all the members of the library arebased on frameworks with selected and preferred characteristics, it isanticipated that the antibodies derived from these repertoires are morestable and provide a better source of useful reagents. (Knappik, U.S.Pat. No. 6,696,248; Sidhu S S, et al., Methods Enzymol. 2000;328:333-63; Lee C V et al., J Mol. Biol. 2004 Jul. 23; 340(5):1073-93).

However, an important limitation of these synthetic libraries is that asignificant proportion of the library members are not expressed becausethe randomly diversified sequences do not allow for proper expressionand/or folding of the protein. This problem is particularly significantfor the CDR3 of the heavy chain. Indeed, this CDR often contributes tomost of the binding energy to the antigen and is highly diverse inlength and sequence. While the other CDR (H1, H2, L1, L2 and L3) canonly adopt a limited number of three dimensional conformations, known ascanonical folds, the number of conformations that can be adopted by theheavy chain CDR3 remains too diverse to be predicted (Al-Lazikani B etal., J Mol. Biol. 1997 Nov. 7; 273(4):927-48). In addition, the use oflong degenerate oligonucleotides used to cover long CDR H3 oftenintroduces single base-pair deletions. These factors significantlyreduce the functional size of synthetic repertoires.

Both natural and synthetic repertoires have advantages and limitations.On one hand, strategies relying on the capture of naturally rearrangedantibody variable genes are not optimal as they include potentially lessfavorable frameworks within the library. A positive aspect is that theserearranged variable genes include CDRs which are compatible with properdomain folding as they have been expressed in context of a naturalantibody. On the other hand, strategies based on selecting frameworksand inserting synthetic diversity benefit from the improved stability ofthe frameworks but are limited by the large number of CDR sequences thatare not compatible with folding and/or expression and can destabilizethe overall domain (FIG. 1A). There is therefore a need for novelapproaches that could combine the benefits of using selected frameworkswith desirable characteristics and combine them with properly foldedCDRs for instance derived from natural repertoires.

All described approaches to generate antibody libraries either bycapturing naturally rearranged antibody sequences or by generatingdiversity by synthetic means are limited by the occurrence of frameshift mutations leading to non-functional antibody sequences. Thesemutations can appear at multiple steps of the molecular handling of theDNA encoding the antibodies such as PCR amplification and DNA fragmentassembly as well as molecular cloning. The frequency of non-functionalmembers in antibody libraries typically ranges from 15% to 45% dependingof the strategies employed to capture or generate the antibody diversity(Persson M A et al., Proc Natl Acad Sci USA. 1991 Mar. 15; 88(6):2432-6;Schoonbroodt S, et al., Nucleic Acids Res. 2005 May 19; 33(9):e81;Söderling E et al., Nat Biotechnol. 2000 August; 18(8):852-6; Rothe etal., J Mol Biol. 2008 Feb. 29; 376(4):1182-200). The frequency ofsequences encoding non functional antibodies has a major impact on theantibody identification process. First, the functional size of thelibrary is reduced and, because non-functional clones often have agrowth advantage during the propagation of the libraries, they expandfaster and can compromise the identification process of antibodycandidates (De Bruin R et al., Nat Biotechnol 1999 Apr. 17: 397-399).These issues are recognized as serious limitations for fully exploitingthe potential of antibody libraries. The generation of highly functionallibraries remains a challenge in the field and has prompted many effortsto improve the process. For instance, multiple diversificationstrategies aiming at mimicking the amino acids usage found in naturalCDR sequences have been used in order to more effectively sample thehuge diversity of possible sequence combination encoded by syntheticCDRs (de Kruif J et al., J Mol Biol. 1995 Apr. 21; 248(1):97-105; SidhuS S et al., J Mol Biol. 2004 Apr. 23; 338(2):299-310). Another approachis to clean up the initial library in order to remove nonfunctionalclones at the potential expense of diversity loss. This has been appliedto the pre-selection of synthetic repertoires by binding the antibodylibrary to a generic ligand. This step allowed for the enrichment oflibrary members that are able to express and to fold properly and can beused to recreate a more functional library (Winter and Tomlinson, U.S.Pat. No. 6,696,245 B2). Regardless of the approach the quality of anylibrary is dependent on the efficiency of the molecular biology methodsapplied to generate the library and generally lead to 15% to 45%non-functional members of the library. There is therefore a need fornovel and highly efficient approaches that minimize the frequency onnon-functional genes due to frame shifts introduced during the molecularcloning steps and that maximize the functionality of libraries bycapturing CDR regions having a high propensity of being correctly foldedinto antibody frameworks with desirable properties. Furthermore, thereis a need for approaches that allow the capture of the CDR sequencesfrom an animal immune repertoire into a therapeutically useful contextsuch as human antibody frameworks in order to improve the generationprocess of high affinity antibodies.

SUMMARY OF THE INVENTION

The present invention provides methods of generating libraries ofnucleic acid sequences that combine the benefits of stable frameworkselection and the insertion of naturally encoded complementaritydetermining regions (CDRs) or amino acid sequences that can fulfill therole of a CDR that have been selected in a natural context of afunctional polypeptide such as an antibody. The method allows for therecovery of long CDRs or amino acid sequences that can fulfill the roleof a CDR that are very difficult to encode using synthetic approaches.This invention, by combining stable frameworks and properly folded CDRsor amino acid sequences that can fulfill the role of a CDR, maximizesthe proportion of functional antibodies in the library and therefore theperformance of the selection process and the quality of selected clones.The invention provides a method to capture naturally expressed CDRs fromdifferent species and to insert them into a human antibody framework.This allows for the use of CDR H3 repertoires that differ significantlyin length and composition when compared to the human repertoire. Theinvention enables the generation of human antibody fragments featuringstructural repertoires derived from other species and thus the capacityto sample different structural spaces. The present methods are also usedto introduce CDRs of synthetic origin or amino acid sequences that canfulfill the role of a CDR with a higher success frequency thanalternative methods introducing fewer errors causing frame shifts in thecoding sequence. Libraries generated using the present methods contain ahigh frequency of functional variants. Libraries of variants generatedaccording to this method are used for selection and screening with anydescribed display, selection and screening technology.

The analysis of immune repertoires from different species or, within aspecies, at different development stages has revealed some strikingdifferences in the characteristics of CDR H3 composition and length. Forinstance the average CDRH3 length in humans is longer in adult whencompared to fetal life or to newborns (Schroeder Jr, H W et al., 2001Blood 98; 2745-2751). Interestingly despite large similarities betweenhuman and primate antibody germline genes, the evolution of the CDRH3length during development differs (Link J M et al., Molecular Immunol.2005 42; 943-955). The comparison of CDR H3 sequences found in mice andhumans clearly shows that the average length is significantly shorter inmice (Rock E P et al., J Exp Med 1994 179; 323-328). During early B celldevelopment in the bone marrow, the average CDR H3 length increases inmice whereas it tends to decrease in humans and in addition the aminoacid composition of the murine and human CDRH3 repertoires differ(Zemlin M et al., 2003 J Mol Biol 334; 733-749; Ivanov I et al., 2005 JImmunol 174; 7773-7780). These examples indicate that different speciesexpress different ranges of CDR H3 repertoires despite the fact thatthey are globally exposed to similar classes of antigens and thebiological significance of these observations remain to be furtherstudied. It has been demonstrated that the shape of the combining siteof antibodies directed against small antigens such as haptens orpeptides differ from those directed against large proteins and the shapeof the combining site is dictated by the length and composition of theCDRs (Collis A et al., J Mol Biol 2003 325; 337-354). From these findingit can be anticipated that the CDR H3 repertoire expressed by differentspecies have varying propensities to react efficiently against differenttarget classes.

The methods and antibody libraries provided herein are designed toexploit the various repertoires expressed by different species for thegeneration of therapeutic antibodies. These repertoires that exploredifferent tridimensional spaces might allow for the generation ofantibodies against a wider variety of target classes and epitopes.Methods to generate libraries form naïve or immunized animals are welldescribed and these methods allow for the capturing of the correspondingrepertoires and the generation of antibodies. However, antibodiesderived from these libraries are not of human origin and are thereforenot well suited for human therapy without performing further engineeringwork such as humanization. There is therefore a need for novel methodsto harness the diversity expressed in the repertoire from differentspecies and to exploit this diversity in the therapeutically usefulcontext of a human antibody.

The methods and antibody libraries provided herein address several ofthe limitations described above and are an improvement over the currentart. First, the methods provided herein combine the benefits of stableframework selection and the insertion of naturally encoded CDRs thathave been selected in a natural context of a functional antibody.Second, the methods allow for a highly efficient insertion of syntheticor natural CDRs sequences into an antibody framework that significantlyminimizes the number of frame shifts in the library and thereforeimproves its quality. Finally, the invention allows for a novel way touse naturally occurring antibody structural diversity by capturingnaturally expressed CDR H3 repertoires from different species and toinsert them into human antibody frameworks. It is thus possible toexploit these structurally diverse repertoires in a productive way forthe generation of antibodies for human therapy.

The methods provided herein generate antibodies that contain a stableframework and correctly folded CDRs or amino acid sequences that canfulfill the role of a CDR. The methods capture the natural diversity ofsequences in stable frameworks.

In the methods provided herein, the germline sequences for frameworkregions 1, 2 and 3 (FR1, FR2 and FR3) are selected from the desiredorganism, for example, from the human genome (see e.g., FIGS. 2 and 6).In one embodiment of this method, selected antibody variable domains aremodified by introducing a stuffer sequence that will serve as anintegration site for diversified sequences. Diversity is introduced intothe sequence outside of the immunoglobulin coding region by introducingrestriction enzyme recognition sites, for example, Type IIs restrictionsites, at a desired location such as the variable heavy chaincomplementarity determining region 3 (CDR H3), the variable light chaincomplementarity determining region 3 (CDR L3), the variable heavy chaincomplementarity determining region 1 (CDR H1), the variable light chaincomplementarity determining region 1 (CDR L1), the variable heavy chaincomplementarity determining region 2 (CDR H2) or the variable lightchain complementarity determining region 2 (CDR L2). While the examplesprovided herein demonstrate diversity at the CDR3 region (in thevariable heavy chain region and/or variable light chain region), it isunderstood that diversity can be achieved at any desired location, suchas, but not limited to, the CDR1 region (in the variable heavy chainregion and/or variable light chain region) or the CDR2 region (in thevariable heavy chain region and/or variable light chain region).Diversified DNA sequences are generated with flanking sequences thatinclude Type IIs restriction sites. In the methods provided herein, thecohesive ends generated by the restriction enzymes are compatible andthe reading frame is maintained, thus allowing the diversified DNAfragments to be ligated into an acceptor framework.

The methods provided herein are also useful for generating amino acidsequences having diversified regions encoded therein. For example, inthe methods provided herein, the sequences for the non-diversifiedportions of the encoded amino acid are selected from the desiredorganism, for example, from the human sequence. A portion of the encodedamino acid sequence is modified by introducing a stuffer sequence thatwill serve as an integration site for diversified sequences. Diversityis introduced into the sequence at the desired location(s) byintroducing restriction enzyme recognition sites, for example, Type IIsrestriction sites, at a desired location within the encoded amino acidsequence. Diversified DNA sequences are generated with flankingsequences that include Type IIs recognition sites. In the methodsprovided herein, the cohesive ends generated by the restriction enzymesare compatible and the reading frame is maintained, thus allowing thediversified DNA fragments to be ligated into an acceptor framework.

In the methods provided herein, an “Acceptor Framework” is generatedusing a “stuffer fragment” of DNA that contain and are, preferably,bordered by two Type IIs restriction enzyme sites. (See e.g., FIG. 6).Preferably, these two Type IIs restriction enzyme sites digest sequencesat the boundary of the site at which diversity is desired, such as, forexample, the CDR H3 region, the CDR L3 region, the CDR H1 region, theCDR L1 region, the CDR H2 region or the CDR L2 region. As used herein,the term “Acceptor Framework” refers to a nucleic acid sequence thatinclude the nucleic acid sequences encoding the FR1, FR2, FR3 and FR4regions, the nucleic acid sequences encoding two CDRs or amino acidsequences that can fulfill the role of these CDRs, and a “stufferfragment” that serves as the site of integration for diversified nucleicacid sequence. For example, in embodiments where diversity at the CDR3region (in the variable heavy chain region and/or the variable lightchain region) is desired, the Acceptor Framework includes the nucleicacid sequences encoding the FR1, FR2, FR3 and FR4 regions, the nucleicacid sequences encoding the CDR1 and CDR2 regions, and a “stufferfragment” that serves as the site of integration for diversified nucleicacid sequence. For example, in embodiments where diversity at the CDR2region (in the variable heavy chain region and/or the variable lightchain region) is desired, the Acceptor Framework includes the nucleicacid sequences encoding the FR1, FR2, FR3 and FR4 regions, the nucleicacid sequences encoding the CDR1 and CDR3 regions, and a “stufferfragment” that serves as the site of integration for diversified nucleicacid sequence. For example, in embodiments where diversity at the CDR1region (in the variable heavy chain regions and/or the variable lightchain regions) is desired, the Acceptor Framework includes the nucleicacid sequences encoding the FR1, FR2, FR3 and FR4 regions, the nucleicacid sequences encoding the CDR2 and CDR3 regions, and a “stufferfragment” that serves as the site of integration for diversified nucleicacid sequence.

The terms “stuffer fragment”, “stuffer DNA fragment” and “stuffersequence” or any grammatical variation thereof are used interchangeablyherein to refer to a nucleic acid sequence that includes at least twoType IIs recognition sites and a diversified sequence. The AcceptorFramework can be a variable heavy chain (VH) Acceptor Framework or avariable light chain (VL) Acceptor Framework. The use of the AcceptorFrameworks and the stuffer fragments contained therein allow for theintegration of a CDR sequence (natural or synthetic) or an amino acidsequence that can fulfill the role of the CDR into the acceptorframework with no donor framework nucleotides or residues containedtherein or needed for integration. For example, the use of the AcceptorFrameworks and the stuffer fragments contained therein allow for theintegration of a CDR sequence (natural or synthetic) selected from CDRH3, CDR L3, CDR H2, CDR L2, CDR H1 and CDR L1, or an amino acid sequencethat can fulfill the role of a CDR selected from CDR H3, CDR L3, CDR H2,CDR L2, CDR H1 and CDR L1 into the acceptor framework with no donorframework nucleotides or residues contained therein or needed forintegration. Thus, upon integration, the stuffer fragment is removed infull, and the coding region of the acceptor protein and the insertedproteins fragments (i.e., the CDRs) are intact.

The methods provided herein use primers that are designed to containcleavage sites for Type IIs restriction enzymes at the boundary of thesite of at which diversity is desired, for example, the CDR H3 region,the CDR L3 region, the CDR H2 region, the CDR L2, the CDR H1 region orthe CDR L1 region. Random, naturally occurring CDR clones (see e.g.,FIG. 10) or synthetic CDR sequences (see e.g., Example 6) or amino acidsequences that can fulfill the role of the CDR are captured in theAcceptor Frameworks used herein. For example, in embodiments wherediversity at the CDR3 region (in the variable heavy chain region and/orthe variable light chain region) is desired, random, naturally occurringCDR3 clones (see e.g., FIG. 10) or synthetic CDR3 sequences (see e.g.,Example 6) or amino acid sequences that can fulfill the role of a CDR3are captured in the Acceptor Frameworks used herein. For example, inembodiments where diversity at the CDR2 region (in the variable heavychain region and/or the variable light chain region) is desired, random,naturally occurring CDR2 clones (see e.g., methods shown in FIG. 10) orsynthetic CDR2 sequences (see e.g., methods shown in Example 6) or aminoacid sequences that can fulfill the role of a CDR2 are captured in theAcceptor Frameworks used herein. For example, in embodiments wherediversity at the CDR1 region (in the variable heavy chain region and/orthe variable light chain region) is desired, random, naturally occurringCDR1 clones (see e.g., methods shown in FIG. 10) or synthetic CDR1sequences (see e.g., methods shown in Example 6) or amino acid sequencesthat can fulfill the role of a CDR1 are captured in the AcceptorFrameworks used herein. As an example, oligonucleotides primers specificfor flanking regions of the DNA sequence encoding the CDR H3 ofimmunoglobulins, i.e., specific for the FR3 and FR4 of the variableregion, were designed. Oligonucleotide primers specific for flankingregions of the DNA sequences encoding other regions, such as, forexample, the CDR L3, CDR H1, CDR L1, CDR H2, or CDR L2, can also bedesigned. These oligonucleotides contain at their 5′ end a site for aType IIs restriction enzyme whereas their 3′ portion matches thetargeted DNA sequence.

In some embodiments, the primer is a nucleic acid selected from thegroup consisting of SEQ ID NOs: 120-254.

The methods provided herein use Type IIs restriction enzymes, such as,for example, FokI, to insert natural CDR sequences, such as, forexample, natural CDR H3, CDR L3, CDR H1, CDR L1, CDR H2, or CDR L2sequences into the acceptor frameworks described herein. The methodsprovided herein use Type IIs restriction enzymes, such as, for example,FokI, to insert synthetic CDR sequences, such as, for example, syntheticCDR H3, CDR L3, CDR H1, CDR L1, CDR H2, or CDR L2 sequences into theacceptor frameworks described herein. The methods provided herein useType IIs restriction enzymes, such as, for example, FokI, to insertamino acid sequences that can fulfill the role of a desired CDR region,such as, for example, an amino acid sequence that can fulfill the roleof a natural or synthetic CDR H3, CDR L3, CDR H1, CDR L1, CDR H2, or CDRL2 region into the acceptor frameworks described herein. The Type IIsrestriction enzymes are enzymes that cleave outside of their recognitionsequence to one side. These enzymes are intermediate in size, typically400-650 amino acids in length, and they recognize sequences that arecontinuous and asymmetric. Suitable Type IIs restriction enzymes, alsoknown as Type IIs restriction endonucleases, and the sequences theyidentify are described, for example, in Szybalski et al., “Class-IISRestriction Enzymes—a Review.” Gene, vol. 100: 13-26 (1991), thecontents of which are hereby incorporated in their entirety byreference.

Primary Libraries include a VH Acceptor Framework and a fixed VLsequence (also referred to as a “dummy VL” sequence) or a VL AcceptorFramework and a fixed VH sequence (also referred to as a “dummy VH”sequence). Thus, Primary Libraries exhibit diversity in only one of theheavy or light chains. Secondary Libraries are generated by ligating aVH Acceptor Framework and a VL Acceptor Framework together (see e.g.,Example 7). Secondary Libraries have diversity in both the heavy andlight chains.

The invention provides methods for producing a collection of nucleicacids, wherein each nucleic acid encodes a human immunoglobulin heavychain variable domain containing a plurality of heavy chaincomplementarity determining region 3 (CDR H3) isolated from theimmunoglobulin variable domain repertoire from a non-human species. Insome embodiments, the method includes the steps of: (a) providing aplurality of Acceptor Framework nucleic acid sequences encoding distincthuman immunoglobulin heavy chain variable domains, each AcceptorFramework nucleic acid sequence containing a first framework region(FR1), a second framework region (FR2), a third framework region (FR3),and a fourth framework region (FR4), wherein the FR1 and FR2 regions areinterspaced by a complementarity determining region 1 (CDR1), the FR2and FR3 regions are interspaced by a complementarity determining region2 (CDR2), and the FR3 and FR4 regions are interspaced by a stuffernucleic acid sequence including at least two Type IIs restriction enzymerecognition sites interspaced by a random nucleic acid sequence; (b)providing a plurality of diversified nucleic acid sequences encodingheavy chain complementarity determining region 3 (CDR H3) sequencesisolated from a non-human species immunoglobulin repertoire wherein eachof the plurality of diversified nucleic acid sequences includes a TypeIIs restriction enzyme recognition site at each extremity; (c) digestingeach of the plurality of nucleic acid sequences encoding the CDR H3regions using a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (b) and digesting thestuffer nucleic acid sequence of step (a) from the Acceptor Frameworkusing a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (a); and (d) ligating thedigested nucleic acid sequences encoding the CDR H3 regions or the aminoacid sequences of step (c) into the digested Acceptor Framework of step(c) such that the FR3 and FR4 regions are interspaced by the nucleicacid sequences encoding the CDR H3 region or the amino acid sequencethat can fulfill the role of a CDR3 region and a complete immunoglobulinvariable domain encoding sequences that do not contain the Type IIsrestriction enzyme recognition sites of steps (a) and (b) are restored.

In some embodiments, step (b) as set forth above is performed byamplifying the CDR H3 sequence from a non human species usingoligonucleotide primers containing a Type IIs restriction site. In someembodiments, step (b) as set forth above is performed by amplifying theCDR H3 sequence from a non human species using oligonucleotide primerscontaining a FokI IIs restriction site. In some embodiments, thenon-human species is non-human primate, rodent, canine, feline, sheep,goat, cattle, horse, or pig.

The invention provides methods for producing a library of nucleic acids,wherein each nucleic acid encodes an immunoglobulin variable domain by(a) providing a plurality of Acceptor Framework nucleic acid sequencesencoding distinct immunoglobulin variable domains, each AcceptorFramework nucleic acid sequence including a first framework region(FR1), a second framework region (FR2), a third framework region (FR3),and a fourth framework region (FR4), wherein the FR1 and FR2 regions areinterspaced by a complementarity determining region 1 (CDR1), the FR2and FR3 regions are interspaced by a complementarity determining region2 (CDR2), and the FR3 and FR4 regions are interspaced by a stuffernucleic acid sequence containing at least two Type IIs restrictionenzyme recognition sites interspaced by a random nucleic acid sequence;(b) providing a plurality of diversified nucleic acid sequences encodingcomplementarity determining region 3 (CDR3) regions or encoding aminoacid sequences that can fulfill the role of a CDR3 region, wherein eachof the plurality of diversified nucleic acid sequences includes a TypeIIs restriction enzyme recognition site at each extremity; (c) digestingeach of the plurality of nucleic acid sequences encoding the CDR3regions or amino acid sequences that can fulfill the role of a CDR3region using a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (b) and digesting thestuffer nucleic acid sequence of step (a) from the Acceptor Frameworkusing a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (a); and (d) ligating thedigested nucleic acid sequences encoding the CDR3 regions or the aminoacid sequences that can fulfill the role of a CDR3 region of step (c)into the digested Acceptor Framework of step (c) such that the FR3 andFR4 regions are interspaced by the nucleic acid sequences encoding theCDR3 region or the amino acid sequence that can fulfill the role of aCDR3 region and a complete immunoglobulin variable domain encodingsequences that do not contain the Type IIs restriction enzymerecognition sites of steps (a) and (b) are restored.

In some embodiments, the Type IIs restriction enzyme recognition sitesof step (a) and step (b) are recognized by the same Type IIs restrictionenzyme. In some embodiments, the Type IIs restriction enzyme recognitionsites of step (a) and step (b) are recognized by different Type IIsrestriction enzymes. For example, the Type IIs restriction enzymerecognition sites are FokI recognition sites, BsaI recognition sites,and/or BsmBI recognition sites.

In some embodiments, the Acceptor Framework nucleic acid sequence isderived from a human gene sequence. For example, the human sequence is ahuman heavy chain variable gene sequence or a sequence derived from ahuman heavy chain variable gene sequence. In some embodiments, the humanheavy chain variable gene sequence is selected from VH1-2, VH1-69,VH1-18, VH3-30, VH3-48, VH3-23, and VH5-51. In some embodiments, thehuman sequence is a human kappa light chain variable gene sequence or asequence derived from a human kappa light chain variable gene sequence.For example, the human kappa light chain variable gene sequence isselected from VK1-33, VK1-39, VK3-11, VK3-15, and VK3-20. In someembodiments, the human sequence is a human lambda light chain variablegene sequence or a sequence derived from a human lambda light chainvariable gene sequence. For example, the human lambda light chainvariable gene sequence is selected from VL1-44 and VL1-51.

In one embodiment, the plurality of diversified nucleic acids encodesCDR3 regions, and the plurality of diversified nucleic acids includesnaturally occurring sequences or sequences derived from immunizedanimals.

In one embodiment, the plurality of diversified nucleic acids includesor is derived from sequences selected from naturally occurring CDR3sequences, naturally occurring Ig sequences from humans, naturallyoccurring Ig sequences from a mammal, naturally occurring sequences froma loop region of a T cell receptor in a mammal, and other naturallydiversified polypeptide collections.

In one embodiment, the plurality of diversified nucleic acids encodesCDR3 regions, and the plurality of diversified nucleic acids includes oris derived from immunoglobulin sequences that occur naturally in humansthat have been exposed to a particular immunogen or sequences derivedfrom animals that have been identified as having been exposed to aparticular antigen.

In one embodiment, the plurality of diversified nucleic acids encodesamino acid sequences that can fulfill the role of a CDR3 region, and theplurality of diversified nucleic acids includes synthetic sequences.

In another embodiment, the plurality of diversified nucleic acidsencodes amino acid sequences that can fulfill the role of a CDR3 region,and the plurality of diversified nucleic acids includes syntheticsequences.

In some embodiments, the plurality of Acceptor Framework nucleic acidsequences include a mixture of at least one variable heavy chain (VH)Acceptor Framework nucleic acid sequence and at least one variable lightchain Acceptor Framework nucleic acid sequence.

In some embodiments, the methods provided include the additional step of(e) transforming the expression vector of step (d) into a host cell andculturing the host cell under conditions sufficient to express theplurality of Acceptor Framework sequences. For example, the host cell isE. coli. In some embodiments, the expression vector is a phagemidvector. For example, the phagemid vector is pNDS1.

The invention also provides methods for producing a library of nucleicacids, wherein each nucleic acid encodes an immunoglobulin variabledomain, by (a) providing a plurality of Acceptor Framework nucleic acidsequences encoding distinct immunoglobulin variable domains, eachAcceptor Framework nucleic acid sequence including a first frameworkregion (FR1), a second framework region (FR2), a third framework region(FR3), and a fourth framework region (FR4), wherein the FR1 and FR2regions are interspaced by a stuffer nucleic acid sequence including atleast two Type IIs restriction enzyme recognition sites interspaced by arandom nucleic acid sequence, the FR2 and FR3 regions are interspaced bya complementarity determining region 2 (CDR2), and the FR3 and FR4regions are interspaced by a complementarity determining region 3(CDR3); (b) providing a plurality of diversified nucleic acid sequencesencoding complementarity determining region 1 (CDR1) regions or encodingamino acid sequences that can fulfill the role of a CDR1 region, whereineach of the plurality of diversified nucleic acid sequences includes aType IIs restriction enzyme recognition site at each extremity; (c)digesting each of the plurality of nucleic acid sequences encoding theCDR1 regions or amino acid sequences that can fulfill the role of a CDR1region using a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (b) and digesting thestuffer nucleic acid sequence of step (a) from the Acceptor Frameworkusing a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (a); and (d) ligating thedigested nucleic acid sequences encoding the CDR1 regions or the aminoacid sequences that can fulfill the role of a CDR1 region of step (c)into the digested Acceptor Framework of step (c) such that the FR1 andFR2 regions are interspaced by the nucleic acid sequences encoding theCDR1 region or the amino acid sequence that can fulfill the role of aCDR1 region and a complete immunoglobulin variable domain encodingsequences that do not contain the Type IIs restriction enzymerecognition sites of steps (a) and (b) are restored.

In some embodiments, the Type IIs restriction enzyme recognition sitesof step (a) and step (b) are recognized by the same Type IIs restrictionenzyme. In some embodiments, the Type IIs restriction enzyme recognitionsites of step (a) and step (b) are recognized by different Type IIsrestriction enzymes. For example, the Type IIs restriction enzymerecognition sites are FokI recognition sites, BsaI recognition sites,and/or BsmBI recognition sites.

In some embodiments, the Acceptor Framework nucleic acid sequence isderived from a human gene sequence. For example, the human sequence is ahuman heavy chain variable gene sequence or a sequence derived from ahuman heavy chain variable gene sequence. In some embodiments, the humanheavy chain variable gene sequence is selected from VH1-2, VH1-69,VH1-18, VH3-30, VH3-48, VH3-23, and VH5-51. In some embodiments, thehuman sequence is a human kappa light chain variable gene sequence or asequence derived from a human kappa light chain variable gene sequence.For example, the human kappa light chain variable gene sequence isselected from VK1-33, VK1-39, VK3-11, VK3-15, and VK3-20. In someembodiments, the human sequence is a human lambda light chain variablegene sequence or a sequence derived from a human lambda light chainvariable gene sequence. For example, the human lambda light chainvariable gene sequence is selected from VL1-44 and VL1-51.

In one embodiment, the plurality of diversified nucleic acids encodesCDR1 regions, and the plurality of diversified nucleic acids includenaturally occurring sequences or sequences derived from immunizedanimals.

In one embodiment, the plurality of diversified nucleic acids includesor is derived from sequences selected from naturally occurring CDR1sequences, naturally occurring Ig sequences from humans, naturallyoccurring Ig sequences from a mammal, naturally occurring sequences froma loop region of a T cell receptor in a mammal, and other naturallydiversified polypeptide collections.

In one embodiment, the plurality of diversified nucleic acids encodesCDR1 regions, and the plurality of diversified nucleic acids includes oris derived from immunoglobulin sequences that occur naturally in humansthat have been exposed to a particular immunogen or sequences derivedfrom animals that have been identified as having been exposed to aparticular antigen.

In one embodiment, the plurality of diversified nucleic acids encodesamino acid sequences that can fulfill the role of a CDR1 region, and theplurality of diversified nucleic acids includes synthetic sequences.

In another embodiment, the plurality of diversified nucleic acidsencodes amino acid sequences that can fulfill the role of a CDR1 region,and the plurality of diversified nucleic acids includes syntheticsequences.

In some embodiments, the plurality of Acceptor Framework nucleic acidsequences include a mixture of at least one variable heavy chain (VH)Acceptor Framework nucleic acid sequence and at least one variable lightchain Acceptor Framework nucleic acid sequence.

In some embodiments, the methods provided include the additional stepsof (e) cloning the library of nucleic acids encoding immunoglobulinvariable domains of step (d) into an expression vector and (f)transforming the expression vector of step (e) into a host cell andculturing the host cell under conditions sufficient to express aplurality of immunoglobulin variable domain encoded by the library. Forexample, the host cell is E. coli. In some embodiments, the expressionvector is a phagemid vector. For example, the phagemid vector is pNDS1.

The invention also provides methods for producing a library of nucleicacids, wherein each nucleic acid encodes an immunoglobulin variabledomain, by (a) providing a plurality of Acceptor Framework nucleic acidsequences encoding distinct immunoglobulin variable domains, eachAcceptor Framework nucleic acid sequence including a first frameworkregion (FR1), a second framework region (FR2), a third framework region(FR3), and a fourth framework region (FR4), wherein the FR1 and FR2regions are interspaced by a complementarity determining region 1(CDR1), the FR2 and FR3 regions are interspaced by a stuffer nucleicacid sequence including at least two Type IIs restriction enzymerecognition sites interspaced by a random nucleic acid sequence, and theFR3 and FR4 regions are interspaced by a complementarity determiningregion 3 (CDR3); (b) providing a plurality of diversified nucleic acidsequences encoding complementarity determining region 2 (CDR2) regionsor encoding amino acid sequences that can fulfill the role of a CDR2region, wherein each of the plurality of diversified nucleic acidsequences includes a Type IIs restriction enzyme recognition site ateach extremity; (c) digesting each of the plurality of nucleic acidsequences encoding the CDR2 regions or amino acid sequences that canfulfill the role of a CDR2 region using a Type IIs restriction enzymethat binds to the Type IIs restriction enzyme recognition site of step(b) and digesting the stuffer nucleic acid sequence of step (a) from theAcceptor Framework using a Type IIs restriction enzyme that binds to theType IIs restriction enzyme recognition site of step (a); and (d)ligating the digested nucleic acid sequences encoding the CDR2 regionsor the amino acid sequences that can fulfill the role of a CDR2 regionof step (c) into the digested Acceptor Framework of step (c) such thatthe FR2 and FR3 regions are interspaced by the nucleic acid sequencesencoding the CDR2 region or the amino acid sequence that can fulfill therole of a CDR2 region and a complete immunoglobulin variable domainencoding sequences that do not contain the Type IIs restriction enzymerecognition sites of steps (a) and (b) are restored.

In some embodiments, the Type IIs restriction enzyme recognition sitesof step (a) and step (b) are recognized by the same Type IIs restrictionenzyme. In some embodiments, the Type IIs restriction enzyme recognitionsites of step (a) and step (b) are recognized by different Type IIsrestriction enzymes. For example, the Type IIs restriction enzymerecognition sites are FokI recognition sites, BsaI recognition sites,and/or BsmBI recognition sites.

In some embodiments, the Acceptor Framework nucleic acid sequence isderived from a human gene sequence. For example, the human sequence is ahuman heavy chain variable gene sequence or a sequence derived from ahuman heavy chain variable gene sequence. In some embodiments, the humanheavy chain variable gene sequence is selected from VH1-2, VH1-69,VH1-18, VH3-30, VH3-48, VH3-23, and VH5-51. In some embodiments, thehuman sequence is a human kappa light chain variable gene sequence or asequence derived from a human kappa light chain variable gene sequence.For example, the human kappa light chain variable gene sequence isselected from VK1-33, VK1-39, VK3-11, VK3-15, and VK3-20. In someembodiments, the human sequence is a human lambda light chain variablegene sequence or a sequence derived from a human lambda light chainvariable gene sequence. For example, the human lambda light chainvariable gene sequence is selected from VL1-44 and VL1-51.

In one embodiment, the plurality of diversified nucleic acids encodesCDR2 regions, and the plurality of diversified nucleic acids includesnaturally occurring sequences or sequences derived from immunizedanimals.

In one embodiment, the plurality of diversified nucleic acids includesor is derived from sequences selected from naturally occurring CDR2sequences, naturally occurring Ig sequences from humans, naturallyoccurring Ig sequences from a mammal, naturally occurring sequences froma loop region of a T cell receptor in a mammal, and other naturallydiversified polypeptide collections.

In one embodiment, the plurality of diversified nucleic acids encodeCDR2 regions, and the plurality of diversified nucleic acids includes oris derived from immunoglobulin sequences that occur naturally in humansthat have been exposed to a particular immunogen or sequences derivedfrom animals that have been identified as having been exposed to aparticular antigen.

In another embodiment, the plurality of diversified nucleic acidsencodes amino acid sequences that can fulfill the role of a CDR2 region,and the plurality of diversified nucleic acids include syntheticsequences.

In some embodiments, the plurality of Acceptor Framework nucleic acidsequences include a mixture of at least one variable heavy chain (VH)Acceptor Framework nucleic acid sequence and at least one variable lightchain Acceptor Framework nucleic acid sequence.

In some embodiments, the methods provided include the additional stepsof (e) cloning the library of nucleic acids encoding immunoglobulinvariable domains of step (d) into an expression vector and (f)transforming the expression vector of step (e) into a host cell andculturing the host cell under conditions sufficient to express aplurality of immunoglobulin variable domain encoded by the library. Forexample, the host cell is E. coli. In some embodiments, the expressionvector is a phagemid vector. For example, the phagemid vector is pNDS1.

The invention also provides methods for making a target-specificantibody, antibody variable region or a portion thereof, by (a)providing a plurality of Acceptor Framework nucleic acid sequencesencoding distinct immunoglobulin variable domains, each AcceptorFramework nucleic acid sequence including a first framework region(FR1), a second framework region (FR2), a third framework region (FR3),and a fourth framework region (FR4), wherein the FR1 and FR2 regions areinterspaced by a complementarity determining region 1 (CDR1), the FR2and FR3 regions are interspaced by a complementarity determining region2 (CDR2), and the FR3 and FR4 regions are interspaced by a stuffernucleic acid sequence including at least two Type IIs restriction enzymerecognition sites interspaced by a random nucleic acid sequence; (b)providing a plurality of diversified nucleic acid sequences encodingcomplementarity determining region 3 (CDR3) regions or encoding aminoacid sequences that can fulfill the role of a CDR3 region, wherein eachof the plurality of diversified nucleic acid sequences includes a TypeIIs restriction enzyme recognition site at each extremity; (c) digestingeach of the plurality of nucleic acid sequences encoding the CDR3regions or amino acid sequences that can fulfill the role of a CDR3region using a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (b) and digesting thestuffer nucleic acid sequence of step (a) using a Type IIs restrictionenzyme that binds to the Type IIs restriction enzyme recognition site ofstep (a); (d) cloning the digested nucleic acid sequences encoding theCDR3 regions or the amino acid sequences that can fulfill the role of aCDR3 region into an expression vector and ligating the digested nucleicacid sequences encoding the CDR3 regions or the amino acid sequencesthat can fulfill the role of a CDR3 region of step (c) into the AcceptorFramework such that the FR3 and FR4 regions are interspaced by thenucleic acid sequences encoding the CDR3 region or the amino acidsequence that can fulfill the role of a CDR3 region and a completeimmunoglobulin variable gene encoding sequence is restored; (e)transforming the expression vector of step (e) into a host cell andculturing the host cell under conditions sufficient to express theplurality of Acceptor Framework sequences; (f) contacting the host cellwith a target antigen; and (g) determining which expressed AcceptorFramework sequences bind to the target antigen.

In some embodiments, the Type IIs restriction enzyme recognition sitesof step (a) and step (b) are recognized by the same Type IIs restrictionenzyme. In some embodiments, the Type IIs restriction enzyme recognitionsites of step (a) and step (b) are recognized by different Type IIsrestriction enzymes. For example, the Type IIs restriction enzymerecognition sites are FokI recognition sites, BsaI recognition sites,and/or BsmBI recognition sites.

In some embodiments, the Acceptor Framework nucleic acid sequence isderived from a human gene sequence. For example, the human sequence is ahuman heavy chain variable gene sequence or a sequence derived from ahuman heavy chain variable gene sequence. In some embodiments, the humanheavy chain variable gene sequence is selected from VH1-2, VH1-69,VH1-18, VH3-30, VH3-48, VH3-23, and VH5-51. In some embodiments, thehuman sequence is a human kappa light chain variable gene sequence or asequence derived from a human kappa light chain variable gene sequence.For example, the human kappa light chain variable gene sequence isselected from VK1-33, VK1-39, VK3-11, VK3-15, and VK3-20. In someembodiments, the human sequence is a human lambda light chain variablegene sequence or a sequence derived from a human lambda light chainvariable gene sequence. For example, the human lambda light chainvariable gene sequence is selected from VL1-44 and VL1-51.

In one embodiment, the plurality of diversified nucleic acids encodesCDR3 regions, and the plurality of diversified nucleic acids includesnaturally occurring sequences or sequences derived from immunizedanimals.

In one embodiment, the plurality of diversified nucleic acids includesor is derived from sequences selected from naturally occurring CDR3sequences, naturally occurring Ig sequences from humans, naturallyoccurring Ig sequences from a mammal, naturally occurring sequences froma loop region of a T cell receptor in a mammal, and other naturallydiversified polypeptide collections.

In one embodiment, the plurality of diversified nucleic acids encodesCDR3 regions, and the plurality of diversified nucleic acids includes oris derived from immunoglobulin sequences that occur naturally in humansthat have been exposed to a particular immunogen or sequences derivedfrom animals that have been identified as having been exposed to aparticular antigen.

In another embodiment, the plurality of diversified nucleic acidsencodes amino acid sequences that can fulfill the role of a CDR3 region,and the plurality of diversified nucleic acids include syntheticsequences.

In some embodiments, the plurality of Acceptor Framework nucleic acidsequences include a mixture of at least one variable heavy chain (VH)Acceptor Framework nucleic acid sequence and at least one variable lightchain Acceptor Framework nucleic acid sequence.

In some embodiments, the expression vector is a phagemid vector. Forexample, the phagemid vector is pNDS1. In some embodiments, the hostcell is E. coli.

In some embodiments, the method includes the additional step of (i)sequencing the immunoglobulin variable domain encoding sequences thatbind the target antigen.

The invention also provides methods for making a target-specificantibody, antibody variable region or a portion thereof, by (a)providing a plurality of Acceptor Framework nucleic acid sequencesencoding distinct immunoglobulin variable domains, each AcceptorFramework nucleic acid sequence including a first framework region(FR1), a second framework region (FR2), a third framework region (FR3),and a fourth framework region (FR4), wherein the FR1 and FR2 regions areinterspaced by a stuffer nucleic acid sequence including at least twoType IIs restriction enzyme recognition sites interspaced by a randomnucleic acid sequence, the FR2 and FR3 regions are interspaced by acomplementarity determining region 2 (CDR2), and the FR3 and FR4 regionsare interspaced by a complementarity determining region 3 (CDR3); (b)providing a plurality of diversified nucleic acid sequences encodingcomplementarity determining region 1 (CDR1) regions or encoding aminoacid sequences that can fulfill the role of a CDR1 region, wherein eachof the plurality of diversified nucleic acid sequences includes a TypeIIs restriction enzyme recognition site at each extremity; (c) digestingeach of the plurality of nucleic acid sequences encoding the CDR1regions or amino acid sequences that can fulfill the role of a CDR1region using a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (b) and digesting thestuffer nucleic acid sequence of step (a) using a Type IIs restrictionenzyme that binds to the Type IIs restriction enzyme recognition site ofstep (a); (d) cloning the digested nucleic acid sequences encoding theCDR1 regions or the amino acid sequences that can fulfill the role of aCDR1 region into an expression vector and ligating the digested nucleicacid sequences encoding the CDR1 regions or the amino acid sequencesthat can fulfill the role of a CDR1 region of step (c) into the AcceptorFramework such that the FR1 and FR2 regions are interspaced by thenucleic acid sequences encoding the CDR1 region or the amino acidsequence that can fulfill the role of a CDR1 region and a completeimmunoglobulin variable gene encoding sequence is restored; (e)transforming the expression vector of step (e) into a host cell andculturing the host cell under conditions sufficient to express theplurality of Acceptor Framework sequences; (f) contacting the host cellwith a target antigen; and (g) determining which expressed AcceptorFramework sequences bind to the target antigen.

In some embodiments, the Type IIs restriction enzyme recognition sitesof step (a) and step (b) are recognized by the same Type IIs restrictionenzyme. In some embodiments, the Type IIs restriction enzyme recognitionsites of step (a) and step (b) are recognized by different Type IIsrestriction enzymes. For example, the Type IIs restriction enzymerecognition sites are FokI recognition sites BsaI recognition sites,and/or BsmBI recognition sites.

In some embodiments, the Acceptor Framework nucleic acid sequence isderived from a human gene sequence. For example, the human sequence is ahuman heavy chain variable gene sequence or a sequence derived from ahuman heavy chain variable gene sequence. In some embodiments, the humanheavy chain variable gene sequence is selected from VH1-2, VH1-69,VH1-18, VH3-30, VH3-48, VH3-23, and VH5-51. In some embodiments, thehuman sequence is a human kappa light chain variable gene sequence or asequence derived from a human kappa light chain variable gene sequence.For example, the human kappa light chain variable gene sequence isselected from VK1-33, VK1-39, VK3-11, VK3-15, and VK3-20. In someembodiments, the human sequence is a human lambda light chain variablegene sequence or a sequence derived from a human lambda light chainvariable gene sequence. For example, the human lambda light chainvariable gene sequence is selected from VL1-44 and VL1-51.

In one embodiment, the plurality of diversified nucleic acids encodesCDR1 regions, and the plurality of diversified nucleic acids includesnaturally occurring sequences or sequences derived from immunizedanimals.

In one embodiment, the plurality of diversified nucleic acids includesor is derived from sequences selected from naturally occurring CDR1sequences, naturally occurring Ig sequences from humans, naturallyoccurring Ig sequences from a mammal, naturally occurring sequences froma loop region of a T cell receptor in a mammal, and other naturallydiversified polypeptide collections.

In one embodiment, the plurality of diversified nucleic acids encodesCDR1 regions, and the plurality of diversified nucleic acids includes oris derived from immunoglobulin sequences that occur naturally in humansthat have been exposed to a particular immunogen or sequences derivedfrom animals that have been identified as having been exposed to aparticular antigen.

In another embodiment, the plurality of diversified nucleic acidsencodes amino acid sequences that can fulfill the role of a CDR1 region,and the plurality of diversified nucleic acids includes syntheticsequences.

In some embodiments, the plurality of Acceptor Framework nucleic acidsequences include a mixture of at least one variable heavy chain (VH)Acceptor Framework nucleic acid sequence and at least one variable lightchain Acceptor Framework nucleic acid sequence.

In some embodiments, the expression vector is a phagemid vector. Forexample, the phagemid vector is pNDS1. In some embodiments, the hostcell is E. coli.

In some embodiments, the method includes the additional step of (i)sequencing the immunoglobulin variable domain encoding sequences thatbind the target antigen.

The invention provides methods for making a target-specific antibody,antibody variable region or a portion thereof, by (a) providing aplurality of Acceptor Framework nucleic acid sequences encoding distinctimmunoglobulin variable domains, each Acceptor Framework nucleic acidsequence including a first framework region (FR1), a second frameworkregion (FR2), a third framework region (FR3), and a fourth frameworkregion (FR4), wherein the FR1 and FR2 regions are interspaced by acomplementarity determining region 1 (CDR1), the FR2 and FR3 regions areinterspaced by a stuffer nucleic acid sequence including at least twoType IIs restriction enzyme recognition sites interspaced by a randomnucleic acid sequence, and the FR3 and FR4 regions are interspaced by acomplementarity determining region 3 (CDR3); (b) providing a pluralityof diversified nucleic acid sequences encoding complementaritydetermining region 2 (CDR2) regions or encoding amino acid sequencesthat can fulfill the role of a CDR2 region, wherein each of theplurality of diversified nucleic acid sequences includes a Type IIsrestriction enzyme recognition site at each extremity; (c) digestingeach of the plurality of nucleic acid sequences encoding the CDR2regions or amino acid sequences that can fulfill the role of a CDR2region using a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (b) and digesting thestuffer nucleic acid sequence of step (a) from the Acceptor Frameworkusing a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (a); (d) ligating thedigested nucleic acid sequences encoding the CDR2 regions or the aminoacid sequences that can fulfill the role of a CDR2 region of step (c)into the digested Acceptor Framework of step (c) such that the FR2 andFR3 regions are interspaced by the nucleic acid sequences encoding theCDR2 region or the amino acid sequence that can fulfill the role of aCDR2 region and complete immunoglobulin variable domain encodingsequences that do not contain the Type IIs restriction enzymerecognition sites of steps (a) and (b) are restored; (e) cloning thelibrary of nucleic acids encoding immunoglobulin variable domains ofstep (d) into an expression vector; (f) transforming the expressionvector of step (e) into a host cell and culturing the host cell underconditions sufficient to express a plurality of immunoglobulin variabledomains encoded by the library; (g) contacting the plurality ofimmunoglobulin variable domains of step (f) with a target antigen; and(h) determining which expressed immunoglobulin variable domain encodingsequences bind to the target antigen.

In some embodiments, the Type IIs restriction enzyme recognition sitesof step (a) and step (b) are recognized by the same Type IIs restrictionenzyme. In some embodiments, the Type IIs restriction enzyme recognitionsites of step (a) and step (b) are recognized by different Type IIsrestriction enzymes. For example, the Type IIs restriction enzymerecognition sites are FokI recognition sites, BsaI recognition sites,and/or BsmBI recognition sites.

In some embodiments, the Acceptor Framework nucleic acid sequence isderived from a human gene sequence. For example, the human sequence is ahuman heavy chain variable gene sequence or a sequence derived from ahuman heavy chain variable gene sequence. In some embodiments, the humanheavy chain variable gene sequence is selected from VH1-2, VH1-69,VH1-18, VH3-30, VH3-48, VH3-23, and VH5-51. In some embodiments, thehuman sequence is a human kappa light chain variable gene sequence or asequence derived from a human kappa light chain variable gene sequence.For example, the human kappa light chain variable gene sequence isselected from VK1-33, VK1-39, VK3-11, VK3-15, and VK3-20. In someembodiments, the human sequence is a human lambda light chain variablegene sequence or a sequence derived from a human lambda light chainvariable gene sequence. For example, the human lambda light chainvariable gene sequence is selected from VL1-44 and VL1-51.

In one embodiment, the plurality of diversified nucleic acids encodesCDR2 regions, and the plurality of diversified nucleic acids includesnaturally occurring sequences or sequences derived from immunizedanimals.

In one embodiment, the plurality of diversified nucleic acids includesor is derived from sequences selected from naturally occurring CDR2sequences, naturally occurring Ig sequences from humans, naturallyoccurring Ig sequences from a mammal, naturally occurring sequences froma loop region of a T cell receptor in a mammal, and other naturallydiversified polypeptide collections.

In one embodiment, the plurality of diversified nucleic acids encodesCDR2 regions, and the plurality of diversified nucleic acids includes oris derived from immunoglobulin sequences that occur naturally in humansthat have been exposed to a particular immunogen or sequences derivedfrom animals that have been identified as having been exposed to aparticular antigen.

In one embodiment, the plurality of diversified nucleic acids encodesamino acid sequences that can fulfill the role of a CDR2 region, and theplurality of diversified nucleic acids includes synthetic sequences.

In another embodiment, the plurality of diversified nucleic acidsencodes amino acid sequences that can fulfill the role of a CDR2 region,and the plurality of diversified nucleic acids includes syntheticsequences.

In some embodiments, the plurality of Acceptor Framework nucleic acidsequences include a mixture of at least one variable heavy chain (VH)Acceptor Framework nucleic acid sequence and at least one variable lightchain Acceptor Framework nucleic acid sequence.

In some embodiments, the host cell is E. coli. In some embodiments, theexpression vector is a phagemid vector. For example, the phagemid vectoris pNDS1.

In some embodiments, the method includes the additional step of (i)sequencing the immunoglobulin variable domain encoding sequences thatbind the target antigen.

The invention also provides methods for producing a library of nucleicacids, wherein each nucleic acid encodes an immunoglobulin variabledomain. These methods include the steps of (a) providing a plurality ofIg Acceptor Framework nucleic acid sequences into which a source ofdiversity is introduced at a single complementarity determining region(CDR) selected from the group consisting of complementarity determiningregion 1 (CDR1), complementarity determining region 2 (CDR2), andcomplementarity determining region 3 (CDR3), wherein the Ig AcceptorFramework sequence includes a stuffer nucleic acid sequence including atleast two Type IIs restriction enzyme recognition sites, and wherein thesource of diversity is a CDR selected from naturally occurring CDRsequences that contain Type IIs restriction enzyme recognition sitesoutside the CDR region, (b) introducing the source of diversity withineach Ig Acceptor Framework by digesting both the source of diversity andthe Ig Acceptor Frameworks with a Type IIs restriction enzyme; and (c)ligating the digested source of diversity into the Ig Acceptor Frameworksuch that a complete immunoglobulin variable domain encoding sequencesthat do not contain the Type IIs restriction enzyme recognition sites ofsteps (a) and (b) are restored.

The naturally occurring CDR region sequences are substantially unalteredfrom their wild-type, i.e., natural state. These naturally occurring CDRregion sequences are flanked by amino acid sequences that have beenengineered (or otherwise artificially manipulated) to contain two TypeIIs restriction enzyme recognition sites, with one Type IIs restrictionenzyme recognition site on each of side of the naturally occurring CDRregion sequence. The Type IIS restriction enzyme recognition sites areoutside the CDR encoding region. The sequence of CDR regions areunaltered at the boundaries of the CDR encoding region—the restrictionenzymes recognize and splice at a region that is up to the boundary ofthe CDR encoding region, but does not splice within the CDR encodingregion.

In some embodiments, the Type IIs restriction enzyme recognition siteswithin the stuffer nucleic acid sequences and flanking the naturallyoccurring CDR sequences are recognized by the same Type IIs restrictionenzyme. In some embodiments, the Type IIs restriction enzyme recognitionsites within the stuffer nucleic acid sequences and flanking thenaturally occurring CDR sequences are recognized by different Type IIsrestriction enzymes. For example, the Type IIs restriction enzymerecognition sites are FokI recognition sites, BsaI recognition sites,and/or BsmBI recognition sites.

In some embodiments, the Ig Acceptor Framework nucleic acid sequence isderived from a human gene sequence. For example, the human sequence is ahuman heavy chain variable gene sequence or a sequence derived from ahuman heavy chain variable gene sequence. In some embodiments, the humanheavy chain variable gene sequence is selected from VH1-2, VH1-69,VH1-18, VH3-30, VH3-48, VH3-23, and VH5-51. In some embodiments, thehuman sequence is a human kappa light chain variable gene sequence or asequence derived from a human kappa light chain variable gene sequence.For example, the human kappa light chain variable gene sequence isselected from VK1-33, VK1-39, VK3-11, VK3-15, and VK3-20. In someembodiments, the human sequence is a human lambda light chain variablegene sequence or a sequence derived from a human lambda light chainvariable gene sequence. For example, the human lambda light chainvariable gene sequence is selected from VL1-44 and VL1-51.

In some embodiments, the set of naturally occurring nucleic acidsincludes or is derived from sequences selected from naturally occurringCDR3 sequences, naturally occurring Ig sequences from humans, naturallyoccurring Ig sequences from a mammal, naturally occurring sequences froma loop region of a T cell receptor in a mammal, and other naturallydiversified polypeptide collections.

In some embodiments, the set of naturally occurring nucleic acids encodeCDR3 regions, and the set of naturally occurring nucleic acids includeimmunoglobulin sequences that occur naturally in humans that have beenexposed to a particular immunogen or sequences derived from animals thathave been identified as having been exposed to a particular antigen.

In some embodiments, the set of naturally occurring nucleic acidsincludes or is derived from sequences selected from naturally occurringCDR1 sequences, naturally occurring Ig sequences from humans, naturallyoccurring Ig sequences from a mammal, naturally occurring sequences froma loop region of a T cell receptor in a mammal, and other naturallydiversified polypeptide collections.

In some embodiments, the set of naturally occurring nucleic acids encodeCDR1 regions, and the set of naturally occurring nucleic acids includesor is derived from immunoglobulin sequences that occur naturally inhumans that have been exposed to a particular immunogen or sequencesderived from animals that have been identified as having been exposed toa particular antigen.

In some embodiments, the set of naturally occurring nucleic acidsincludes or is derived from sequences selected from naturally occurringCDR2 sequences, naturally occurring Ig sequences from humans, naturallyoccurring Ig sequences from a mammal, naturally occurring sequences froma loop region of a T cell receptor in a mammal, and other naturallydiversified polypeptide collections.

In some embodiments, the set of naturally occurring nucleic acidsencodes CDR2 regions, and the set of naturally occurring nucleic acidsincludes immunoglobulin sequences that occur naturally in humans thathave been exposed to a particular immunogen or sequences derived fromanimals that have been identified as having been exposed to a particularantigen.

In some embodiments, the plurality of Ig Acceptor Framework nucleic acidsequences include a mixture of at least one variable heavy chain (VH)Acceptor Framework nucleic acid sequence and at least one variable lightchain (VL) Acceptor Framework nucleic acid sequence.

In some embodiments, the methods provided include the additional stepsof (e) cloning the library of nucleic acids encoding immunoglobulinvariable domains of step (d) into an expression vector and (f)transforming the expression vector of step (e) into a host cell andculturing the host cell under conditions sufficient to express aplurality of immunoglobulin variable domain encoded by the library. Forexample, the host cell is E. coli. In some embodiments, the expressionvector is a phagemid vector. For example, the phagemid vector is pNDS1.

The invention also provides methods for producing a library of nucleicacids, wherein each nucleic acid encodes an immunoglobulin variabledomain. These methods include the steps of (a) providing a plurality ofIg Acceptor Framework nucleic acid sequences into which a source ofdiversity is introduced at a single complementarity determining region(CDR) selected from the group consisting of complementarity determiningregion 1 (CDR1), complementarity determining region 2 (CDR2), andcomplementarity determining region 3 (CDR3), where the Ig AcceptorFramework sequence includes a stuffer nucleic acid sequence including atleast two Type IIs restriction enzyme recognition sites, and wherein thesource of diversity is a CDR selected from synthetically produced CDRsequences that contain Type IIs restriction enzyme recognition sitesoutside the CDR region, (b) introducing the source of diversity withineach Ig Acceptor Framework by digesting both the source of diversity andthe Ig Acceptor Framework with a Type IIs restriction enzyme; and (c)ligating the digested source of diversity into the Ig Acceptor Frameworksuch that a complete immunoglobulin variable domain encoding sequencesthat do not contain the Type IIs restriction enzyme recognition sites ofsteps (a) and (b) are restored.

In some embodiments, the Type IIs restriction enzyme recognition siteswithin the stuffer nucleic acid sequences and the synthetically producedCDR sequences are recognized by the same Type IIs restriction enzyme. Insome embodiments, the Type IIs restriction enzyme recognition siteswithin the stuffer nucleic acid sequences and the synthetically producedCDR sequences are recognized by different Type IIs restriction enzymes.For example, the Type IIs restriction enzyme recognition sites are FokIrecognition sites, BsaI recognition sites, and/or BsmBI recognitionsites.

In some embodiments, the Ig Acceptor Framework nucleic acid sequence isderived from a human sequence. For example, the human sequence is ahuman heavy chain variable gene sequence or a sequence derived from ahuman heavy chain variable gene sequence. In some embodiments, the humanheavy chain variable gene sequence is selected from VH1-2, VH1-69,VH1-18, VH3-30, VH3-48, VH3-23, and VH5-51. In some embodiments, thehuman sequence is a human kappa light chain variable gene sequence or asequence derived from a human kappa light chain variable gene sequence.For example, the human kappa light chain variable gene sequence isselected from VK1-33, VK1-39, VK3-11, VK3-15, and VK3-20. In someembodiments, the human sequence is a human lambda light chain variablegene sequence or a sequence derived from a human lambda light chainvariable gene sequence. For example, the human lambda light chainvariable gene sequence is selected from VL1-44 and VL1-51.

In some embodiments, the plurality of diversified nucleic acids encodesamino acid sequences that can fulfill the role of a CDR3 region, and theplurality of diversified nucleic acids includes synthetic sequences.

In some embodiments, the plurality of diversified nucleic acids encodesamino acid sequences that can fulfill the role of a CDR1 region, and theplurality of diversified nucleic acids includes synthetic sequences.

In some embodiments, the plurality of diversified nucleic acids encodeamino acid sequences that can fulfill the role of a CDR2 region, and theplurality of diversified nucleic acids includes synthetic sequences.

In some embodiments, the plurality of Ig Acceptor Framework nucleic acidsequences includes a mixture of at least one variable heavy chain (VH)Acceptor Framework nucleic acid sequence and at least one variable lightchain Acceptor Framework nucleic acid sequence.

In some embodiments, the methods provided include the additional stepsof (e) cloning the library of nucleic acids encoding immunoglobulinvariable domains of step (d) into an expression vector and (f)transforming the expression vector of step (e) into a host cell andculturing the host cell under conditions sufficient to express aplurality of immunoglobulin variable domain encoded by the library. Forexample, the host cell is E. coli. In some embodiments, the expressionvector is a phagemid vector. For example, the phagemid vector is pNDS1.

The invention also provides methods for making an immunoglobulinpolypeptide. These methods include the steps of (a) providing aplurality of Ig Acceptor Framework nucleic acid sequences into which asource of diversity is introduced at a single complementaritydetermining region (CDR) selected from the group consisting ofcomplementarity determining region 1 (CDR1), complementarity determiningregion 2 (CDR2), and complementarity determining region 3 (CDR3),wherein the Ig Acceptor Framework sequence includes a stuffer nucleicacid sequence including at least two Type IIs restriction enzymerecognition sites, and wherein the source of diversity is a CDR selectedfrom naturally occurring CDR sequences that contain Type IIs restrictionenzyme recognition sites outside the CDR region, (b) introducing thesource of diversity within each Ig Acceptor Framework by digesting boththe source of diversity and the Ig Acceptor Frameworks with a Type IIsrestriction enzyme; (c) ligating the digested source of diversity intothe Ig Acceptor Framework such that a complete immunoglobulin variablegene encoding sequence is restored; and (d) cloning the completeimmunoglobulin variable gene encoding sequence from step (c) into anexpression vector; and (e) transforming the expression vector of step(d) into a host cell and culturing the host cell under conditionssufficient to express the complete immunoglobulin gene encodingsequences that do not contain the Type IIs restriction enzymerecognition sites are restored.

In these embodiments, the naturally occurring CDR region sequences aresubstantially unaltered from their wild-type, i.e., natural state. Thesenaturally occurring CDR region sequences are flanked by amino acidsequences that have been engineered (or otherwise artificiallymanipulated) to contain two Type IIs restriction enzyme recognitionsites, with one Type IIs restriction enzyme recognition site on each ofside of the naturally occurring CDR region sequence.

In some embodiments, the Type IIs restriction enzyme recognition siteswithin the stuffer nucleic acid sequences and flanking the naturallyoccurring CDR sequences are recognized by the same Type IIs restrictionenzyme. In some embodiments, the Type IIs restriction enzyme recognitionsites within the stuffer nucleic acid sequences and flanking thenaturally occurring CDR sequences are recognized by different Type IIsrestriction enzymes. For example, the Type IIs restriction enzymerecognition sites are FokI recognition sites, BsaI recognition sites,and/or BsmBI recognition sites.

In some embodiments, the Acceptor Framework nucleic acid sequence isderived from a human gene sequence. For example, the human sequence is ahuman heavy chain variable gene sequence or a sequence derived from ahuman heavy chain variable gene sequence. In some embodiments, the humanheavy chain variable gene sequence is selected from VH1-2, VH1-69,VH1-18, VH3-30, VH3-48, VH3-23, and VH5-51. In some embodiments, thehuman sequence is a human kappa light chain variable gene sequence or asequence derived from a human kappa light chain variable gene sequence.For example, the human kappa light chain variable gene sequence isselected from VK1-33, VK1-39, VK3-11, VK3-15, and VK3-20. In someembodiments, the human sequence is a human lambda light chain variablegene sequence or a sequence derived from a human lambda light chainvariable gene sequence. For example, the human lambda light chainvariable gene sequence is selected from VL1-44 and VL1-51.

In some embodiments, the set of naturally occurring nucleic acidsincludes or is derived from sequences selected from naturally occurringCDR3 sequences, naturally occurring Ig sequences from humans, naturallyoccurring Ig sequences from a mammal, naturally occurring sequences froma loop region of a T cell receptor in a mammal, and other naturallydiversified polypeptide collections.

In some embodiments, the set of naturally occurring nucleic acids encodeCDR3 regions, and the set of naturally occurring nucleic acids includeimmunoglobulin sequences that occur naturally in humans that have beenexposed to a particular immunogen or sequences derived from animals thathave been identified as having been exposed to a particular antigen.

In some embodiments, the set of naturally occurring nucleic acidsincludes or is derived from sequences selected from naturally occurringCDR1 sequences, naturally occurring Ig sequences from humans, naturallyoccurring Ig sequences from a mammal, naturally occurring sequences froma loop region of a T cell receptor in a mammal, and other naturallydiversified polypeptide collections.

In some embodiments, the set of naturally occurring nucleic acids encodeCDR1 regions, and the set of naturally occurring nucleic acids includesor is derived from immunoglobulin sequences that occur naturally inhumans that have been exposed to a particular immunogen or sequencesderived from animals that have been identified as having been exposed toa particular antigen.

In some embodiments, the set of naturally occurring nucleic acidsincludes or is derived from sequences selected from naturally occurringCDR2 sequences, naturally occurring Ig sequences from humans, naturallyoccurring Ig sequences from a mammal, naturally occurring sequences froma loop region of a T cell receptor in a mammal, and other naturallydiversified polypeptide collections.

In some embodiments, the set of naturally occurring nucleic acidsencodes CDR2 regions, and the set of naturally occurring nucleic acidsincludes immunoglobulin sequences that occur naturally in humans thathave been exposed to a particular immunogen or sequences derived fromanimals that have been identified as having been exposed to a particularantigen.

In some embodiments, the plurality of Acceptor Framework nucleic acidsequences include a mixture of at least one variable heavy chain (VH)Acceptor Framework nucleic acid sequence and at least one variable lightchain Acceptor Framework nucleic acid sequence.

In some embodiments, the expression vector is a phagemid vector. In someembodiments, the host cell is E. coli.

In some embodiments, the method also includes the steps of contactingthe host cell with a target antigen, and determining which expressedcomplete Ig variable gene encoding sequences bind to the target antigen,thereby identifying target specific antibodies, antibody variableregions or portions thereof. In some embodiments, the method includesthe additional step of (i) sequencing the immunoglobulin variable domainencoding sequences that bind the target antigen.

The invention also provides methods for making an immunoglobulinpolypeptide. These methods include the steps of (a) providing aplurality of Ig Acceptor Framework nucleic acid sequences into which asource of diversity is introduced at a single complementaritydetermining region (CDR) selected from the group consisting ofcomplementarity determining region 1 (CDR1), complementarity determiningregion 2 (CDR2), and complementarity determining region 3 (CDR3),wherein the Ig Acceptor Framework sequence includes a stuffer nucleicacid sequence including at least two Type IIs restriction enzymerecognition sites, and wherein the source of diversity is a CDR selectedfrom synthetically produced CDR sequences that contain Type IIsrestriction enzyme recognition sites outside the CDR region, (b)introducing the source of diversity within each Ig Acceptor Framework bydigesting both the source of diversity and the Ig Acceptor Frameworkwith a Type IIs restriction enzyme; (c) ligating the digested source ofdiversity into the Ig Acceptor Framework such that a completeimmunoglobulin variable gene encoding sequence is restored; (d) cloningthe ligated Ig Acceptor Framework from step (c) into an expressionvector; and (e) transforming the expression vector of step (d) into ahost cell and culturing the host cell under conditions sufficient toexpress the complete immunoglobulin gene encoding sequences that do notcontain the Type IIs restriction enzyme recognition sites are restored.

In some embodiments, the Type IIs restriction enzyme recognition siteswithin the stuffer nucleic acid sequences and the synthetically producedCDR sequences are recognized by the same Type IIs restriction enzyme. Insome embodiments, the Type IIs restriction enzyme recognition siteswithin the stuffer nucleic acid sequences and the synthetically producedCDR sequences are recognized by different Type IIs restriction enzymes.For example, the Type IIs restriction enzyme recognition sites are FokIrecognition sites, BsaI recognition sites, and/or BsmBI recognitionsites.

In some embodiments, the Ig Acceptor Framework nucleic acid sequence isderived from a human gene sequence. For example, the human sequence is ahuman heavy chain variable gene sequence or a sequence derived from ahuman heavy chain variable gene sequence. In some embodiments, the humanheavy chain variable gene sequence is selected from VH1-2, VH1-69,VH1-18, VH3-30, VH3-48, VH3-23, and VH5-51. In some embodiments, thehuman sequence is a human kappa light chain variable gene sequence or asequence derived from a human kappa light chain variable gene sequence.For example, the human kappa light chain variable gene sequence isselected from VK1-33, VK1-39, VK3-11, VK3-15, and VK3-20. In someembodiments, the human sequence is a human lambda light chain variablegene sequence or a sequence derived from a human lambda light chainvariable gene sequence. For example, the human lambda light chainvariable gene sequence is selected from VL1-44 and VL1-51.

In some embodiments, the plurality of diversified nucleic acids encodesamino acid sequences that can fulfill the role of a CDR3 region, and theplurality of diversified nucleic acids includes synthetic sequences.

In some embodiments, the plurality of diversified nucleic acids encodesamino acid sequences that can fulfill the role of a CDR1 region, and theplurality of diversified nucleic acids includes synthetic sequences.

In some embodiments, the plurality of diversified nucleic acids encodeamino acid sequences that can fulfill the role of a CDR2 region, and theplurality of diversified nucleic acids includes synthetic sequences.

In some embodiments, the plurality of Ig Acceptor Framework nucleic acidsequences includes a mixture of at least one variable heavy chain (VH)Acceptor Framework nucleic acid sequence and at least one variable lightchain Acceptor Framework nucleic acid sequence.

In some embodiments, the expression vector is a phagemid vector. In someembodiments, the host cell is E. coli.

In some embodiments, the method also includes the steps of contactingthe host cell with a target antigen, and determining which expressedcomplete Ig variable gene encoding sequences bind to the target antigen,thereby identifying target specific antibodies, antibody variableregions or portions thereof. In some embodiments, the method includesthe additional step of (i) sequencing the immunoglobulin variable domainencoding sequences that bind the target antigen.

The invention provides methods for producing a collection of nucleicacids, wherein each nucleic acid encodes a human immunoglobulin variabledomain including a plurality of complementarity determining region 3(CDR3) sequences isolated separately from the immunoglobulin variabledomain repertoire from a mammalian species. The invention also providesmethods for producing a collection of nucleic acids, wherein eachnucleic acid encodes a human immunoglobulin variable domain including aplurality of complementarity determining region 2 (CDR2) sequencesisolated separately from the immunoglobulin variable domain repertoirefrom a mammalian species. The invention also provides methods forproducing a collection of nucleic acids, wherein each nucleic acidencodes a human immunoglobulin variable domain including a plurality ofcomplementarity determining region 1 (CDR1) sequences isolatedseparately from the immunoglobulin variable domain repertoire from amammalian species.

The invention provides methods for producing a collection of nucleicacids, wherein each nucleic acid encodes a human immunoglobulin variabledomain including a plurality of complementarity determining region 3(CDR3) sequences isolated separately from the immunoglobulin variabledomain repertoire from a non-human mammalian species. The invention alsoprovides methods for producing a collection of nucleic acids, whereineach nucleic acid encodes a human immunoglobulin variable domainincluding a plurality of complementarity determining region 2 (CDR2)sequences isolated separately from the immunoglobulin variable domainrepertoire from a non-human mammalian species. The invention alsoprovides methods for producing a collection of nucleic acids, whereineach nucleic acid encodes a human immunoglobulin variable domainincluding a plurality of complementarity determining region 1 (CDR1)sequences isolated separately from the immunoglobulin variable domainrepertoire from a non-human mammalian species.

In some embodiments, the non-human species is non-human primate, rodent,canine, feline, sheep, goat, cattle, horse, a member of the Camelidaefamily, llama, camel, dromedary, or pig.

The invention provides methods for producing a collection of nucleicacids, wherein each nucleic acid encodes a human immunoglobulin variabledomain including a plurality of complementarity determining region 3(CDR3) sequences isolated separately from the immunoglobulin variabledomain repertoire from a human. The invention provides methods forproducing a collection of nucleic acids, wherein each nucleic acidencodes a human immunoglobulin variable domain including a plurality ofcomplementarity determining region 2 (CDR2) sequences isolatedseparately from the immunoglobulin variable domain repertoire from ahuman. The invention provides methods for producing a collection ofnucleic acids, wherein each nucleic acid encodes a human immunoglobulinvariable domain including a plurality of complementarity determiningregion 1 (CDR1) sequences isolated separately from the immunoglobulinvariable domain repertoire from a human.

The invention provides methods for producing a collection of nucleicacids, wherein each nucleic acid encodes a human immunoglobulin variabledomain including a plurality of complementarity determining region 3(CDR3) sequences isolated separately from the immunoglobulin variabledomain repertoire from a non-human species.

In some embodiments, these methods includes the steps of (a) providing aplurality of Acceptor Framework nucleic acid sequences encoding distincthuman immunoglobulin variable domains, each Acceptor Framework nucleicacid sequence comprising a first framework region (FR1), a secondframework region (FR2), a third framework region (FR3), and a fourthframework region (FR4), wherein the FR1 and FR2 regions are interspacedby a complementarity determining region 1 (CDR1), the FR2 and FR3regions are interspaced by a complementarity determining region 2(CDR2), and the FR3 and FR4 regions are interspaced by a stuffer nucleicacid sequence comprising at least two Type IIs restriction enzymerecognition sites interspaced by a random nucleic acid sequence; (b)providing a plurality of diversified nucleic acid sequences encodingcomplementarity determining region 3 (CDR3) sequences isolated from themammalian species immunoglobulin repertoire wherein each of theplurality of diversified nucleic acid sequences comprises a Type IIsrestriction enzyme recognition site at each extremity; (c) digestingeach of the plurality of nucleic acid sequences encoding the CDR3regions using a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (b) and digesting thestuffer nucleic acid sequence of step (a) from the Acceptor Frameworkusing a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (a); and (d) ligating thedigested nucleic acid sequences encoding the CDR3 regions or the aminoacid sequences of step (c) into the digested Acceptor Framework of step(c) such that the FR3 and FR4 regions are interspaced by the nucleicacid sequences encoding the CDR3 region or the amino acid sequence thatcan fulfill the role of a CDR3 region and a complete immunoglobulinvariable domain encoding sequences that do not contain the Type IIsrestriction enzyme recognition sites of steps (a) and (b) are restored.These steps may also be performed using a plurality of diversifiednucleic acid sequences encoding complementarity determining region 2(CDR2) sequences isolated from the mammalian species immunoglobulinrepertoire. These steps may also be performed using a plurality ofdiversified nucleic acid sequences encoding complementarity determiningregion 1 (CDR1) sequences isolated from the mammalian speciesimmunoglobulin repertoire.

In some embodiments, step (b) is performed by amplifying the CDR3sequence from a mammalian species using oligonucleotide primerscontaining a Type IIs restriction site. In some embodiments, theoligonucleotide primer is designed to enhance compatibility between themammalian CDR3 sequence and the Acceptor Framework encoding a humanimmunoglobulin variable domain. In some embodiments, the oligonucleotideprimer is designed to modify the sequence at the boundaries of themammalian CDR3 sequences to allow efficient ligation via compatiblecohesive ends into the Acceptor Framework encoding a humanimmunoglobulin variable domain. In some embodiments the mammalian DNAsequences flanking the CDR3 regions might not upon cleavage by Type IISrestriction enzymes generate cohesive ends compatible with the cohesiveends of the digested Acceptor Frameworks. In such cases theoligonucleotides used for amplification are designed to modify thetarget mammalian sequence so that after cleavage with a Type IISrestriction enzyme, the cohesive ends are compatible and efficientligation can occur. These steps can also be performed by amplifying theCDR2 sequence from a mammalian species using oligonucleotide primerscontaining a Type IIs restriction site. These steps can also beperformed by amplifying the CDR1 sequence from a mammalian species usingoligonucleotide primers containing a Type IIs restriction site.

In some embodiments, step (b) is performed by amplifying the CDR3sequence from a non human species using oligonucleotide primerscontaining a FokI IIs restriction site. These steps can also beperformed by amplifying the CDR2 sequence from a mammalian species usingoligonucleotide primers containing a FokI IIs restriction site. Thesesteps can also be performed by amplifying the CDR1 sequence from amammalian species using oligonucleotide primers containing a FokI IIsrestriction site.

In some embodiments, the Type IIs restriction enzyme recognition sitesof step (a) and step (b) are recognized by a different Type IIsrestriction enzyme. In some embodiments, the Type IIs restriction enzymerecognition sites are BsmBI recognition sites, BsaI recognition sites,FokI recognition sites or a combination thereof.

In some embodiments, the diversified nucleic acid sequences encodingCDR3 sequences encode heavy chain CDR3 (CDR H3) sequences. In someembodiments, the diversified nucleic acid sequences encoding CDR3sequences encode light chain CDR3 (CDR L3) sequences. In someembodiments, the diversified nucleic acid sequences encoding CDR2sequences encode heavy chain CDR2 (CDR H2) sequences. In someembodiments, the diversified nucleic acid sequences encoding CDR2sequences encode light chain CDR2 (CDR L2) sequences. In someembodiments, the diversified nucleic acid sequences encoding CDR1sequences encode heavy chain CDR1 (CDR H1) sequences. In someembodiments, the diversified nucleic acid sequences encoding CDR1sequences encode light chain CDR1 (CDR L1) sequences.

In some embodiments, the Acceptor Framework nucleic acid sequenceincludes or is derived from at least a portion of a human heavy chainvariable gene sequence selected from VH1-2, VH1-69, VH1-18, VH3-30,VH3-48, VH3-23, and VH5-51. In some embodiments, the Acceptor Frameworknucleic acid sequence includes is derived from at least a portion of ahuman kappa light chain variable gene sequence. For example, the humankappa light chain variable gene sequence is selected from VK1-33,VK1-39, VK3-11, VK3-15, and VK3-20. In some embodiments, the AcceptorFramework nucleic acid sequence includes or is derived from at least aportion of a human lambda light chain variable gene sequence. Forexample, the human lambda light chain variable gene sequence is selectedfrom VL1-44 and VL1-51.

In some embodiments, the plurality of Acceptor Framework nucleic acidsequences comprises a mixture of at least one variable heavy chain (VH)Acceptor Framework nucleic acid sequence and at least one variable lightchain Acceptor Framework nucleic acid sequence.

In some embodiments, the methods described herein also include the stepsof (e) cloning the library of nucleic acids encoding immunoglobulinvariable domains of step (d) into an expression vector and (f)transforming the expression vector of step (e) into a host cell andculturing the host cell under conditions sufficient to express aplurality of immunoglobulin variable domain encoded by the library. Insome embodiments, the expression vector is a phagemid or phage vector.In some embodiments, the host cell is E. coli.

The invention provides methods for producing a collection of nucleicacids, wherein each nucleic acid encodes a human immunoglobulin variabledomain including a plurality of complementarity determining region 3(CDR3) sequences isolated separately from immunoglobulin variabledomains from an immunized non-human mammal or non-human species. Theinvention also provides methods for producing a collection of nucleicacids, wherein each nucleic acid encodes a human immunoglobulin variabledomain including a plurality of complementarity determining region 2(CDR2) sequences isolated separately from immunoglobulin variabledomains from an immunized non-human mammal. The invention also providesmethods for producing a collection of nucleic acids, wherein eachnucleic acid encodes a human immunoglobulin variable domain including aplurality of complementarity determining region 1 (CDR1) sequencesisolated separately from immunoglobulin variable domains from animmunized non-human mammal.

In some embodiments, the non-human species is non-human primate, rodent,canine, feline, sheep, goat, cattle, horse, a member of the Camelidaefamily, llama, camel, dromedary, or pig.

In some embodiments, the methods include the steps of (a) providing aplurality of Acceptor Framework nucleic acid sequences encoding distincthuman immunoglobulin variable domains, each Acceptor Framework nucleicacid sequence comprising a first framework region (FR1), a secondframework region (FR2), a third framework region (FR3), and a fourthframework region (FR4), wherein the FR1 and FR2 regions are interspacedby a complementarity determining region 1 (CDR1), the FR2 and FR3regions are interspaced by a complementarity determining region 2(CDR2), and the FR3 and FR4 regions are interspaced by a stuffer nucleicacid sequence comprising at least two Type IIs restriction enzymerecognition sites interspaced by a random nucleic acid sequence; (b)providing a plurality of diversified nucleic acid sequences encodingcomplementarity determining region 3 (CDR3) sequences isolated from theimmunized non-human mammal wherein each of the plurality of diversifiednucleic acid sequences comprises a Type IIs restriction enzymerecognition site at each extremity; (c) digesting each of the pluralityof nucleic acid sequences encoding the CDR3 regions using a Type IIsrestriction enzyme that binds to the Type IIs restriction enzymerecognition site of step (b) and digesting the stuffer nucleic acidsequence of step (a) from the Acceptor Framework using a Type IIsrestriction enzyme that binds to the Type IIs restriction enzymerecognition site of step (a); and (d) ligating the digested nucleic acidsequences encoding the CDR3 regions or the amino acid sequences of step(c) into the digested Acceptor Framework of step (c) such that the FR3and FR4 regions are interspaced by the nucleic acid sequences encodingthe CDR3 region or the amino acid sequence that can fulfill the role ofa CDR3 region and a complete immunoglobulin variable domain encodingsequences that do not contain the Type IIs restriction enzymerecognition sites of steps (a) and (b) are restored. These steps mayalso be performed using a plurality of diversified nucleic acidsequences encoding complementarity determining region 2 (CDR2) sequencesisolated from the immunized non-human mammal. These steps may also beperformed using a plurality of diversified nucleic acid sequencesencoding complementarity determining region 1 (CDR1) sequences isolatedfrom the immunized non-human mammal.

In some embodiments, step (b) is performed by amplifying the CDR3sequence from the immunized non-human mammal using oligonucleotideprimers containing a Type IIs restriction site. In some embodiments, theoligonucleotide primer is designed to enhance compatibility between themammalian CDR3 sequence and the Acceptor Framework encoding a humanimmunoglobulin variable domain. In some embodiments, the oligonucleotideprimer is designed to modify the sequence at the boundaries of themammalian CDR3 sequences to allow efficient ligation via compatiblecohesive ends into the Acceptor Framework encoding a humanimmunoglobulin variable domain. In some embodiments the mammalian DNAsequences flanking the CDR3 regions might not upon cleavage by Type IISrestriction enzymes generate cohesive ends compatible with the cohesiveends of the digested Acceptor Frameworks. In such cases theoligonucleotides used for amplification are designed to modify thetarget mammalian sequence so that after cleavage with a Type IISrestriction enzyme, the cohesive ends are compatible and efficientligation can occur. These steps can also be performed by amplifying theCDR2 sequence from the immunized non-human mammal using oligonucleotideprimers containing a Type IIs restriction site. These steps can also beperformed by amplifying the CDR1 sequence from the immunized non-humanmammal using oligonucleotide primers containing a Type IIs restrictionsite.

In some embodiments, step (b) is performed by amplifying the CDR H3sequence from the non-human mammal using oligonucleotide primerscontaining a FokI IIs restriction site. These steps can also beperformed by amplifying the CDR2 sequence from the non-human mammalusing oligonucleotide primers containing a FokI IIs restriction site.These steps can also be performed by amplifying the CDR1 sequence fromthe non-human mammal using oligonucleotide primers containing a FokI IIsrestriction site.

In some embodiments, the Type IIs restriction enzyme recognition sitesof step (a) and step (b) are recognized by a different Type IIsrestriction enzyme. In some embodiments, the Type IIs restriction enzymerecognition sites are BsmBI recognition sites, BsaI recognition sites,FokI recognition sites or a combination thereof.

In some embodiments, the diversified nucleic acid sequences encodingCDR3 sequences encode heavy chain CDR3 (CDR H3) sequences. In someembodiments, the diversified nucleic acid sequences encoding CDR3sequences encode light chain CDR3 (CDR L3) sequences. In someembodiments, the diversified nucleic acid sequences encoding CDR2sequences encode heavy chain CDR2 (CDR H2) sequences. In someembodiments, the diversified nucleic acid sequences encoding CDR2sequences encode light chain CDR2 (CDR L2) sequences. In someembodiments, the diversified nucleic acid sequences encoding CDR1sequences encode heavy chain CDR1 (CDR H1) sequences. In someembodiments, the diversified nucleic acid sequences encoding CDR1sequences encode light chain CDR1 (CDR L1) sequences.

In some embodiments, the Acceptor Framework nucleic acid sequenceincludes or is derived from at least a portion of a human heavy chainvariable gene sequence selected from VH1-2, VH1-69, VH1-18, VH3-30,VH3-48, VH3-23, and VH5-51.

In some embodiments, the Acceptor Framework nucleic acid sequenceincludes or is derived from at least a portion of a human kappa lightchain variable gene sequence. For example, the human kappa light chainvariable gene sequence is selected from VK1-33, VK1-39, VK3-11, VK3-15,and VK3-20. In some embodiments, the Acceptor Framework nucleic acidsequence includes or is derived from at least a portion of a humanlambda light chain variable gene sequence. For example, the human lambdalight chain variable gene sequence is selected from VL1-44 and VL1-51.

In some embodiments, the plurality of Acceptor Framework nucleic acidsequences comprises a mixture of at least one variable heavy chain (VH)Acceptor Framework nucleic acid sequence and at least one variable lightchain Acceptor Framework nucleic acid sequence.

In some embodiments, the methods also include the steps of (e) cloningthe library of nucleic acids encoding immunoglobulin variable domains ofstep (d) into an expression vector and (f) transforming the expressionvector of step (e) into a host cell and culturing the host cell underconditions sufficient to express a plurality of immunoglobulin variabledomain encoded by the library. In some embodiments, the host cell is E.coli. In some embodiments, the expression vector is a phagemid or phagevector.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A is a schematic representation of a protein domain with aframework and loops providing contact residues with another protein ormolecule. Several situations are depicted: A stable protein domain withproperly folded loop regions; properly folded loops inserted into adomain of limited intrinsic stability; an intrinsically stable proteindomain which stability is affected by the loop regions.

FIG. 1B is a schematic representation of different types of libraries ofprotein repertoires generated using different diversificationstrategies.

FIG. 2 is a schematic representation of an antibody variable AcceptorFramework. Framework regions, CDRs and type IIS-RM restriction site areindicated.

FIG. 3 is a schematic representation of a strategy used for capturingCDRH3 sequences from natural repertoires.

FIG. 4 is a schematic representation of the benefit of using primerscontaining Type IIS-RM restriction enzymes for the amplification andinsertion of natural CDR regions into Acceptor Frameworks.

FIG. 5 is an illustration depicting the germline gene sequences of thevariable heavy and light chain domain selected for the generation ofAcceptor Frameworks.

FIG. 6 is a schematic representation of an amplification strategy usedfor the generation of Acceptor Frameworks by addition to the germlinesequences of a stuffer fragment and a FR4 region.

FIG. 7, top panel, is an illustration depicting the sequence detail ofStuffer fragments of VH acceptor Framework. DNA sequences recognized andcleaved by the restriction enzyme BsmBI are boxed in red and blackrespectively and indicated in the lower panel of the figure. The readingframe corresponding to the antibody variable sequence is underlined.

FIG. 8 is an illustration depicting the sequences of the 20 AcceptorFrameworks.

FIG. 9 is a schematic representation of the pNDS1 vector alone orcombined with a dummy heavy chain variable region or a dummy lightvariable region.

FIG. 10 is a table depicting the sequences of CDRH3 sequences that wereretrieved from a human cDNA source and inserted into human AcceptorFrameworks.

FIG. 11 is a table representing the design of synthetic CDR sequencesfor VH, VK and Vλ. The positions are numbered according to the Kabatnumbering scheme. The theoretical diversity of the CDR using a definedcodon diversification strategy (NNS, DVK, NVT, DVT) is indicated. Thestrategies adopted for VH CDR synthesis are boxed.

FIG. 12 is a schematic representation and sequence detail of syntheticCDR insertion into an Acceptor Framework.

FIG. 13 is a schematic representation of Primary libraries and the chainrecombination performed to generate Secondary libraries.

FIG. 14 is a schematic representation of the generation of Acceptor VHlibraries combined with VL synthetic libraries and the capture of CDRH3repertoires of human or non-human origin.

FIG. 15 is a schematic representation of the MnA, MiB and MiC librarygeneration using the CDRH3 repertoire from naïve mice or mice immunizedwith hIFNγ or hCCL5/RANTES as a source of diversity. The size of thelibraries is indicated in the top panels. The bottom panels show thedistribution of CDRH3 lengths found in these libraries.

FIG. 16 is a series of graphs depicting phage output titration duringselection against hIFNγ with the secondary libraries AD1 and AE1.

FIG. 17 is a series of graphs depicting phage output titration duringselection against monoclonal antibody 5E3 with the secondary librariesAD1 and AE1.

FIG. 18 is a series of graphs depicting the frequency of CDR H3 lengthsfound in the AE1 and AD1 libraries and after three rounds of selectionagainst the monoclonal antibody 5E3. The distribution of each CDR H3length within the different VH families is indicated. However, when CDRH3 are longer than 16 amino acids, the 70 bp sequences delivered by theIllumina Sequencing platform do not cover enough framework sequence tounambiguously identify the VH1 family and therefore the VH family isindicated as undetermined.

FIG. 19 is a series of graphs depicting dose response ELISA usingpurified 6 scFv preparations against mouse 5E3 or an irrelevant mouseantibody 1A6. The seven clones encode different scFvs. Clone A6 is ascFv specific for hIFNγ and was used as a negative control.

FIG. 20 is a graph that depicts dose response ELISA using purified scFvpreparations against hIFNγ and compared to a positive scFv specific forhIFNγ (A6).

FIG. 21 is a graph that depicts the inhibitory effect of purified scFvpreparations in a luciferase reporter gene assay driven by hIFNγ. Theneutralizing activity of two scFv candidates (AD1R4P1A9 and AE14R3P2E4)was compared to the activity of a positive control scFv (G9) and anegative control scFv (D11).

FIG. 22 is a graph that depicts the inhibitory effect of purified scFvpreparations in a MHCII induction assay in response to hIFNγ. Theneutralizing activity of two scFv candidates (AD1R4P1A9 and AE14R3P2E4)was compared to the activity of a negative control scFv (D11).

FIG. 23 is a series of graphs depicting the inhibitory effect of the twocandidates AD1R4P1A9 and AE14R3P2E4 reformatted into IgG in a luciferasereporter gene assay driven by hIFNγ. The neutralizing activity of twoIgGs was compared to the activity of an irrelevant IgG directed againsthuman RANTES (NI-0701).

FIG. 24 is a series of graphs depicting a dose response ELISA using theIgG G11 and DA4 against mouse 5E3, chimeric rat 5E3 and thecorresponding mouse and rat isotype antibodies.

FIG. 25 is a series of graphs depicting an ELISA for the detection ofmouse 5E3 in different dilutions of mouse serum using the anti-idiotypicIgGs G11 and DA4 as capture antibodies.

FIG. 26 is a graph that depicts phage output/input ratios duringselection against hIFNγ with the libraries MnA and MiB.

FIG. 27 is a graph depicting the hit rates obtained in a scFv ELISAscreening with clones derived from the MnA, MiB and MiC libraries aftereach round of selection against hIFNγ. The threshold was set to half thesignal obtained with the A6 control scFv.

FIG. 28 is a graph that represents the distribution frequency of scFvgiving different levels of signal in binding experiments against hIFNγobtained with clones derived from the MnA and MiB libraries.

FIG. 29 is a graph that depicts dose response ELISA using purified scFvpreparations from clones derived from the MnA and MiB libraries againsthIFNγ and compared to a positive scFv specific for hIFNγ (A6).

DETAILED DESCRIPTION OF THE INVENTION

Synthetic protein libraries and in particular synthetic antibodylibraries are attractive as it is possible during the library generationprocess to select the building blocks composing these synthetic proteinsand include desired characteristics. An important limitation, however,is that the randomization of portions of these synthetic proteins togenerate a collection of variants often leads to non-functional proteinsand thus can dramatically decrease the functional library size and itsperformance. Another limitation of synthetic diversity is that thelibrary size needed to cover the theoretical diversity of randomizedamino acid stretches cannot be covered because of practical limitations.Even with display systems such as ribosome display a diversity of 10¹³to 10¹⁴ can be generated and sampled which can maximally cover thecomplete randomization of stretches of 9 amino acids. As the averagesize of natural CDR H3 (also referred to herein as the heavy chain CDR3or VH CDR3) is above 9 and can be over 20 amino acids in length,synthetic diversity is not a practicable approach to generate such CDRs.

The combination of methods generally used for DNA handling and that areused in the course of the generation of a library of protein variantsintroduces errors in the DNA sequences. These errors can lead toalterations in the reading frame of the DNA that will no longer encode afunctional polypeptide. Typically, antibody libraries generated usingassembly of DNA fragments by PCR and/or restriction cloning containbetween 15% and 45% sequences that are not in the correct reading framefor protein translation. These non-functional library members cancompromise the efficiency of the antibody selection and identificationprocess and are thus recognized as a limitation in the field. Themethods described allow for a more robust introduction of diversity intoan antibody library by using an alternative cloning strategy. Typicallythe frequency of in-frame sequences is approximately 90%. Anotheradvantage of the invention is that it combines selected acceptorantibody variable frameworks with CDR loops that have a high probabilityof correct folding. It allows for the capture of long CDRs that aredifficult to cover with synthetic randomization approaches. Furthermorethe methods described do not employ any modification within the codingregion of acceptor antibody variable for cloning of the diversifiedsequences. Another advantage of this method is that several sources ofdiversity can be captured into the same set of acceptor antibodyframeworks. These sources include but are not limited to: naturalantibody CDRs of human or other mammal origin, CDR from chickenantibodies, CDRs of antibody-like molecules such as VHH from camelids,IgNARs from sharks, variable loops from T cell receptors. In addition,natural CDRs can be derived from naïve or immunized animals. In thelatter case, the CDRs retrieved are enriched in sequences that wereinvolved in recognition of the antigen used for immunization.

A unique feature of the methods described herein is the efficientcapture of heavy chain CDR3 coding sequences from non-human species andtheir insertion into human immunoglobulin frameworks. Using thesemethods, it is therefore possible to generate different antibodycombining sites that are shaped by the captured CDRH3 repertoire fromanother species and allow for the sampling of a different tridimensional space. These methods allow for the generation of humanantibodies with novel specificities targeting a different range oftarget classes and epitopes than those accessible to a human CDRH3repertoire. Furthermore, these novel antibodies encode human frameworkas well as CDR1 and CDR2 regions and thus are suitable for humantherapy.

In this method selected protein domains, as exemplified by antibodyvariable domains, are modified by introducing a stuffer sequence thatwill serve as an integration site for diversified sequences. Uponintegration, the stuffer fragment is removed in full, thus leavingintact the coding region of the acceptor protein and the insertedproteins fragments (i.e., the CDRs). This integration event is mediatedby a the use of Type IIs restriction enzyme that recognizes a definedsite in the DNA sequence but cleave the DNA at a defined distance fromthis site. This approach has two major advantages: (1) it allows for thedigestion of acceptors framework without affecting their codingsequences (no need to engineer silent restrictions sites); and (2) itallows for the digestion and cloning of naturally diversified sequencesthat by definition do not possess compatible restriction sites.

As described above, prior attempts to generate libraries and/or displaysof antibody sequences differ from the methods provided herein. Forexample, some methods require the grafting of each CDR, as described forexample by U.S. Pat. No. 6,300,064, in which restriction enzyme sitesare engineered at the boundary of each CDR, not just the CDR H3 region.In other methods, CDR sequences from natural sources are amplified andrearranged, as described in, e.g., U.S. Pat. No. 6,989,250. In somemethods, such as those described in US Patent Application PublicationNo. 20060134098, sequences from a mouse (or other mammal) is added to ahuman framework, such that the resulting antibody has CDR1 and CDR2regions of murine origin and a CDR3 region of human origin. Othermethods, such as those described in US Patent Application PublicationNo. 20030232333, generate antibodies that have synthetic CDR1 and/orCDR1/CDR2 regions along with a natural CDR3 region. However, thesemethods fail to provide libraries that contain stable framework regionsand correctly folded CDRs.

The methods provided herein design the antibody acceptor frameworks fordiversity cloning. A strategy was designed to introduce diversity intothe CDR3 of selected human antibody domains that avoids the modificationof the sequence of the original framework. The strategy relies on theintroduction outside of the immunoglobulin coding region of Type IIsrestriction sites. This class of restriction enzymes recognizesasymmetric and uninterrupted sequence of 4-7 base pairs but cleave DNAat a defined distance of up to 20 bases independently of the DNAsequence found at the cleavage site. In order to take advantage of thissystem for cloning of diversified sequences into selected frameworks,acceptor frameworks containing a stuffer DNA fragment, instead of theCDR3, that includes two Type IIs restriction sites were designed.Similarly, diversified DNA sequences are generated with flankingsequences that include Type IIs. Provided that the cohesive endsgenerated by the restriction enzymes are compatible and that readingframe is maintained, the DNA fragments can be ligated into the acceptorframework and restore the encoded CDR3 in the new context of theacceptor antibody framework (FIG. 2).

The methods provided herein capture natural CDR diversity. The strategythat was developed to capture naturally diversified protein fragments asa source of diversity also takes advantage of Type IIs restrictionenzymes. As an example, oligonucleotides primers specific for flankingregions of the DNA sequence encoding the CDR H3 of immunoglobulins,i.e., specific for the FR3 and FR4 of the variable region, weredesigned. These oligonucleotides contain at their 5′ end a site for aType IIs restriction enzyme whereas their 3′ portion matches thetargeted DNA sequence. The restriction enzyme site used is preferably anenzyme that cleaves DNA far away from the DNA recognition site such asFokI. This is a key element of the method as it allows for the efficientamplification of natural DNA sequences as it maintains a good matchbetween the 3′ end of the primer and the DNA flanking the CDR H3 whileallowing for excision of the CDRH3 coding sequence by DNA cleavage atthe boundary between the CDR and framework regions (FIG. 3). Thisprecise excision of the CDR coding sequence is very difficult using TypeII enzymes that cleave DNA at their recognition site as thecorresponding restriction site is not present in the natural DNAsequences and that introduction of such sites during amplification wouldbe difficult due poor primer annealing. Thus this method allows for theamplification of diversified protein sequences and their insertion intoany the acceptor antibody framework regardless of origin of amplifieddiversity (FIG. 4).

The methods described herein produce a library of nucleic acids, whereineach nucleic acid encodes an immunoglobulin variable domain by: (a)providing a plurality of Acceptor Framework nucleic acid sequencesencoding distinct immunoglobulin variable domains, each AcceptorFramework nucleic acid sequence including a first framework region(FR1), a second framework region (FR2), a third framework region (FR3),and a fourth framework region (FR4), wherein the FR1 and FR2 regions areinterspaced by a complementarity determining region 1 (CDR1), the FR2and FR3 regions are interspaced by a complementarity determining region2 (CDR2), and the FR3 and FR4 regions are interspaced by a stuffernucleic acid sequence containing at least two Type IIs restrictionenzyme recognition sites interspaced by a random nucleic acid sequence;(b) providing a plurality of diversified nucleic acid sequences encodingcomplementarity determining region 3 (CDR3) regions or encoding aminoacid sequences that can fulfill the role of a CDR3 region, wherein eachof the plurality of diversified nucleic acid sequences includes a TypeIIs restriction enzyme recognition site at each extremity; (c) digestingeach of the plurality of nucleic acid sequences encoding the CDR3regions or amino acid sequences that can fulfill the role of a CDR3region using a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (b) and digesting thestuffer nucleic acid sequence of step (a) from the Acceptor Frameworkusing a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (a); and (d) ligating thedigested nucleic acid sequences encoding the CDR3 regions or the aminoacid sequences that can fulfill the role of a CDR3 region of step (c)into the digested Acceptor Framework of step (c) such that the FR3 andFR4 regions are interspaced by the nucleic acid sequences encoding theCDR3 region or the amino acid sequence that can fulfill the role of aCDR3 region and a complete immunoglobulin variable domain encodingsequences that do not contain the Type IIs restriction enzymerecognition sites of steps (a) and (b) are restored.

The methods provided herein produce a method for producing a library ofnucleic acids, wherein each nucleic acid encodes an immunoglobulinvariable domain by: (a) providing a plurality of Acceptor Frameworknucleic acid sequences encoding distinct immunoglobulin variabledomains, each Acceptor Framework nucleic acid sequence including a firstframework region (FR1), a second framework region (FR2), a thirdframework region (FR3), and a fourth framework region (FR4), wherein theFR1 and FR2 regions are interspaced by a stuffer nucleic acid sequencecontaining at least two Type IIs restriction enzyme recognition sitesinterspaced by a random nucleic acid sequence, the FR2 and FR3 regionsare interspaced by a complementarity determining region 2 (CDR2), andthe FR3 and FR4 regions are interspaced by a complementarity determiningregion 3 (CDR3); (b) providing a plurality of diversified nucleic acidsequences encoding complementarity determining region 1 (CDR1) regionsor encoding amino acid sequences that can fulfill the role of a CDR1region, wherein each of the plurality of diversified nucleic acidsequences includes a Type IIs restriction enzyme recognition site ateach extremity; (c) digesting each of the plurality of nucleic acidsequences encoding the CDR1 regions or amino acid sequences that canfulfill the role of a CDR1 region using a Type IIs restriction enzymethat binds to the Type IIs restriction enzyme recognition site of step(b) and digesting the stuffer nucleic acid sequence of step (a) from theAcceptor Framework using a Type IIs restriction enzyme that binds to theType IIs restriction enzyme recognition site of step (a); and (d)ligating the digested nucleic acid sequences encoding the CDR1 regionsor the amino acid sequences that can fulfill the role of a CDR1 regionof step (c) into the digested Acceptor Framework of step (c) such thatthe FR1 and FR2 regions are interspaced by the nucleic acid sequencesencoding the CDR1 region or the amino acid sequence that can fulfill therole of a CDR1 region and a complete immunoglobulin variable domainencoding sequences that do not contain the Type IIs restriction enzymerecognition sites of steps (a) and (b) are restored.

The methods provided herein produce a library of nucleic acids, whereineach nucleic acid encodes an immunoglobulin variable domain, by: (a)providing a plurality of Acceptor Framework nucleic acid sequencesencoding distinct immunoglobulin variable domains, each AcceptorFramework nucleic acid sequence including a first framework region(FR1), a second framework region (FR2), a third framework region (FR3),and a fourth framework region (FR4), wherein the FR1 and FR2 regions areinterspaced by a complementarity determining region 1 (CDR1), the FR2and FR3 regions are interspaced by a stuffer nucleic acid sequenceincluding at least two Type IIs restriction enzyme recognition sitesinterspaced by a random nucleic acid sequence, and the FR3 and FR4regions are interspaced by a complementarity determining region 3(CDR3); (b) providing a plurality of diversified nucleic acid sequencesencoding complementarity determining region 2 (CDR2) regions or encodingamino acid sequences that can fulfill the role of a CDR2 region, whereineach of the plurality of diversified nucleic acid sequences includes aType IIs restriction enzyme recognition site at each extremity; (c)digesting each of the plurality of nucleic acid sequences encoding theCDR2 regions or amino acid sequences that can fulfill the role of a CDR2region using a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (b) and digesting thestuffer nucleic acid sequence of step (a) from the Acceptor Frameworkusing a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (a); and (d) ligating thedigested nucleic acid sequences encoding the CDR2 regions or the aminoacid sequences that can fulfill the role of a CDR2 region of step (c)into the digested Acceptor Framework of step (c) such that the FR2 andFR3 regions are interspaced by the nucleic acid sequences encoding theCDR2 region or the amino acid sequence that can fulfill the role of aCDR2 region and a complete immunoglobulin variable domain encodingsequences that do not contain the Type IIs restriction enzymerecognition sites of steps (a) and (b) are restored.

In some embodiments, the Type IIs restriction enzyme recognition sitesof step (a) and step (b) in the methods set forth above are recognizedby a different Type IIs restriction enzyme. For example, in someembodiments, the Type IIs restriction enzyme recognition sites are BsmBIrecognition sites, BsaI recognition sites, FokI recognition sites or acombination thereof.

In some embodiments, the Acceptor Framework nucleic acid sequence isderived from a human gene sequence. For example, in some embodiments,the human sequence is a human heavy chain variable gene sequence or asequence derived from a human heavy chain variable gene sequence. Insome embodiments, the human heavy chain variable gene sequence isselected from VH1-2, VH1-69, VH1-18, VH3-30, VH3-48, VH3-23, and VH5-51.

In some embodiments, the human sequence is a human kappa light chainvariable gene sequence or a sequence derived from a human kappa lightchain variable gene sequence. For example, in some embodiments, thehuman kappa light chain variable gene sequence is selected from VK1-33,VK1-39, VK3-11, VK3-15, and VK3-20.

In some embodiments, the human sequence is a human lambda light chainvariable gene sequence or a sequence derived from a human lambda lightchain variable gene sequence. For example, in some embodiments, thehuman lambda light chain variable gene sequence is selected from VL1-44and VL1-51.

In some embodiments, the plurality of diversified nucleic acids includesor is derived from sequences selected from naturally occurring CDR3sequences, naturally occurring Ig sequences from humans, naturallyoccurring Ig sequences from a mammal, naturally occurring sequences froma loop region of a T cell receptor in a mammal, and other naturallydiversified polypeptide collections.

In some embodiments, the plurality of diversified nucleic acids encodesCDR3 regions, and the plurality of diversified nucleic acids includes oris derived from immunoglobulin sequences that occur naturally in humansthat have been exposed to a particular immunogen or sequences derivedfrom animals that have been identified as having been exposed to aparticular antigen.

In some embodiments, the plurality of diversified nucleic acids encodesamino acid sequences that can fulfill the role of a CDR3 region, and theplurality of diversified nucleic acids includes synthetic sequences.

In some embodiments, the plurality of diversified nucleic acids includesor is derived from sequences selected from naturally occurring CDR1sequences, naturally occurring Ig sequences from humans, naturallyoccurring Ig sequences from a mammal, naturally occurring sequences froma loop region of a T cell receptor in a mammal, and other naturallydiversified polypeptide collections.

In some embodiments, the plurality of diversified nucleic acids encodesCDR1 regions, and the plurality of diversified nucleic acids includes oris derived from immunoglobulin sequences that occur naturally in humansthat have been exposed to a particular immunogen or sequences derivedfrom animals that have been identified as having been exposed to aparticular antigen.

In some embodiments, the plurality of diversified nucleic acids encodesamino acid sequences that can fulfill the role of a CDR1 region, and theplurality of diversified nucleic acids includes synthetic sequences.

In some embodiments, the plurality of diversified nucleic acids includesor is derived from sequences selected from naturally occurring CDR2sequences, naturally occurring Ig sequences from humans, naturallyoccurring Ig sequences from a mammal, naturally occurring sequences froma loop region of a T cell receptor in a mammal, and other naturallydiversified polypeptide collections.

In some embodiments, the plurality of diversified nucleic acids encodesCDR2 regions, and the plurality of diversified nucleic acids includes oris derived from immunoglobulin sequences that occur naturally in humansthat have been exposed to a particular immunogen or sequences derivedfrom animals that have been identified as having been exposed to aparticular antigen.

In some embodiments, the plurality of diversified nucleic acids encodesamino acid sequences that can fulfill the role of a CDR2 region, and theplurality of diversified nucleic acids includes synthetic sequences.

In some embodiments, the plurality of Acceptor Framework nucleic acidsequences includes a mixture of at least one variable heavy chain (VH)Acceptor Framework nucleic acid sequence and at least one variable lightchain Acceptor Framework nucleic acid sequence.

In some embodiments, the methods provided herein further include thesteps of (e) cloning the library of nucleic acids encodingimmunoglobulin variable domains of step (d) into an expression vectorand (f) transforming the expression vector of step (e) into a host celland culturing the host cell under conditions sufficient to express aplurality of immunoglobulin variable domain encoded by the library.

In some embodiments, the host cell is E. coli. In some embodiments, theexpression vector is a phagemid vector.

The methods provided herein generate or otherwise produce atarget-specific antibody, antibody variable region or a portion thereof,by: (a) providing a plurality of Acceptor Framework nucleic acidsequences encoding distinct immunoglobulin variable domains, eachAcceptor Framework nucleic acid sequence including a first frameworkregion (FR1), a second framework region (FR2), a third framework region(FR3), and a fourth framework region (FR4), wherein the FR1 and FR2regions are interspaced by a complementarity determining region 1(CDR1), the FR2 and FR3 regions are interspaced by a complementaritydetermining region 2 (CDR2), and the FR3 and FR4 regions are interspacedby a stuffer nucleic acid sequence having at least two Type IIsrestriction enzyme recognition sites interspaced by a random nucleicacid sequence; (b) providing a plurality of diversified nucleic acidsequences encoding complementarity determining region 3 (CDR3) regionsor encoding amino acid sequences that can fulfill the role of a CDR3region, wherein each of the plurality of diversified nucleic acidsequences includes a Type IIs restriction enzyme recognition site ateach extremity; (c) digesting each of the plurality of nucleic acidsequences encoding the CDR3 regions or amino acid sequences that canfulfill the role of a CDR3 region using a Type IIs restriction enzymethat binds to the Type IIs restriction enzyme recognition site of step(b) and digesting the stuffer nucleic acid sequence of step (a) from theAcceptor Framework using a Type IIs restriction enzyme that binds to theType IIs restriction enzyme recognition site of step (a); (d) ligatingthe digested nucleic acid sequences encoding the CDR3 regions or theamino acid sequences that can fulfill the role of a CDR3 region of step(c) into the digested Acceptor Framework of step (c) such that the FR3and FR4 regions are interspaced by the nucleic acid sequences encodingthe CDR3 region or the amino acid sequence that can fulfill the role ofa CDR3 region and complete immunoglobulin variable domain encodingsequences that do not contain the Type IIs restriction enzymerecognition sites of steps (a) and (b) are restored; (e) cloning thelibrary of nucleic acids encoding immunoglobulin variable domains ofstep (d) into an expression vector; (f) transforming the expressionvector of step (e) into a host cell and culturing the host cell underconditions sufficient to express a plurality of immunoglobulin variabledomains encoded by the library; (g) contacting the plurality ofimmunoglobulin domains of step (f) with a target antigen; and (h)determining which expressed immunoglobulin variable domain encodingsequences bind to the target antigen.

The methods provided herein generate or otherwise produce atarget-specific antibody, antibody variable region or a portion thereof,by: (a) providing a plurality of Acceptor Framework nucleic acidsequences encoding distinct immunoglobulin variable domains, eachAcceptor Framework nucleic acid sequence including a first frameworkregion (FR1), a second framework region (FR2), a third framework region(FR3), and a fourth framework region (FR4), wherein the FR1 and FR2regions are interspaced by a stuffer nucleic acid sequence including atleast two Type IIs restriction enzyme recognition sites interspaced by arandom nucleic acid sequence, the FR2 and FR3 regions are interspaced bya complementarity determining region 2 (CDR2), and the FR3 and FR4regions are interspaced by a complementarity determining region 3(CDR3); (b) providing a plurality of diversified nucleic acid sequencesencoding complementarity determining region 1 (CDR1) regions or encodingamino acid sequences that can fulfill the role of a CDR1 region, whereineach of the plurality of diversified nucleic acid sequences includes aType IIs restriction enzyme recognition site at each extremity; (c)digesting each of the plurality of nucleic acid sequences encoding theCDR1 regions or amino acid sequences that can fulfill the role of a CDR1region using a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (b) and digesting thestuffer nucleic acid sequence of step (a) from the Acceptor Frameworkusing a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (a); (d) ligating thedigested nucleic acid sequences encoding the CDR1 regions or the aminoacid sequences that can fulfill the role of a CDR1 region of step (c)into the digested Acceptor Framework of step (c) such that the FR1 andFR2 regions are interspaced by the nucleic acid sequences encoding theCDR1 region or the amino acid sequence that can fulfill the role of aCDR1 region and complete immunoglobulin variable domain encodingsequences that do not contain the Type IIs restriction enzymerecognition sites of steps (a) and (b) are restored; (e) cloning thelibrary of nucleic acids encoding immunoglobulin variable domains ofstep (d) into an expression vector; (f) transforming the expressionvector of step (e) into a host cell and culturing the host cell underconditions sufficient to express a plurality of immunoglobulin variabledomains encoded by the library; (g) contacting the plurality ofimmunoglobulin domains of step (f) with a target antigen; and (g)determining which expressed immunoglobulin variable domain encodingsequences bind to the target antigen.

The methods provided herein generate or otherwise produce atarget-specific antibody, antibody variable region or a portion thereof,by: (a) providing a plurality of Acceptor Framework nucleic acidsequences encoding distinct immunoglobulin variable domains, eachAcceptor Framework nucleic acid sequence including a first frameworkregion (FR1), a second framework region (FR2), a third framework region(FR3), and a fourth framework region (FR4), wherein the FR1 and FR2regions are interspaced by a complementarity determining region 1(CDR1), the FR2 and FR3 regions are interspaced by a stuffer nucleicacid sequence including at least two Type IIs restriction enzymerecognition sites interspaced by a random nucleic acid sequence, and theFR3 and FR4 regions are interspaced by a complementarity determiningregion 3 (CDR3); (b) providing a plurality of diversified nucleic acidsequences encoding complementarity determining region 2 (CDR2) regionsor encoding amino acid sequences that can fulfill the role of a CDR2region, wherein each of the plurality of diversified nucleic acidsequences includes a Type IIs restriction enzyme recognition site ateach extremity; (c) digesting each of the plurality of nucleic acidsequences encoding the CDR2 regions or amino acid sequences that canfulfill the role of a CDR2 region using a Type IIs restriction enzymethat binds to the Type IIs restriction enzyme recognition site of step(b) and digesting the stuffer nucleic acid sequence of step (a) from theAcceptor Framework using a Type IIs restriction enzyme that binds to theType IIs restriction enzyme recognition site of step (a); (d) ligatingthe digested nucleic acid sequences encoding the CDR2 regions or theamino acid sequences that can fulfill the role of a CDR2 region of step(c) into the digested Acceptor Framework of step (c) such that the FR2and FR3 regions are interspaced by the nucleic acid sequences encodingthe CDR2 region or the amino acid sequence that can fulfill the role ofa CDR2 region and complete immunoglobulin variable domain encodingsequences that do not contain the Type IIs restriction enzymerecognition sites of steps (a) and (b) are restored; (e) cloning thelibrary of nucleic acids encoding immunoglobulin variable domains ofstep (d) into an expression vector; (f) transforming the expressionvector of step (e) into a host cell and culturing the host cell underconditions sufficient to express a plurality of immunoglobulin variabledomains encoded by the library; (g) contacting the plurality ofimmunoglobulin variable domains of step (f) with a target antigen; and(h) determining which expressed immunoglobulin variable domain encodingsequences bind to the target antigen.

In some embodiments, the methods provided herein further include thestep of (i) sequencing the immunoglobulin variable domain encodingsequences that bind the target antigen.

In some embodiments, the Type IIs restriction enzyme recognition sitesof step (a) and step (b) are recognized by a different Type IIsrestriction enzyme.

In some embodiments, the Type IIs restriction enzyme recognition sitesare BsmBI recognition sites, BsaI recognition sites, FokI recognitionsites or a combination thereof.

In some embodiments, the Acceptor Framework nucleic acid sequence isderived from a human gene sequence. For example, in some embodiments,the human sequence is a human heavy chain variable gene sequence or asequence derived from a human heavy chain variable gene sequence. Forexample, in some embodiments, the human heavy chain variable genesequence is selected from VH1-2, VH1-69, VH1-18, VH3-30, VH3-48, VH3-23,and VH5-51.

In some embodiments, the human sequence is a human kappa light chainvariable gene sequence or a sequence derived from a human kappa lightchain variable gene sequence. For example, in some embodiments, thehuman kappa light chain variable gene sequence is selected from VK1-33,VK1-39, VK3-11, VK3-15, and VK3-20.

In some embodiments, the human sequence is a human lambda light chainvariable gene sequence or a sequence derived from a human lambda lightchain variable gene sequence. For example, in some embodiments, thehuman lambda light chain variable gene sequence is selected from VL1-44and VL1-51.

In some embodiments, the plurality of diversified nucleic acids includesor is derived from sequences selected from naturally occurring CDR3sequences, naturally occurring Ig sequences from humans, naturallyoccurring Ig sequences from a mammal, naturally occurring sequences froma loop region of a T cell receptor in a mammal, and other naturallydiversified polypeptide collections.

In some embodiments, the plurality of diversified nucleic acids encodesCDR3 regions, and the plurality of diversified nucleic acids includes oris derived from immunoglobulin sequences that occur naturally in humansthat have been exposed to a particular immunogen or sequences derivedfrom animals that have been identified as having been exposed to aparticular antigen.

In some embodiments, the plurality of diversified nucleic acids encodesamino acid sequences that can fulfill the role of a CDR3 region, and theplurality of diversified nucleic acids includes synthetic sequences.

In some embodiments, the plurality of diversified nucleic acids includesor is derived from sequences selected from naturally occurring CDR1sequences, naturally occurring Ig sequences from humans, naturallyoccurring Ig sequences from a mammal, naturally occurring sequences froma loop region of a T cell receptor in a mammal, and other naturallydiversified polypeptide collections.

In some embodiments, the plurality of diversified nucleic acids encodesCDR1 regions, and the plurality of diversified nucleic acids includes oris derived from immunoglobulin sequences that occur naturally in humansthat have been exposed to a particular immunogen or sequences derivedfrom animals that have been identified as having been exposed to aparticular antigen.

In some embodiments, the plurality of diversified nucleic acids encodesamino acid sequences that can fulfill the role of a CDR1 region, and theplurality of diversified nucleic acids includes synthetic sequences.

In some embodiments, the plurality of diversified nucleic acids includedor is derived from sequences selected from naturally occurring CDR2sequences, naturally occurring Ig sequences from humans, naturallyoccurring Ig sequences from a mammal, naturally occurring sequences froma loop region of a T cell receptor in a mammal, and other naturallydiversified polypeptide collections.

In some embodiments, the plurality of diversified nucleic acids encodesCDR2 regions, and the plurality of diversified nucleic acids includes oris derived from immunoglobulin sequences that occur naturally in humansthat have been exposed to a particular immunogen or sequences derivedfrom animals that have been identified as having been exposed to aparticular antigen.

In some embodiments, the plurality of Acceptor Framework nucleic acidsequences includes a mixture of at least one variable heavy chain (VH)Acceptor Framework nucleic acid sequence and at least one variable lightchain Acceptor Framework nucleic acid sequence.

In some embodiments, the expression vector is a phagemid vector. In someembodiments, the host cell is E. coli.

Unless otherwise defined, scientific and technical terms used inconnection with the present invention shall have the meanings that arecommonly understood by those of ordinary skill in the art. Further,unless otherwise required by context, singular terms shall includepluralities and plural terms shall include the singular. Generally,nomenclatures utilized in connection with, and techniques of, cell andtissue culture, molecular biology, and protein and oligo- orpolynucleotide chemistry and hybridization described herein are thosewell known and commonly used in the art. Standard techniques are usedfor recombinant DNA, oligonucleotide synthesis, and tissue culture andtransformation (e.g., electroporation, lipofection). Enzymatic reactionsand purification techniques are performed according to manufacturer'sspecifications or as commonly accomplished in the art or as describedherein. The foregoing techniques and procedures are generally performedaccording to conventional methods well known in the art and as describedin various general and more specific references that are cited anddiscussed throughout the present specification. See e.g., Sambrook etal. Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring HarborLaboratory Press, Cold Spring Harbor, N.Y. (1989)). The nomenclaturesutilized in connection with, and the laboratory procedures andtechniques of, analytical chemistry, synthetic organic chemistry, andmedicinal and pharmaceutical chemistry described herein are those wellknown and commonly used in the art. Standard techniques are used forchemical syntheses, chemical analyses, pharmaceutical preparation,formulation, and delivery, and treatment of patients.

As utilized in accordance with the present disclosure, the followingterms, unless otherwise indicated, shall be understood to have thefollowing meanings:

As used herein, the term “antibody” refers to immunoglobulin moleculesand immunologically active portions of immunoglobulin (Ig) molecules,i.e., molecules that contain an antigen binding site that specificallybinds (immunoreacts with) an antigen. By “specifically bind” or“immunoreacts with” or “immunospecifically bind” is meant that theantibody reacts with one or more antigenic determinants of the desiredantigen and does not react with other polypeptides or binds at muchlower affinity (K_(d)>10⁻⁶). Antibodies include, but are not limited to,polyclonal, monoclonal, chimeric, dAb (domain antibody), single chain,F_(ab), F_(ab′) and F_((ab′)2) fragments, scFvs, and an F_(ab)expression library.

The basic antibody structural unit is known to comprise a tetramer. Eachtetramer is composed of two identical pairs of polypeptide chains, eachpair having one “light” (about 25 kDa) and one “heavy” chain (about50-70 kDa). The amino-terminal portion of each chain includes a variableregion of about 100 to 110 or more amino acids primarily responsible forantigen recognition. The carboxy-terminal portion of each chain definesa constant region primarily responsible for effector function. Ingeneral, antibody molecules obtained from humans relate to any of theclasses IgG, IgM, IgA, IgE and IgD, which differ from one another by thenature of the heavy chain present in the molecule. Certain classes havesubclasses as well, such as IgG₁, IgG₂, and others. Furthermore, inhumans, the light chain may be a kappa chain or a lambda chain.

The term “monoclonal antibody” (MAb) or “monoclonal antibodycomposition”, as used herein, refers to a population of antibodymolecules that contain only one molecular species of antibody moleculeconsisting of a unique light chain gene product and a unique heavy chaingene product. In particular, the complementarity determining regions(CDRs) of the monoclonal antibody are identical in all the molecules ofthe population. MAbs contain an antigen binding site capable ofimmunoreacting with a particular epitope of the antigen characterized bya unique binding affinity for it.

The term “antigen-binding site,” or “binding portion” refers to the partof the immunoglobulin molecule that participates in antigen binding. Theantigen binding site is formed by amino acid residues of the N-terminalvariable (“V”) regions of the heavy (“H”) and light (“L”) chains. Threehighly divergent stretches within the V regions of the heavy and lightchains, referred to as “hypervariable regions,” are interposed betweenmore conserved flanking stretches known as “framework regions,” or“FRs”. Thus, the term “FR” refers to amino acid sequences which arenaturally found between, and adjacent to, hypervariable regions inimmunoglobulins. In an antibody molecule, the three hypervariableregions of a light chain and the three hypervariable regions of a heavychain are disposed relative to each other in three dimensional space toform an antigen-binding surface. The antigen-binding surface iscomplementary to the three-dimensional surface of a bound antigen, andthe three hypervariable regions of each of the heavy and light chainsare referred to as “complementarity-determining regions,” or “CDRs.” Theassignment of amino acids to each domain is in accordance with thedefinitions of Kabat Sequences of Proteins of Immunological Interest(National Institutes of Health, Bethesda, Md. (1987 and 1991)), orChothia & Lesk J. Mol. Biol. 196:901-917 (1987), Chothia et al. Nature342:878-883 (1989).

As used herein, the term “epitope” includes any protein determinantcapable of specific binding to an immunoglobulin, an scFv, or a T-cellreceptor. The term “epitope” includes any protein determinant capable ofspecific binding to an immunoglobulin or T-cell receptor. Epitopicdeterminants usually consist of chemically active surface groupings ofmolecules such as amino acids or sugar side chains and usually havespecific three dimensional structural characteristics, as well asspecific charge characteristics. For example, antibodies may be raisedagainst N-terminal or C-terminal peptides of a polypeptide. An antibodyis said to specifically bind an antigen when the dissociation constantis ≦1 μM; e.g., ≦100 nM, preferably ≦10 nM and more preferably ≦1 nM.

As used herein, the terms “immunological binding,” and “immunologicalbinding properties” refer to the non-covalent interactions of the typewhich occur between an immunoglobulin molecule and an antigen for whichthe immunoglobulin is specific. The strength, or affinity ofimmunological binding interactions can be expressed in terms of thedissociation constant (K_(d)) of the interaction, wherein a smallerK_(d) represents a greater affinity. Immunological binding properties ofselected polypeptides can be quantified using methods well known in theart. One such method entails measuring the rates of antigen-bindingsite/antigen complex formation and dissociation, wherein those ratesdepend on the concentrations of the complex partners, the affinity ofthe interaction, and geometric parameters that equally influence therate in both directions. Thus, both the “on rate constant” (K_(on)) andthe “off rate constant” (K_(off)) can be determined by calculation ofthe concentrations and the actual rates of association and dissociation.(See Nature 361:186-87 (1993)). The ratio of K_(off)/K_(on) enables thecancellation of all parameters not related to affinity, and is equal tothe dissociation constant K_(d). (See, generally, Davies et al. (1990)Annual Rev Biochem 59:439-473). An antibody of the present invention issaid to specifically bind to its target, when the equilibrium bindingconstant (K_(d)) is ≦1 μM, e.g., ≦100 nM, preferably ≦10 nM, and morepreferably ≦1 nM, as measured by assays such as radioligand bindingassays or similar assays known to those skilled in the art.

The term “isolated polynucleotide” as used herein shall mean apolynucleotide of genomic, cDNA, or synthetic origin or some combinationthereof, which by virtue of its origin the “isolated polynucleotide” (1)is not associated with all or a portion of a polynucleotide in which the“isolated polynucleotide” is found in nature, (2) is operably linked toa polynucleotide which it is not linked to in nature, or (3) does notoccur in nature as part of a larger sequence. Polynucleotides inaccordance with the invention include the nucleic acid moleculesencoding the heavy chain immunoglobulin molecules, and nucleic acidmolecules encoding the light chain immunoglobulin molecules describedherein.

The term “isolated protein” referred to herein means a protein of cDNA,recombinant RNA, or synthetic origin or some combination thereof, whichby virtue of its origin, or source of derivation, the “isolated protein”(1) is not associated with proteins found in nature, (2) is free ofother proteins from the same source, e.g., free of marine proteins, (3)is expressed by a cell from a different species, or (4) does not occurin nature.

The term “polypeptide” is used herein as a generic term to refer tonative protein, fragments, or analogs of a polypeptide sequence. Hence,native protein fragments, and analogs are species of the polypeptidegenus. Polypeptides in accordance with the invention comprise the heavychain immunoglobulin molecules, and the light chain immunoglobulinmolecules described herein, as well as antibody molecules formed bycombinations comprising the heavy chain immunoglobulin molecules withlight chain immunoglobulin molecules, such as kappa light chainimmunoglobulin molecules, and vice versa, as well as fragments andanalogs thereof.

The term “naturally-occurring” as used herein as applied to an objectrefers to the fact that an object can be found in nature. For example, apolypeptide or polynucleotide sequence that is present in an organism(including viruses) that can be isolated from a source in nature andwhich has not been intentionally modified by man in the laboratory orotherwise is naturally-occurring.

The term “operably linked” as used herein refers to positions ofcomponents so described are in a relationship permitting them tofunction in their intended manner. A control sequence “operably linked”to a coding sequence is ligated in such a way that expression of thecoding sequence is achieved under conditions compatible with the controlsequences.

The term “control sequence” as used herein refers to polynucleotidesequences which are necessary to effect the expression and processing ofcoding sequences to which they are ligated. The nature of such controlsequences differs depending upon the host organism in prokaryotes, suchcontrol sequences generally include promoter, ribosomal binding site,and transcription termination sequence in eukaryotes, generally, suchcontrol sequences include promoters and transcription terminationsequence. The term “control sequences” is intended to include, at aminimum, all components whose presence is essential for expression andprocessing, and can also include additional components whose presence isadvantageous, for example, leader sequences and fusion partnersequences. The term “polynucleotide” as referred to herein means apolymeric boron of nucleotides of at least 10 bases in length, eitherribonucleotides or deoxynucleotides or a modified form of either type ofnucleotide. The term includes single and double stranded forms of DNA.

As used herein, the twenty conventional amino acids and theirabbreviations follow conventional usage. See Immunology—A Synthesis (2ndEdition, E. S. Golub and D. R. Gren, Eds., Sinauer Associates,Sunderland Mass. (1991)). Stereoisomers (e.g., D-amino acids) of thetwenty conventional amino acids, unnatural amino acids such as α-,α-disubstituted amino acids, N-alkyl amino acids, lactic acid, and otherunconventional amino acids may also be suitable components forpolypeptides of the present invention. Examples of unconventional aminoacids include: 4 hydroxyproline, γ-carboxyglutamate,ε-N,N,N-trimethyllysine, ε-N-acetyllysine, O-phosphoserine,N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine,σ-N-methylarginine, and other similar amino acids and imino acids (e.g.,4-hydroxyproline). In the polypeptide notation used herein, theleft-hand direction is the amino terminal direction and the right-handdirection is the carboxy-terminal direction, in accordance with standardusage and convention.

As applied to polypeptides, the term “substantial identity” means thattwo peptide sequences, when optimally aligned, such as by the programsGAP or BESTFIT using default gap weights, share at least 80 percentsequence identity, preferably at least 90 percent sequence identity,more preferably at least 95 percent sequence identity, and mostpreferably at least 99 percent sequence identity.

Preferably, residue positions which are not identical differ byconservative amino acid substitutions.

Conservative amino acid substitutions refer to the interchangeability ofresidues having similar side chains. For example, a group of amino acidshaving aliphatic side chains is glycine, alanine, valine, leucine, andisoleucine; a group of amino acids having aliphatic-hydroxyl side chainsis serine and threonine; a group of amino acids having amide-containingside chains is asparagine and glutamine; a group of amino acids havingaromatic side chains is phenylalanine, tyrosine, and tryptophan; a groupof amino acids having basic side chains is lysine, arginine, andhistidine; and a group of amino acids having sulfur-containing sidechains is cysteine and methionine. Preferred conservative amino acidssubstitution groups are: valine-leucine-isoleucine,phenylalanine-tyrosine, lysine-arginine, alanine valine,glutamic-aspartic, and asparagine-glutamine.

As discussed herein, minor variations in the amino acid sequences ofantibodies or immunoglobulin molecules are contemplated as beingencompassed by the present invention, providing that the variations inthe amino acid sequence maintain at least 75%, more preferably at least80%, 90%, 95%, and most preferably 99%. In particular, conservativeamino acid replacements are contemplated. Conservative replacements arethose that take place within a family of amino acids that are related intheir side chains. Genetically encoded amino acids are generally dividedinto families: (1) acidic amino acids are aspartate, glutamate; (2)basic amino acids are lysine, arginine, histidine; (3) non-polar aminoacids are alanine, valine, leucine, isoleucine, proline, phenylalanine,methionine, tryptophan, and (4) uncharged polar amino acids are glycine,asparagine, glutamine, cysteine, serine, threonine, tyrosine. Thehydrophilic amino acids include arginine, asparagine, aspartate,glutamine, glutamate, histidine, lysine, serine, and threonine. Thehydrophobic amino acids include alanine, cysteine, isoleucine, leucine,methionine, phenylalanine, proline, tryptophan, tyrosine and valine.Other families of amino acids include (i) serine and threonine, whichare the aliphatic-hydroxy family; (ii) asparagine and glutamine, whichare the amide containing family; (iii) alanine, valine, leucine andisoleucine, which are the aliphatic family; and (iv) phenylalanine,tryptophan, and tyrosine, which are the aromatic family. For example, itis reasonable to expect that an isolated replacement of a leucine withan isoleucine or valine, an aspartate with a glutamate, a threonine witha serine, or a similar replacement of an amino acid with a structurallyrelated amino acid will not have a major effect on the binding orproperties of the resulting molecule, especially if the replacement doesnot involve an amino acid within a framework site. Whether an amino acidchange results in a functional peptide can readily be determined byassaying the specific activity of the polypeptide derivative. Assays aredescribed in detail herein. Fragments or analogs of antibodies orimmunoglobulin molecules can be readily prepared by those of ordinaryskill in the art. Preferred amino- and carboxy-termini of fragments oranalogs occur near boundaries of functional domains. Structural andfunctional domains can be identified by comparison of the nucleotideand/or amino acid sequence data to public or proprietary sequencedatabases. Preferably, computerized comparison methods are used toidentify sequence motifs or predicted protein conformation domains thatoccur in other proteins of known structure and/or function. Methods toidentify protein sequences that fold into a known three-dimensionalstructure are known. Bowie et al. Science 253:164 (1991). Thus, theforegoing examples demonstrate that those of skill in the art canrecognize sequence motifs and structural conformations that may be usedto define structural and functional domains in accordance with theinvention.

Preferred amino acid substitutions are those which: (1) reducesusceptibility to proteolysis, (2) reduce susceptibility to oxidation,(3) alter binding affinity for forming protein complexes, (4) alterbinding affinities, and (4) confer or modify other physicochemical orfunctional properties of such analogs. Analogs can include variousmuteins of a sequence other than the naturally-occurring peptidesequence. For example, single or multiple amino acid substitutions(preferably conservative amino acid substitutions) may be made in thenaturally-occurring sequence (preferably in the portion of thepolypeptide outside the domain(s) forming intermolecular contacts. Aconservative amino acid substitution should not substantially change thestructural characteristics of the parent sequence (e.g., a replacementamino acid should not tend to break a helix that occurs in the parentsequence, or disrupt other types of secondary structure thatcharacterizes the parent sequence). Examples of art-recognizedpolypeptide secondary and tertiary structures are described in Proteins,Structures and Molecular Principles (Creighton, Ed., W. H. Freeman andCompany, New York (1984)); Introduction to Protein Structure (C. Brandenand J. Tooze, eds., Garland Publishing, New York, N.Y. (1991)); andThornton et al. Nature 354:105 (1991).

As used herein, the terms “label” or “labeled” refers to incorporationof a detectable marker, e.g., by incorporation of a radiolabeled aminoacid or attachment to a polypeptide of biotinyl moieties that can bedetected by marked avidin (e.g., streptavidin containing a fluorescentmarker or enzymatic activity that can be detected by optical orcalorimetric methods). In certain situations, the label or marker canalso be therapeutic. Various methods of labeling polypeptides andglycoproteins are known in the art and may be used. Examples of labelsfor polypeptides include, but are not limited to, the following:radioisotopes or radionuclides (e.g., ³H, ¹⁴C, ¹⁵N, ³⁵S, ⁹⁰Y, ⁹⁹Tc,¹¹¹In, ¹²⁵I, ¹³¹I) fluorescent labels (e.g., FITC, rhodamine, lanthanidephosphors), enzymatic labels (e.g., horseradish peroxidase,p-galactosidase, luciferase, alkaline phosphatase), chemiluminescent,biotinyl groups, predetermined polypeptide epitopes recognized by asecondary reporter (e.g., leucine zipper pair sequences, binding sitesfor secondary antibodies, metal binding domains, epitope tags). In someembodiments, labels are attached by spacer arms of various lengths toreduce potential steric hindrance. The term “pharmaceutical agent ordrug” as used herein refers to a chemical compound or compositioncapable of inducing a desired therapeutic effect when properlyadministered to a patient.

Other chemistry terms herein are used according to conventional usage inthe art, as exemplified by The McGraw-Hill Dictionary of Chemical Terms(Parker, S., Ed., McGraw-Hill, San Francisco (1985)).

As used herein, “substantially pure” means an object species is thepredominant species present (i.e., on a molar basis it is more abundantthan any other individual species in the composition), and preferably asubstantially purified fraction is a composition wherein the objectspecies comprises at least about 50 percent (on a molar basis) of allmacromolecular species present.

Generally, a substantially pure composition will comprise more thanabout 80 percent of all macromolecular species present in thecomposition, more preferably more than about 85%, 90%, 95%, and 99%.Most preferably, the object species is purified to essential homogeneity(contaminant species cannot be detected in the composition byconventional detection methods) wherein the composition consistsessentially of a single macromolecular species.

The term patient includes human and veterinary subjects.

Antibodies are purified by well-known techniques, such as affinitychromatography using protein A or protein G, which provide primarily theIgG fraction of immune serum. Subsequently, or alternatively, thespecific antigen which is the target of the immunoglobulin sought, or anepitope thereof, may be immobilized on a column to purify the immunespecific antibody by immunoaffinity chromatography. Purification ofimmunoglobulins is discussed, for example, by D. Wilkinson (TheScientist, published by The Scientist, Inc., Philadelphia Pa., Vol. 14,No. 8 (Apr. 17, 2000), pp. 25-28).

The invention will be further described in the following examples, whichdo not limit the scope of the invention described in the claims.

EXAMPLES Example 1 Cloning of Immunoglobulin Variable Germline Genes

Seven human heavy chain variable germline genes (VH1-2, VH1-69, VH1-18,VH3-30, VH3-48, VH3-23, VH5-51), five human kappa light chain variablegermline genes (VK1-33, VK1-39, VK3-11, VK3-15, VK3-20) and two humanlambda light chain variable germline genes (VL1-44, VL1-51) wereselected to construct the libraries (Lefranc, M.-P. et al., 1999 NucleicAcids Research, 27, 209-212). These genes were selected because they areoften used in human expressed antibody repertoires and the frameworksthey encode show favorable stability and expression profiles asindividual domains or in the context of a VH/VL pair (Ewert S et al., JMol. Biol. 2003 Jan. 17; 325(3):531-53). Two sets of specific primerswere used to amplify these genes from human genomic DNA by nested PCR.This approach was necessary as the 5′ sequences of germline genes of thesame family are identical or very similar. For each gene, a first pairof primers, called genomic locators, was designed to be specific to the5′ and 3′ untranslated regions flanking the germline gene. The secondpair was designed to be specific for the beginning of the framework 1region (FR1) and the end of the FR2. The 14 independent PCR productswere cloned into pGEMT-easy (Promega, Madison Wis.) and their identityand integrity were verified by sequencing. The amino acid sequence ofthe selected germline genes is shown in FIG. 5.

The primers and primer combination used are indicated below.

Genomic Locators

5 K1-33 TGTTTCTAATCGCAGGTGCCAGATG (SEQ ID NO: 120) 3 K1-33ATTTATGTTATGACTTGTTACACTG (SEQ ID NO: 121) 5 K1-39TATTTGTTTTTATGTTTCCAATCTC (SEQ ID NO: 122) 3 K1-39CCTTGGAGGTTTATGTTATGACTTG (SEQ ID NO: 123) 5 K3-11TTATTTCCAATTTCAGATACCACCG (SEQ ID NO: 124) 3 K3-11TTGTTGGGGTTTTTGTTTCATGTGG (SEQ ID NO: 125) 5 K3-15TATTTCCAATTTCAGATACCACTGG (SEQ ID NO: 126) 3 K3-15ATGTTGAATCACTGTGGGAGGCCAG (SEQ ID NO: 127) 5 K3-20TTATTTCCAATCTCAGATACCACCG (SEQ ID NO: 128) 3 K3-20TTTTGTTTCAAGCTGAATCACTGTG (SEQ ID NO: 129) 5 L1-44ATGTCTGTGTCTCTCTCACTTCCAG (SEQ ID NO: 130) 3 L1-44TTCCCCATTGGCCTGGAGCACTGTG (SEQ ID NO: 131) 5 L1-51GTGTCTGTGTCTCTCCTGCTTCCAG (SEQ ID NO: 132) 3 L1-51CTTGTCTCAGTTCCCCATTGGGCTG (SEQ ID NO: 133) 5 H1-2ATCTCATCCACTTCTGTGTTCTCTC (SEQ ID NO: 134) 3 H1-2TTGGGTTTCTGACACCCTCAGGATG (SEQ ID NO: 135) 5 H1-18CAGGCCAGTCATGTGAGACTTCACC (SEQ ID NO: 136) 3 H1-18CTGCCTCCTCCCTGGGGTTTCTGAA (SEQ ID NO: 137) 5 H1-69CCCCTGTGTCCTCTCCACAGGTGTC (SEQ ID NO: 138) 3 H1-69CCGGCACAGCTGCCTTCTCCCTCAG (SEQ ID NO: 139) 5 DP-47 GAGGTGCAGCTGTTGGAG(SEQ ID NO: 140) 5 H3-23 TCTGACCAGGGTTTCTTTTTGTTTGC (SEQ ID NO: 141)3 H3-23 TTGTGTCTGGGCTCACAATGACTTC (SEQ ID NO: 142) 5 H3-30TGGCATTTTCTGATAACGGTGTCC (SEQ ID NO: 143) 3 H3-30CTGCAGGGAGGTTTGTGTCTGGGCG (SEQ ID NO: 144) 5 H3-48ATATGTGTGGCAGTTTCTGACCTTG (SEQ ID NO: 145) 3 H3-48GGTTTGTGTCTGGTGTCACACTGAC (SEQ ID NO: 146) 5 H5-aGAGTCTGTGCCGGAAGTGCAGCTGG (SEQ ID NO: 147)

Specific for Coding Sequence

5 VH1 TATCAGGTGCAGCTGGTGCAG (SEQ ID NO: 148) 5 VH3 TATCAGGTGCAGCTGGTGGAG(SEQ ID NO: 149) 5 VH5 TATGAGGTGCAGCTGGTGCAG (SEQ ID NO: 150) 3 VH1/3ATATCTCTCGCACAGTAATACAC (SEQ ID NO: 151) 3 VH3 ATATCTCTCGCACAGTAATATAC(SEQ ID NO: 152) 3 VH5 ATATGTCTCGCACAGTAATACAT (SEQ ID NO: 153) 5 VK1TATGACATCCAGATGACCCAGTCTCCATCCTC (SEQ ID NO: 154) 3 DPK9ATAGGAGGGGTACTGTAACT (SEQ ID NO: 155) 3 DPK1 ATAGGAGGGAGATTATCATA(SEQ ID NO: 156) 5 DPK22_L6 TATGAAATTGTGTTGACGCAGTCT (SEQ ID NO: 157)3 DPK22 ATAGGAGGTGAGCTACCATACTG (SEQ ID NO: 158) 5 DPK21TATGAAATAGTGATGACGCAGTCT (SEQ ID NO: 159) 3 DPK21ATAGGAGGCCAGTTATTATACTG (SEQ ID NO: 160) 3 L6 CAGCGTAGCAACTGGCCTCCTAT(SEQ ID NO: 161) 5 DPL2 TACAGTCTGTGCTGACTCAG (SEQ ID NO: 162) 3 DPL2ATAGGACCATTCAGGCTGTCATC (SEQ ID NO: 163) 5 DPL5 TATCAGTCTGTGTTGACGCAG(SEQ ID NO: 164) 3 DPL5 ATAGGAGCACTCAGGCTGCTAT (SEQ ID NO: 165)

Primer Combinations Used to Amplify Selected Germline Genes.

1st PCR 2nd PCR Family germline 5′ 3′ 5′ 3′ VH1 DP-8/75 HV 1-2 5 H1-2 3H1-2 5 VH1 3 VH1/3 DP-10 HV 1-69 5 H1-69 3 H1-69 5 VH1 3 VH1/3 DP-14 HV1-18 5 H1-18 3 H1-18 5 VH1 3 VH1/3 VH3 DP-49 HV 3-30 5 H3-30 3 H3-30 5VH3 3 VH1/3 DP-51 HV 3-48 5 H3-48 3 H3-48 5 VH3 3 VH1/3 DP-47 HV 3-23 5H3-23 3 H3-23 5 VH3 3 VH3 VH5 HV 5a 5 H5a 3 VH5 5 VH5 3 VH5 VKI DPK-1 KV1-33 5 K 1-33 3 K 1-33 5 VK1 3 DPK-1 DPK-9 KV 1-39 5 K 1-39 3 K 1-39 5VK1 3 DPK-9 VKIII L6 KV 3-11 5 K3-11 3 K3-11 5 DPK22_L6 3 L6 DPK-21 KV3-15 5 K3-15 3 K3-15 5 DPK21 3 DPK21 DPK-22 KV 3-20 5 K3-20 3 K3-20 5DPK22_L6 3 DPK22 VL1 DPL-2 LV 1-44 5 L1-44 3 L1-44 5 DPL2 3 DPL2 DPL-5LV 1-51 5 L1-51 3 L1-51 5 DPL5 3 DPL5

Example 2 Generation of Acceptor Frameworks

The sequences of the selected germline genes were analyzed for thepresence of Type IIs restriction sites. No BsmBI site was present in theselected antibody variable germline genes. Two BsmBI sites were found inthe backbone of pNDS1, the phagemid vector in which the AcceptorFramework would be cloned. These two sites were removed by site-directedmutagenesis so that unique BsmBI sites could be introduced into thestuffer DNA sequences of the Acceptor Frameworks. Each germline gene wasamplified by multiple nested PCR in order to add a stuffer DNA sequenceat the 3′ end of the FR3 sequence followed by a sequence encoding FR4which is specific for each corresponding variable segment (VH, Vk, Vλ).The amino acid sequence of VH FR4 corresponds to the FR4 region encodedby the germline J genes JH1, JH3, JH4 and JH5. The amino acid sequenceof VK FR4 corresponds to the FR4 region encoded by the germline J genesJK1. The amino acid sequence of Vλ FR4 corresponds to the FR4 regionencoded by the germline J genes JL2 and JL3. Two variants of the Vk FR4sequence were generated with a single amino acid substitution atposition 106 (Arginine or Glycine). For the Acceptor Framework based onthe germline gene VH3-23, two variants were also constructed differingby a single amino acid (Lysine to Arginine) at position 94, the lastresidue of FR3. During the final amplification step SfiI/NcoI and XhoIsites were introduced at the 5′ and 3′ end of the VH, respectively.

Similarly, SalI and NotI sites were introduced at the 5′ and 3′ end ofthe VL, respectively (FIG. 6). The stuffer fragment was designed so thatthe translation reading frame was shifted thus preventing the expressionof any functional protein from the Acceptor Frameworks (FIG. 7). Theprimers used in this process are listed below.

VH 5 VH1 (SEQ ID NO: 166) CAGCCGGCCATGGCCCAGGTGCAGCTGGTGCAG 5 VH3-30(SEQ ID NO: 167) CAGCCGGCCATGGCCCAGGTGCAGCTGGTGGAG 5 VH3-23(SEQ ID NO: 168) CAGCCGGCCATGGCCGAGGTGCAGCTGTTGGAG 5 VH3-48(SEQ ID NO: 169) CAGCCGGCCATGGCCGAGGTGCAGCTGGTGGAGTCTGGGGGAG 5 VH5-51(SEQ ID NO: 170) CAGCCGGCCATGGCCGAGGTGCAGCTGGTGCAG 3 VH1/3(SEQ ID NO: 171) CTTACCGTTATTCGTCTCATCTCGCACAGTAATACAC 3 VH3-23(SEQ ID NO: 172) CTTACCGTTATTCGTCTCATTTCGCACAGTAATATAC 3 VH3-48(SEQ ID NO: 173) CTCGCACAGTAATACACAGCCGTGTCCTCGGCTCTCAGGCTG 3 VH5-51(SEQ ID NO: 174) CTTACCGTTATTCGTCTCATCTCGCACAGTAATACAT 3 VHext1(SEQ ID NO: 175) CAATACGCGTTTAAACCTGGTAAACCGCCTTACCGTTATTCGTCTCA3 VHext2 (SEQ ID NO: 176)GTTCCCTGGCCCCAAGAGACGCGCCTTCCCAATACGCGTTTAAACCTG 3 VHext3(SEQ ID NO: 177) CCTCCACCGCTCGAGACTGTGACCAGGGTTCCCTGGCCCCAAGAG VK 5 VK1(SEQ ID NO: 178) CGGGTCGACGGACATCCAGATGACCCAGTC 5 VK3-11(SEQ ID NO: 179) CGGGTCGACGGAAATTGTGTTGACACAGTCTCCAGC 5 VK3-15(SEQ ID NO: 180) CGGGTCGACGGAAATAGTGATGACGCAGTCTCCAGC 5 VK3-20(SEQ ID NO: 181) CGGGTCGACGGAAATTGTGTTGACGCAGTCTCCAGG 3 VK1-33(SEQ ID NO: 182) CCTTACCGTTATTCGTCTCGCTGCTGACAGTAATATGTTGCAATA 3 VK1-39(SEQ ID NO: 183) CCTTACCGTTATTCGTCTCGCTGCTGACAGTAGTAAGTTGCAAAA 3 VK3(SEQ ID NO: 184) CCTTACCGTTATTCGTCTCGCTGCTGACAGTAATAAACTGCAAAATC3 VKext1 (SEQ ID NO: 185)CCAATACGCGTTTAAACCTGGTAAACCGCCTTACCGTTATTCGTCTC 3 VKext2(SEQ ID NO: 186) GGTCCCTTGGCCGAATGAGACGCGCCTTCCCAATACGCGTTTAAAC3 Vkext3R (SEQ ID NO: 187) GTGCGGCCGCCCGTTTGATTTCCACCTTGGTCCCTTGGCCGAATG3 VKext3G (SEQ ID NO: 188) GTGCGGCCGCCCCTTTGATTTCCACCTTGGTCCCTTGGCCGAATGVλ 5 VL1-44 (SEQ ID NO: 189) CGGGTCGACGCAGTCTGTGCTGACTCAGCCAC 5 VL1-51(SEQ ID NO: 190) CGGGTCGACGCAGTCTGTGTTGACGCAGCCGC 3 VL1-44(SEQ ID NO: 191) CCTTACCGTTATTCGTCTCCTGCTGCACAGTAATAATC 3 VL1-51(SEQ ID NO: 192) CCTTACCGTTATTCGTCTCCTGTTCCGCAGTAATAATC 3 Vlext2(SEQ ID NO: 193) CCCTCCGCCGAACACAGAGACGCGCCTTCCCAATACGCGTTTAAAC 3 Vlext3(SEQ ID NO: 194) GTGCGGCCGCCCCTAGGACGGTCAGCTTGGTCCCTCCGCCGAACACAGA

The sequences of the 20 final assembled Acceptor Frameworks are shown inFIG. 8.

Example 3 Generation of Phagemid Acceptor Vectors Containing anInvariant Variable Domain

The phagemid vector pNDS1 used for the expression of scFv was firstmodified to remove two BsmBI sites. A VH3-23 domain containing a definedCDR3 sequence was cloned into the modified pNDS1 using the SfiI and XhoIrestriction sites to obtain the phagemid vector pNDS_VHdummy. Thisdomain contained a BsmBI site in the FR4 region, which was corrected bysilent site directed mutagenesis. In parallel, a VK1-39 domaincontaining a defined CDR3 sequence was then cloned into the modifiedpNDS1 using the SalI and NotI restriction sites to obtain the phagemidvector pNDS_VKdummy (FIG. 9). The 8 VH Acceptor Frameworks were clonedinto pNDS_VKdummy using the SalI and NotI restrictions sites. The 12 VLAcceptor Frameworks were cloned into pNDS_VHdummy using the SfiI andXhoI restrictions sites. The resulting 20 pNDS phagemid vectors that arelisted below could at this stage be used for cloning of diversified CDR3using the BsmBI sites present in the stuffer DNA fragments.

VH Acceptors: pNDS_VH1-2_VKd; pNDS_VH1-18_VKd; pNDS_VH1-69_VKd;pNDS_VH3-23R_VKd; pNDS_VH3-23K_VKd; pNDS_VH3-30_VKd; pNDS_VH5-51_VKd;pNDS_VH3-48_VKd.

VL Acceptors: pNDS_VHd_VK1-33G; pNDS_VHd_VK1-33R; pNDS_VHd_VK1-39G;pNDS_VHd_VK1-39R; pNDS_VHd_VK3-11G; pNDS_VHd_VK3-11R; pNDS_VHd_VK3-15G;pNDS_VHd_VK3-15R; pNDS_VHd_VK3-20G; pNDS_VHd_VK3-20R; pNDS_VHd_VL1-44;pNDS_VHd_VK1-51.

Example 4 Capturing Natural CDR H3 Diversity from Human Repertoires

Multiple sources of human cDNA were used as a template for amplificationof CDR H3 sequences. These sources included human fetal spleen as wellas pools of male and female normal adult peripheral blood purifiedcells. Several strategies for amplification have been used in order torecover CDR H3 sequences originating from rearranged VH cDNA encoded bya specific germline gene or CDR H3 sequences originating from any VHcDNA.

First, mixtures of primers matching the 5′ coding regions of themajority of human VH families were used in combination with primermixtures matching all the human JH regions. This allowed for PCRamplification a majority of heavy chain immunoglobulin variable genes.The expected amplification products of approximately 400 base pairs (bp)were isolated by agarose gel electrophoresis and purified. This DNAserved as template in a second PCR step using primers with a 13 bp and14 bp match for the end FR3 region and the beginning of FR4,respectively. In most cases, the last residue of the FR3 is either anarginine or a lysine. As the last bp matches are critical for primerextension by the polymerase, two different 5′ primers were used: 5VHR_FOK (SEQ ID NO: 205 shown below) and 5 VHK_FOK (SEQ ID NO: 206 shownbelow). Importantly, these primers also contain a FokI restriction sitefor excision of the CDR H3 sequence (FIG. 4). The primers used in thesecond PCR step were biotinylated at their 5′ end to facilitatedownstream purification steps (see example 5). This two step approachallows for an efficient amplification of the CDR H3 sequences despitethe limited number of base pairs matches. Amplifications were performedat varying annealing temperatures (between 30° C. and 70° C.) and withseveral thermostable DNA polymerases to establish optimal conditions. Anannealing temperature of 55-58° C. in combination with GoTaq polymerase(Promega) was found to be optimal for this set of primers. The secondamplification product was separated on a 2% agarose gel and resulted ina smear in the lower part of the gel corresponding to CDR H3 ofdifferent length. Either the complete DNA smear was extracted from thegel or a region corresponding to larger DNA fragments in order to enrichfor long CDR H3.

Alternatively, the first amplification step was performed using the 5′primer 5 VH3-23H2 (SEQ ID NO: 201 shown below), which is specific forthe sequence encoding the CDR H2 of the germline VH3-23. As thedifferent germline genes are diverse in this CDR, VH cDNAs encoded bythe selected germline gene can be preferentially amplified. Thesubsequent purification and amplification steps were identical. In thisway, it is possible to retrieve CDRs originating from a specificframework environment and to re-introduce them into the same, a similaror different framework.

Below is a list of primers used for the amplification of natural humanCDR H3 repertoires.

1st PCR step 5 VH1/5 (SEQ ID NO: 195)CCGCACAGCCGGCCATGGCCCAGGTGCAGCTGGTGCAGTCTGG 5 VH3 (SEQ ID NO: 196)CCGCACAGCCGGCCATGGCCGAGGTGCAGCTGGTGGAGTCTGG 5 VH2 (SEQ ID NO: 197)CCGCACAGCCGGCCATGGCCCAGRTCACCTTGCTCGAGTCTGG 5 VH4 (SEQ ID NO: 198)CCGCACAGCCGGCCATGGCCCAGGTGCAGCTGCAGGAGTCGGG 5 VH4DP64 (SEQ ID NO: 199)CCGCACAGCCGGCCATGGCCCAGCTGCAGCTGCAGGAGTCCGG 5 VH4DP63 (SEQ ID NO: 200)CCGCACAGCCGGCCATGGCCCAGGTGCAGCTACAGCAGTGGGG 5 VH3-23H2 (SEQ ID NO: 201)TGGAGTGGGTCTCAGCTATTAGTGGTAGTGGT 3 HJ1/2 (SEQ ID NO: 202)CGATGGGCCCTTGGTGGAGGCTGAGGAGACRGTGACCAGGGTGCC 3 HJ3/6 (SEQ ID NO: 203)CGATGGGCCCTTGGTGGAGGCTGAAGAGACGGTGACCRTKGTCCC 3 HJ4/5 (SEQ ID NO: 204)CGATGGGCCCTTGGTGGAGGCTGAGGAGACGGTGACCAGGGTTCC 2nd PCR step 5 VHR_FOK(SEQ ID NO: 205) GAGCCGAGGACACGGCCGGATGTTACTGTGCGAGA 5 VHK_FOK(SEQ ID NO: 206) GAGCCGAGGACACGGCCGGATGTTACTGTGCGAAA 3 JH1_FOK(SEQ ID NO: 207) GAGGAGACGGTGACGGATGTGCCCTGGCCCCA 3 JH2_FOK(SEQ ID NO: 208) GAGGAGACGGTGACGGATGTGCCACGGCCCCA 3 JH3456_FOK(SEQ ID NO: 209) GAGGAGACGGTGACGGATGTYCCTTGGCCCCA

Example 5 Generation of Primary Libraries by Cloning Natural Human CDRH3 into Acceptor Frameworks

The amplified CDR H3 were digested with FokI, and the cleavedextremities as well as undigested DNA was removed using streptavidincoated magnetic beads. In parallel, pNDS VH Acceptor vectors weredigested using BsmBI. As the overhangs generated by these digestions arecompatible, the collection of natural CDR H3 was able to be ligated intothe VH Acceptor Framework restoring the appropriate reading frame. Theligated DNA was purified and concentrated for transformation intocompetent E. coli XL1 Blue cells, and random clones analyzed bysequencing in order to check that CDR H3 sequence had been reconstitutedand that junctions between the CDR and the Framework region are correct(FIG. 10). The results indicated that all the clones contained CDR H3sequences and that the reading frame was restored, thus encoding animmunoglobulin variable heavy chain. In addition, all the CDRs weredifferent, indicating that a large diversity of naturally occurringsequences had been captured by this approach. The length of the CDR H3was also variable and relatively long CDRs of 10 to 15 residues werefound, thus underscoring the advantage of this approach for samplinglong CDR sequences that are difficult to cover using syntheticdiversity.

Using this method, natural CDR H3 sequences, derived either from pooledhuman peripheral blood purified cells or human fetal spleen, were clonedinto each of the pNDS VH Acceptor Frameworks and transformed intoelectrocompetent E. coli TG1 cells and plated on 2×TYAG Bioassay plates(2×TY media containing 100 μg/ml ampicillin and 2% glucose). Afterovernight incubation at 30° C., 10 ml of 2×TYAG liquid medium was addedto the plates and the cells were scraped from the surface andtransferred to a 50 ml polypropylene tube. 2×TYAG containing 50%glycerol was added to the cell suspension to obtain a finalconcentration of 17% glycerol. Aliquots of the libraries were stored at−80° C. In this process, 14 primary libraries were generatedrepresenting a total of 8.1×10⁹ transformants. 180 randomly pickedclones were sequenced to determine the quality and diversity of thelibraries. All clones encoded different VH sequences and >89% were inframe. These primary libraries contain diversity in the CDR H3 only asthey are combined with a dummy VL domain.

Example 6 Generation of Primary Libraries by Cloning Synthetic CDR3 intoAcceptor Frameworks

Although the method is of particular interest for retrieving naturaldiversity, it can also be applied for the integration of syntheticdiversity into Acceptor Frameworks. Synthetic CDR3 sequences weredesigned for both the VH and VL. The design took into account thefrequency of CDRs with a given length and the diversification strategy(NNS, DVK, NVT or DVT codons) that would allow a complete coverage ofthe theoretical diversity within a reasonable number of transformants ina library (˜5×10⁹ transformants) (FIG. 11). Key residues to maintain thecanonical structure of the CDR were kept constant in the design of CDR3for VK and Vλ chains. For the heavy chain, only CDR3 with up to 10diversified positions were generated as the number of clones required tocover the diversity encoded by longer CDRs is beyond practical limits oftransformation efficiency.

Degenerate oligonucleotides of different length were synthesized usingNNS, NVT, DVK or DVT randomized codons. For each CDR H3, twooligonucleotides were synthesized encoding either a methionine or aphenylalanine at position 100z (FIG. 11). Each oligonucleotide wasextended and amplified with two external biotinylated primers togenerate double stranded DNA fragments encoding the designed CDRs. Theseexternal primers contain BsmBI restriction sites for subsequent excisionof the CDR sequence and insertion into the Acceptor Frameworks (FIG.12). The assembled DNA fragments were processed without gel purificationand digested with BsmBI. The cleaved extremities as well as undigestedDNA was removed using streptavidin coated magnetic beads. The digestedDNA fragments were concentrated by ethanol precipitation and ligatedinto the corresponding pNDS VH, VK or Vλ Acceptor vectors. Ligationproducts were purified and concentrated for transformation intoelectrocompetent E. coli TG1 cells and plated on 2×TYAG Bioassay plates(2×TY media containing 100 μg/ml ampicillin and 2% glucose). Afterovernight incubation at 30° C., 10 ml of 2×TYAG liquid medium was addedto the plates and the cells were scraped from the surface andtransferred to a 50 ml polypropylene tube. 2×TYAG containing 50%glycerol was added to the cell suspension to obtain a finalconcentration of 17% glycerol Aliquots of the libraries were stored at−80° C. A total of 24 primary heavy chain libraries were generatedrepresenting a total of 1.6×10¹⁰ transformants. Similarly, 13 primarylight chain libraries were generated representing a total of 6.9×10⁹transformants. These primary libraries contain diversity in the CDR H3only as they are combined with a dummy VL domain. A total of 330randomly picked clones were sequenced to determine the quality anddiversity of the libraries. All clones encoded different variable domainsequences and >90% were in frame. This low frequency of sequencescontaining shifts in the reading frame is in sharp contrast with resultstraditionally obtained during the construction of synthetic antibodyfragment libraries using overlapping PCR approaches which are more proneto the introduction of insertion, and significant loss of functionalclones (15-45%) has frequently been reported.

The diversity in these primary libraries was restricted to the CDR H3 orCDR L3 as they are combined with a dummy VL or VH chain, respectively.

Primers used for synthetic CDR assembly are listed below.

5 H3_R_biot ATGATGCTGCTGGCACGTCTCCGAGA (SEQ ID NO: 210) 3 H3_M_biotCCACGTCATCCGATCCGTCTCCCCCAATAATCCAT (SEQ ID NO: 211) 3 H3_F_biotCCACGTCATCCGATCCGTCTCCCCCAATAATCAAA (SEQ ID NO: 212) H3_4nnsFGCTGGCACGTCTCCGAGANNSNNSNNSNNSTTTGATTATTGGGGGAGACG (SEQ ID NO: 213)H3_4nnsM GCTGGCACGTCTCCGAGANNSNNSNNSNNSATGGATTATTGGGGGAGACG(SEQ ID NO: 214) H3_5nnsFGCTGGCACGTCTCCGAGANNSNNSNNSNNSNNSTTTGATTATTGGGGGAGACG (SEQ ID NO: 215)H3_5nnsM GCTGGCACGTCTCCGAGANNSNNSNNSNNSNNSATGGATTATTGGGGGAGACG(SEQ ID NO: 216) H3_6nnsFGCTGGCACGTCTCCGAGANNSNNSNNSNNSNNSNNSTTTGATTATTGGGGGAGACG(SEQ ID NO: 217) H3_6nnsMGCTGGCACGTCTCCGAGANNSNNSNNSNNSNNSNNSATGGATTATTGGGGGAGACG(SEQ ID NO: 218) H3_6dvkFGCTGGCACGTCTCCGAGADVKDVKDVKDVKDVKDVKTTTGATTATTGGGGGAGACG(SEQ ID NO: 219) H3_6dvkMGCTGGCACGTCTCCGAGADVKDVKDVKDVKDVKDVKATGGATTATTGGGGGAGACG(SEQ ID NO: 220) H3_7dvkFGCTGGCACGTCTCCGAGADVKDVKDVKDVKDVKDVKDVKTTTGATTATTGGGGGAGACG(SEQ ID NO: 221) H3_7dvkMGCTGGCACGTCTCCGAGADVKDVKDVKDVKDVKDVKDVKATGGATTATTGGGGGAGACG(SEQ ID NO: 222) H3_7nvtFGCTGGCACGTCTCCGAGANVTNVTNVTNVTNVTNVTNVTTTTGATTATTGGGGGAGACG(SEQ ID NO: 223) H3_7nvtMGCTGGCACGTCTCCGAGANVTNVTNVTNVTNVTNVTNVTATGGATTATTGGGGGAGACG(SEQ ID NO: 224) H3_8nvtFGCTGGCACGTCTCCGAGANVTNVTNVTNVTNVTNVTNVTNVTTTTGATTATTGGGGGAGACG(SEQ ID NO: 225) H3_8nvtMGCTGGCACGTCTCCGAGANVTNVTNVTNVTNVTNVTNVTNVTATGGATTATTGGGGGAGACG(SEQ ID NO: 226) H3_9nvtFGCTGGCACGTCTCCGAGANVTNVTNVTNVTNVTNVTNVTNVTNVTTTTGATTATTGGGGGAGACG(SEQ ID NO: 227) H3_9nvtMGCTGGCACGTCTCCGAGANVTNVTNVTNVTNVTNVTNVTNVTNVTATGGATTATTGGGGGAGACG(SEQ ID NO: 228) H3_9dvtFGCTGGCACGTCTCCGAGADVTDVTDVTDVTDVTDVTDVTDVTDVTTTTGATTATTGGGGGAGACG(SEQ ID NO: 229) H3_9dvtMGCTGGCACGTCTCCGAGADVTDVTDVTDVTDVTDVTDVTDVTDVTATGGATTATTGGGGGAGACG(SEQ ID NO: 230) H3_10dvtFGCTGGCACGTCTCCGAGADVTDVTDVTDVTDVTDVTDVTDVTDVTDVTTTTGATTATTGGGGGAGACG(SEQ ID NO: 231) H3_10dvtMGCTGGCACGTCTCCGAGADVTDVTDVTDVTDVTDVTDVTDVTDVTDVTATGGATTATTGGGGGAGACG(SEQ ID NO: 232) 5 KL3_biot CCGGTGTAGCGAAGGCGTCTCAGCAG (SEQ ID NO: 233)3 KL3_biot TAGGGTCGCCTTGATCGTCTCCCGAAGGTCGG (SEQ ID NO: 234) K_4nnsGAAGGCGTCTCAGCAGNNSNNSNNSNNSCCGACCTTCGGGAGACG (SEQ ID NO: 235) K_5nnsGAAGGCGTCTCAGCAGNNSNNSNNSNNSCCGNNSACCTTCGGGAGACG (SEQ ID NO: 236) K_6nnsGAAGGCGTCTCAGCAGNNSNNSNNSNNSNNSCCGNNSACCTTCGGGAGACG (SEQ ID NO: 237)5 L44W_biot CGGTCAGTCGCAATACGTCTCCAGCATGGGAT (SEQ ID NO: 238)5 L44Y_biot CGGTCAGTCGCAATACGTCTCCAGCATATGAT (SEQ ID NO: 239) 3 L_biotCAGGACCAGTCTCGTGAGGATCGTCTCAACAC (SEQ ID NO: 240) L44W_4nnsCGTCTCCAGCATGGGATNNSNNSNNSNNSGTGTTGAGACGATCCTC (SEQ ID NO: 241)L44Y_4nns  CGTCTCCAGCATATGATNNSNNSNNSNNSGTGTTGAGACGATCCTC(SEQ ID NO: 242) L44W_5nnsCGTCTCCAGCATGGGATNNSNNSNNSNNSNNSGTGTTGAGACGATCCTC (SEQ ID NO: 243)L44Y_5nns CGTCTCCAGCATATGATNNSNNSNNSNNSNNSGTGTTGAGACGATCCTC(SEQ ID NO: 244) L44W_6nnsCGTCTCCAGCATGGGATNNSNNSNNSNNSNNSNNSGTGTTGAGACGATCCTC (SEQ ID NO: 245)L44Y_6nns CGTCTCCAGCATATGATNNSNNSNNSNNSNNSNNSGTGTTGAGACGATCCTC(SEQ ID NO: 246) 5 L51W_biot CGGTCAGTCGCAATACGTCTCGAACATGGGAT(SEQ ID NO: 247) 5 L51Y_biot CGGTCAGTCGCAATACGTCTCGAACATATGAT(SEQ ID NO: 248) L51W_4nnsCGTCTCGAACATGGGATNNSNNSNNSNNSGTGTTGAGACGATCCTC (SEQ ID NO: 249)L51Y_4nns CGTCTCGAACATATGATNNSNNSNNSNNSGTGTTGAGACGATCCTC(SEQ ID NO: 250) L51W_5nnsCGTCTCGAACATGGGATNNSNNSNNSNNSNNSGTGTTGAGACGATCCTC  (SEQ ID NO: 251)L51Y_5nns CGTCTCGAACATATGATNNSNNSNNSNNSNNSGTGTTGAGACGATCCTC (SEQ ID NO: 252) L51W_6nnsCGTCTCGAACATGGGATNNSNNSNNSNNSNNSNNSGTGTTGAGACGATCCTC (SEQ ID NO: 253)L51Y_6nns CGTCTCGAACATATGATNNSNNSNNSNNSNNSNNSGTGTTGAGACGATCCTC(SEQ ID NO: 254)

Example 7 Generation of Secondary Libraries

In order to generate libraries of scFv carrying diversity in both theheavy and light chains, the Primary synthetic light chain libraries werecombined with either the Primary synthetic heavy chain libraries or thePrimary natural heavy chain libraries (FIG. 13). Phagemid DNA wasprepared from each primary library and digested with XhoI/NotIrestriction enzymes. The DNA fragments corresponding to the linker andlight chains from the Primary synthetic libraries were inserted byligation into the digested Primary natural or synthetic heavy chainvectors. Alternatively the Linker-VL sequence was also amplified withspecific primers before digestion with XhoI/NotI and ligation. Theligation products were purified by phenol/chloroform extraction andprecipitation before transformation into electrocompetent E. coli TG1cells and plating on 2×TYAG Bioassay plates (2×TY media containing 100μg/ml ampicillin and 2% glucose). After overnight incubation at 30° C.,10 ml of 2×TYAG liquid medium was added to the plates and the cells werescraped from the surface and transferred to a 50 ml polypropylene tube.2×TYAG containing 50% glycerol was added to the cell suspension toobtain a final concentration of 17% glycerol. Aliquots of the librarieswere stored at −80° C. To limit the number of libraries to berecombined, they were pooled by chain subclasses (i.e., VH1, VH3, VH5,VK1, VK3, Vλ1) and thus 9 library combination were performed for (i.e.,VH1×VK1, VH1×VK3, VH1×Vλ1, VH3×VK1, VH3×VK3, VH3×Vλ1, VH5×VK1, VH5×VK3,VH5×Vλ1). The total size of the Secondary synthetic libraries (carryingsynthetic diversity in both the VH and VL) was 7.3×10⁹ transformants.The total size of the Secondary natural libraries (carrying naturaldiversity in the VH and synthetic diversity in the VL) was 1.5×10¹⁰transformants.

Example 8 Generation of Human Antibody Libraries Displaying a CDRH3Repertoire Derived from a Non-Human Species

In order to utilize alternative sources of diversity that would allowexploring a different tri-dimensional space within the antibodycombining site, a library was created by capturing the CDRH3 of mice andintroduced them into a collection of human antibody frameworks. For thisapproach an acceptor library containing a collection of VL genes withsynthetic CDR L3 diversity was constructed and combined with acollection of acceptor sequences containing a stuffer DNA sequence readysuitable for Type IIS restriction cloning as described in Example 2.This library represents the starting point for rapid generation ofsecondary libraries with multiple sources of natural (human as well asnon-human) or synthetic CDR H3. In this example, natural CDR H3diversity was captured from naïve Balb/c mice and mice that had beenimmunized with hIFNγ or hCCL5 (hRANTES).

The first step was the generation of acceptor libraries by cloning acollection of VL containing synthetic CDR L3 diversity into acceptor VHframework vectors (FIG. 14). The VL sequences were derived from theseven Primary Synthetic Libraries described in Example 6 by PCRamplification using primers 5′ biot-VHdummy and 3′ biot-fdtseq. Theresulting VL containing fragments of approximately 400 bp were digestedusing XhoI/NotI and purified on spin columns to remove primers andenzymes. Similarly the pNDS VH acceptor vectors containing a CDRH3stuffer and a dummy light chain were digested with XhoI/NotI and SwaI(SwaI cutting inside the VL dummy) and purified on Chroma Spin TEcolumns with a cutoff of 1000 bp to get rid of the VL dummy fragment.The digested VL fragments were then ligated into the VH acceptor vectors(FIG. 14). To limit the number of libraries to be recombined, VHacceptor vectors and VL fragments were pooled by chain subclasses (i.e.,VH1, VH3, VH5, Vκ1, Vκ3, Vλ1) and thus nine library combinations wereperformed (i.e., VH1×Vκ1, VH1×Vκ3, VH1×Vλ1, VH3×Vκ1, VH3×Vκ3, VH3×Vλ1,VH5×Vκ1, VH5×Vκ3, VH5×Vλ1). The ligation products were transformed intoelectrocompetent E. coli TG1 cells and plated on 2×TYAG Bioassay plates(2×TY medium containing 100 μg/ml ampicillin and 2% glucose). Afterovernight incubation at 30° C., 6 ml of 2×TYAG liquid medium was addedto the plates and the cells were scraped from the surface andtransferred to a 50 ml polypropylene tube. Glycerol 50% was added to thecell suspension to obtain a final concentration of 17% glycerol.Aliquots of the libraries were stored at −80° C. The total size of thisacceptor library, carrying synthetic diversity in the CDR L3, was1.9×10⁹ transformants.

The next step was to isolate CDRH3 sequences from a non-human source.Cells were isolated from the spleen of five naïve or immunized Balb/cmice and total RNA was purified. cDNA was obtained from the extractedRNA by RT-PCR. This cDNA was used as template to isolate and amplifymouse VH by PCR. A series of PCRs were performed using 15 different 5′primers (one for each mouse VH subgroup) specific for the beginning ofthe FR1 region and a pool of 3′ primers (four primers covering the JHregion). These first PCRs were pooled and purified on a 2% agarose gel.The purified DNA served as template to perform a second PCR to isolatethe mouse CDR H3 region.

The 5′ and 3′ primers for this second PCR target the FR3 and FR4 regionsof mouse VH, respectively. These primers added a FokI restriction sitein order to allow for precise excision of the CDR H3 and cloning intothe human acceptor vectors. However, alignments of murine VH sequencesrevealed that sequence at the 5′ boundary of murine CDR-H3 and that arelocated at the cleavage site of FokI almost always differ from humansequence by one base, whereas the 3′ end matched between these twospecies. The sequences cleaved by FokI are boxed in Table below:

Consequently the base had to be corrected during the secondamplification step in order to generate cohesive ends that arecompatible with the cohesive ends generated upon digestion of theAcceptor Frameworks. Efficient amplification was observed suggestingthat this conversion occurred readily. At the 3′ end, mouse and humansequences that will be cut by the Type IIS restriction enzymes areidentical thus avoiding any correction issues.

Primers for the second amplification were biotinylated at their 5′ endsto facilitate downstream purification steps. The acceptor vectors weredigested with BsmBI and purified on Chroma Spin TE columns having acutoff of 1000 bp. After digestion and purification, the nine differentlibrary combinations were pooled in equimolar ratio for ligation of thecaptured mouse CDRH3.

The ligated DNA was purified by phenol/chloroform extractions andconcentrated by precipitation before transformation into competent E.coli TG1 cells and plated on 2×TYAG Bioassay plates (2×TY mediumcontaining 100 μg/ml ampicillin and 2% glucose). After overnightincubation at 30° C., 6 ml of 2×TYAG liquid medium was added to theplates and the cells were scraped from the surface and transferred to a50 ml polypropylene tube. Glycerol 50% was added to the cell suspensionto obtain a final concentration of 17% glycerol. Aliquots of thelibraries were stored at −80° C. Three libraries of similar size wereobtained: MnA, 2.5×10⁸ transformants (carrying a restricted naturalhuman framework diversity, naïve mouse diversity in the CDR H3 andsynthetic diversity in the CDR L3); MiB, 7.3×10⁷ transformants (carryinga restricted natural human framework diversity, immune mouse diversityagainst hIFNγ in the CDR H3 and synthetic diversity in the CDR L3) andMiC, 1.8×10⁸ transformants (carrying a restricted natural humanframework diversity, immune mouse diversity against hCCL5 in the CDR H3and synthetic diversity in the CDR L3). Random clones were analyzed bysequencing in order to check that CDR H3 sequence had been reconstitutedand that junctions between the CDR and the Framework regions werecorrect. The results indicated that all the clones contained CDR H3sequences and that the reading frame was restored, thus encoding animmunoglobulin variable heavy chain. All the CDRs were different andresembled typical mouse CDR H3 sequences indicating that a largediversity of naturally occurring mouse CDRH3 sequences had been capturedby this approach. In addition, the analysis of the CDRH3 length profilesindicated that a Gaussian distribution was captured in the naïve librarythat corresponds to the expected distribution of lengths in normal mouserepertoire. In contrast, in the two immune libraries the profiles weredifferent suggesting that a different CDRH3 repertoire had been captured(FIG. 15).

Primers Used for CDRH3 Amplification from Mice

1^(st) PCR 5′ primers: m5 VH1 (SEQ ID NO: 256)ATGCGGCCCAGCCGGCCATGGCCSAGGTYCAGCTBCAGCAGTC m5 VH2 (SEQ ID NO: 257)ATGCGGCCCAGCCGGCCATGGCCCAGGTTCACCTGCAGCARTC m5 VH3 (SEQ ID NO: 258)ATGCGGCCCAGCCGGCCATGGCCCAGGTRCAGCTGAAGGAGTC m5 VH4 (SEQ ID NO: 259)ATGCGGCCCAGCCGGCCATGGCCCAGGTCCAACTVCAGCARCC m5 VH5 (SEQ ID NO: 260)ATGCGGCCCAGCCGGCCATGGCCCAGATCCAGTTGGTVCAGTC m5 VH6 (SEQ ID NO: 261)ATGCGGCCCAGCCGGCCATGGCCCAGGTGCAGCTGAAGSASTC m5 VH7 (SEQ ID NO: 262)ATGCGGCCCAGCCGGCCATGGCCGAGGTGCAGSKGGTGGAGTC m5 VH8 (SEQ ID NO: 263)ATGCGGCCCAGCCGGCCATGGCCGAAGTGAARSTTGAGGAGTC m5 VH9 (SEQ ID NO: 264)ATGCGGCCCAGCCGGCCATGGCCGAKGTSVAGCTTCAGGAGTC m5 VH10 (SEQ ID NO: 265)ATGCGGCCCAGCCGGCCATGGCCGAGGTGAASSTGGTGGAATC m5 VH11 (SEQ ID NO: 266)ATGCGGCCCAGCCGGCCATGGCCGAGGTGAAGCTGRTGGARTC m5 VH12 (SEQ ID NO: 267)ATGCGGCCCAGCCGGCCATGGCCGARGTGAAGCTGRTGGAGTC m5 VH13 (SEQ ID NO: 268)ATGCGGCCCAGCCGGCCATGGCCGAAGTGCAGCTGTTGGAGAC m5 VH14 (SEQ ID NO: 269)ATGCGGCCCAGCCGGCCATGGCCGARGTGAAGCTTCTCSAGTC m5 VH15 (SEQ ID NO: 270)ATGCGGCCCAGCCGGCCATGGCCCARGTTACTCTGAAAGAGT 3′ primers: m3 HJ1(SEQ ID NO: 271) CCTGAACCGCCGCCTCCGCTCGAGACGGTGACCGTGGTCCC m3 HJ2(SEQ ID NO: 272) CCTGAACCGCCGCCTCCGCTCGAGACTGTGAGAGTGGTGCC m3 HJ3(SEQ ID NO: 273) CCTGAACCGCCGCCTCCGCTCGAGACAGTGACCAGAGTCCC m3 HJ4(SEQ ID NO: 274) CCTGAACCGCCGCCTCCGCTCGAGACGGTGACTGAGGTTCC 2^(nd) PCR 5′primers: 5 VHR_FOK_Biot (SEQ ID NO: 275)GAGCCGAGGACACGGCCGGATGTTACTGTGCGAGA 3′ primers: 3′mJH1_Fok_Biot(SEQ ID NO: 276) GGGGCGCAGGGACATCCGTCACCGTCTCCTC 3′mJH2_Fok_Biot(SEQ ID NO: 277) GAGGAGACTGTGAGGGATGTGCCTTGGCCCCA 3′JH1_Fok(SEQ ID NO: 278) GAGGAGACGGTGACGGATGTGCCCTGGCCCCA 3′mJH4_Fok_biot(SEQ ID NO: 279) GAGGAGACGGTGACGGATGTTCCTTGACCCCA

Example 9 Phage Rescue of the Libraries

Each Primary and Secondary library was rescued independently accordingto standard phage display procedures briefly summarized hereafter. Avolume of cell from the frozen library aliquots sufficient to cover atleast 10 times the theoretical diversity of the library was added to 500ml of 2×TYAG and grown at 37° C. with agitation (240 rpm) until an OD600of 0.3 to 0.5 was reached. The culture was then super-infected withMK13K07 helper phage and incubated for one hour at 37° C. (150 rpm). Themedium was then changed by centrifuging the cells at 2000 rpm for 10minutes, removing the medium and resuspending the pellet in 500 ml of2×TY-AK (100 μm/ml ampicillin; 50 μg/ml kanamycin). The culture was thengrown overnight at 30° C. (240 rpm). The culture was centrifuged at 4000rpm for 20 minutes to pellet the cells. The supernatant was collectedand 30% (vol/vol) of PEG 8000 (20%)/2.5M NaCl was added to precipitatethe phage particles by incubating the mixture 1 hour on ice. The phageparticles were collected by centrifugation at 10,000 rpm for 30 minutesand resuspended in 10 ml of TE buffer (10 mM tris-HCl pH 8.0; 1 mMEDTA). The resuspended solution was centrifuged at 10,000 rpm to clearthe bacterial debris and the precipitation procedure was repeated. Afterfinal resuspension, phage was titrated by infection of E. coli andabsorption at 280 nm. The display level of scFv at the surface of phagewas also evaluated by Western blot analysis using an anti-c-mycmonoclonal antibody. Purified phage from different libraries was storedfrozen at −80° C. after addition of glycerol to a final concentration of15% (w/v).

In order to use a manageable number of libraries during selectionprocedures, the purified phage was pooled into 4 working libraries:AA1—Phage from all Primary synthetic VH libraries; AB1—Phage from allPrimary synthetic VL libraries; AC1—Phage from all Primary natural VHlibraries; AD1—Phage from all Secondary natural libraries; AE1—Phagefrom all Secondary synthetic libraries; MnA—Libraries with diversitycaptured from naïve mice; MiB—Libraries with diversity captured frommice immunized with hIFNγ; MiC—Libraries with diversity captured frommice immunized with hCCL5/RANTES.

Example 10 High Throughput Sequencing of Antibody Libraries

The quality and diversity of a library can be evaluated by DNAsequencing of random library members. In most cases a few hundred clonesare sequenced which represent only a very small fraction of the library(less than 1 in 10,000,000 library members). In order to analyze theperformance of the methods provide herein, next generation sequencingtechnology was used to analyze a more representative number of librarymembers. DNA isolated from the library AE1 was used as a template forhigh throughput sequencing using an illumina Genome Analyzer instrument.This next-generation DNA sequencing system allows for billions of basesto be read in a few days. The sequencing reads are relatively short(about 70 bases) but perfectly compatible with our library design. Asthe diversity is confined to the CDR3 regions a 70 base read issufficient to cover the CDRH3 and part of the framework 3 region for VHfamily identification. This technology has been applied to sequenceseveral millions of CDRH3 regions from the AE1 library. 5,078,705sequences were obtained for a total of 365,666,760 bases. Analysis ofthe data indicated that 5,007,022 sequences (98.6% of the total) wereunique. A total of 4,680,882 sequences could be unambiguously ascribedto a VH family (VH1, VH3 and VH5) and the representation of the VHfamilies in the AE1 library determined (41% VH1; 30% VH3; 29% VH5). Animportant finding was that the proportion of in frame inserts rangedbetween 88 and 91%. This data confirmed in a far more statistical mannerthe sequencing results of the 24 primary VH synthetic librariesdescribed in Example 6. This combined set of sequencing datademonstrates that the type IIs restriction cloning process used in thismethod is very robust, leading to an efficient and productive insertionin the 24 independent library constructions performed to generate the VHdiversity of the AE1 library.

The sequencing of millions of library members represents anunprecedented quality control step for an antibody library. The resultsdemonstrate that the method allows for the generation of high qualityand high diversity libraries in a reproducible and robust manner.

Example 11 Phage Display Selections Using Secondary Libraries

Liquid phase selections against human interferon gamma (hIFNγ): Aliquotsof AD1 and AE1 phage libraries (10¹¹-10¹² Pfu) were blocked with PBScontaining 3% (w/v) skimmed milk for one hour at room temperature on arotary mixer. Blocked phage was then deselected on streptavidin magneticbeads (Dynal M-280) for one hour at room temperature on a rotary mixer.Deselected phage was then incubated with in vivo biotinylated hIFNγ (100nM) for two hours at room temperature on a rotary mixer. Beads werecaptured using a magnetic stand followed by four washes with PBS/0.1%Tween 20 and 3 washes with PBS. Beads were then directly added to 10 mlof exponentially growing TG1 cells and incubated for one hour at 37° C.with slow shaking (100 rpm). An aliquot of the infected TG1 was serialdiluted to titer the selection output. The remaining infected TG1 werespun at 3000 rpm for 15 minutes and re-suspended in 0.5 ml 2×TYAG (2×TYmedia containing 100 μg/ml ampicillin and 2% glucose) and spread on2×TYAG agar Bioassay plates. After overnight incubation at 30° C., 10 mlof 2×TYAG was added to the plates and the cells were scraped from thesurface and transferred to a 50 ml polypropylene tube. 2×TYAG containing50% glycerol was added to the cell suspension to obtain a finalconcentration of 17% glycerol. Aliquots of the selection round were keptat −80° C. Phage outputs were titrated after each round and theprogressive increase in outputs indicated that the enrichment of clonesspecific for the target was occurring (FIG. 16).

Selections by panning against the rat monoclonal antibody 5E3:Immunotubes were coated with 5E3 at 10 μg/ml in PBS over night at 4° C.and immunotubes for phage deselection were coated with an irrelevant ratantibody under the same conditions. After washing immunotubes wereblocked with PBS containing 3% (w/v) skimmed milk for one hour at roomtemperature. Aliquots of AD1 and AE1 phage libraries (10¹¹-10¹² Pfu)were blocked with PBS containing 3% (w/v) skimmed milk for one hour atroom temperature on a rotary mixer. Blocked phage was then deselected inthe immunotubes coated with an irrelevant rat antibody for one hour atroom temperature on a rotary mixer. Deselected phage was thentransferred to the immunotubes coated with 5E3 and incubated for twohours at room temperature on a rotary mixer. Tubes were washed fivetimes with PBS/0.1% Tween 20 and 3 times with PBS. Phage was eluted withTEA 100 mM for 10 minutes and neutralized with 1M Tris HCl pH 7.5. Phagewas added to 10 ml of exponentially growing TG1 cells and incubated forone hour at 37° C. with slow shaking (100 rpm). An aliquot of theinfected TG1 was serial diluted to titer the selection output. Theremaining infected TG1 were spun at 3000 rpm for 15 minutes andre-suspended in 0.5 ml 2×TYAG (2×TY media containing 100 μg/mlampicillin and 2% glucose) and spread on 2×TYAG agar Bioassay plates.After overnight incubation at 30° C., 10 ml of 2×TYAG was added to theplates and the cells were scraped from the surface and transferred to a50 ml polypropylene tube. 2×TYAG containing 50% glycerol was added tothe cell suspension to obtain a final concentration of 17% glycerol.Aliquots of the selection round were kept at −80° C. Rounds of selectionwere performed by alternating between rat 5E3 and a chimeric version of5E3 in which the variable region were fused to mouse constant domains.These alternating rounds were performed in order to enrich for clonesspecific for the variable region of 5E3 and generate anti-idiotypicantibodies. Phage outputs were titrated after each round and theprogressive increase in outputs indicated that the enrichment of clonesspecific for the target was occurring (FIG. 17).

Phage rescue: 100 μA of cell suspension obtained from previous selectionrounds were added to 20 ml of 2×TYAG and grown at 37° C. with agitation(240 rpm) until an OD600 of 0.3 to 0.5 was reached. The culture was thensuper-infected with 3.3×10¹⁰ MK13K07 helper phage and incubated for onehour at 37° C. (150 rpm). The medium was then changed by centrifugingthe cells at 2000 rpm for 10 minutes, removing the medium andresuspending the pellet in 20 ml of 2×TY-AK (100 μg/ml ampicillin; 50μg/ml kanamycin). The culture was then grown overnight at 30° C. (240rpm).

Monoclonal phage rescue for ELISA: Single clones were picked into amicrotiter plate containing 150 μl of 2×TYAG media (2% glucose) per welland grown at 37° C. (100-120 rpm) for 5-6 h. M13KO7 helper phage wasadded to each well to obtain a multiplicity of infection (MOI) of 10(i.e., 10 phage for each cell in the culture) and incubated at 37° C.(100 rpm) for 1 h. Following growth, plates were centrifuged at 3,200rpm for 10 min. Supernatant was carefully removed, cells resuspended in150 μl 2×TYAK medium and grown overnight at 30° C. (120 rpm). For theELISA, the phage are blocked by adding 150 μl of 2× concentration PBScontaining 5% skimmed milk powder followed by one hour incubation atroom temperature. The plates were then centrifuged 10 minutes at 3000rpm and the phage containing supernatant used for the ELISA.

Phage ELISA: ELISA plates (Maxisorb, NUNC) were coated overnight with 2μg/ml hIFNγ in PBS or 2 μg/ml rat 5E3 in PBs. Control plates were coatedwith 2 μg/ml BSA or an irrelevant rat monoclonal antibody. Plates werethen blocked with 3% skimmed milk/PBS at room temperature for 1 h.Plates were washed 3 times with PBS 0.05% Tween 20 before transferringthe pre-blocked phage supernatants and incubation for one hour at roomtemperature. Plates were then washed 3 times with PBS 0.05% Tween 20. 50μl of 3% skimmed milk/PBS containing (HRP)-conjugated anti-M13 antibody(Amersham, diluted 1:10,000) to each well. Following incubation at roomtemperature for 1 hr, the plates were washed 5 times with PBS 0.05%Tween 20. The ELISA was then revealed by adding 50 μl of TMB (Sigma) and50 μl of 2N H₂SO₄ to stop the reaction. Absorption intensity was read at450 nm. Clones specific for hIFNγ could be identified and the hit ratesranged between 10% and 30% after the third round of selection. Clonesspecific for the variable region of 5E3 could also be identified and thehit rates ranged between 7 and 48% after the third round of selection.

Phage clone sequencing: Single clones were grown in 5 ml of 2×TYAG media(2% glucose) per well and grown at 37° C. (120 rpm) overnight. The nextday phagemid DNA was purified and used for DNA sequencing using a primerspecific for pNDS1: mycseq, 5′-CTCTTCTGAGATGAGTTTTTG. (SEQ ID NO: 255).

Large scale scFv purification: A starter culture of 1 ml of 2×TYAG wasinoculated with a single colony from a freshly streaked 2×TYAG agarplate and incubated with shaking (240 rpm) at 37° C. for 5 hours. 0.9 mlof this culture was used to inoculate a 400 ml culture of the same mediaand was grown overnight at 30° C. with vigorous shaking (300 rpm).

The next day the culture was induced by adding 400 μl of 1M IPTG andincubation was continued for an additional 3 hours. The cells werecollected by centrifugation at 5,000 rpm for 10 minutes at 4° C.Pelleted cells were resuspended in 10 ml of ice-cold TES buffercomplemented with protease inhibitors as described above. Osmotic shockwas achieved by adding 15 ml of 1:5 diluted TES buffer and incubationfor 1 hour on ice. Cells were centrifuged at 10,000 rpm for 20 minutesat 4° C. to pellet cell debris. The supernatant was carefullytransferred to a fresh tube. Imidazole was added to the supernatant to afinal concentration of 10 mM. 1 ml of Ni-NTA resin (Qiagen),equilibrated in PBS was added to each tube and incubated on a rotarymixer at 4° C. (20 rpm) for 1 hour. The tubes were centrifuged at 2,000rpm for 5 minutes and the supernatant carefully removed. The pelletedresin was resuspended in 10 ml of cold (4° C.) Wash buffer 1 (50 mMNaH₂PO₄, 300 mM NaCl, 10 mM imidazole, pH to 8.0). The suspension wasadded to a polyprep column (Biorad). 8 ml of cold Wash Buffer 2 (50 mMNaH₂PO₄, 300 mM NaCl, 20 mM imidazole, pH to 8.0) were used to wash thecolumn by gravity flow. The scFv were eluted from the column with 2 mlof Elution buffer (50 mM NaH₂PO₄, 300 mM NaCl, 250 mM imidazole, pH to8.0). Fractions were analyzed by absorption at 280 nm and proteincontaining fractions were pooled before buffer exchange on a PD10desalting column (Amersham) equilibrated with PBS. The scFv in PBS wereanalyzed by SDS-PAGE and quantified by absorption at 280 nm. Thepurified scFv were aliquoted and stored at −20° C. and at 4° C.

Example 12 Analysis of CDR3 Profiles Obtained after Selection Using HighThroughput Sequencing

Using next generation sequencing technology as described in Example 10,the distribution of CDR H3 lengths within each VH family in the AE1 andAD1 libraries as well as in the output obtained after the third round ofselection was analyzed. The profiles of the AE1 and AD1 libraries areclearly different (FIG. 18). The CDR H3 length distribution in the AE1library corresponds to the intended library design, with lengths rangingbetween 9-15 amino acids. In contrast, much longer CDR H3 of up to 22amino acids are found in the AD1 library, and the profile corresponds tothe length distribution observed in human natural repertoires. Theseresults confirm that a human natural CDR H3 repertoire has been capturedduring the construction of the AD1 library. A similar analysis performedafter three rounds of selection against 5E3 revealed that completelydifferent CDR H3 length profiles were selected. In particular, adramatic enrichment of CDR H3 of 8 and 21 amino acids in length could beobserved in the selection performed with the AD1 library. This set ofdata demonstrated that different CDR H3 profiles were enriched from thetwo libraries after selection against the same target. Furthermore, thisanalysis demonstrates that, using the present invention, long CDR H3that are very difficult to cover using synthetic diversity could becaptured into selected human frameworks and selected.

Example 13 Evaluating Identified scFvs in Binding Assays

Purified scFvs preparations of clones having different sequences andthat were identified positive against the variable region of 5E3 weretested for binding against chimeric 5E3 in a dose response ELISA. Thesepreparations were also tested against an irrelevant mouse antibody(1A6). ELISA plates (Maxisorb, NUNC) were coated overnight with 2 μg/mlmouse 5E3 in PBS. Control plates were coated with 2 μg/ml 1A6 monoclonalantibody. Plates were then blocked with 3% skimmed milk/PBS at roomtemperature for 1 h. Plates were washed 3 times with PBS 0.05% Tween 20before adding different concentrations of purified scFv and incubationfor one hour at room temperature. Plates were then washed 3 times withPBS 0.05% Tween 20. 50 μl of 3% skimmed milk/PBS containing(HRP)-conjugated anti-myc antibody to each well. Following incubation atroom temperature for 1 hr, the plates were washed 5 times with PBS 0.05%Tween 20. The ELISA was then revealed by adding 50 μl of Amplex Redfluorescent substrate and the signal was read on fluorescencespectrophotometer. The data shows that most of the clones are highlyspecific for 5E3 as they do not recognize 1A6 and that they are directedagainst the variable regions of 5E3 (FIG. 19).

Similarly, purified scFvs preparations of clones having differentsequences and that were identified in phage ELISA as binders againsthIFNγ were tested for binding against hIFNγ in a dose responseexperiment. ELISA plates (Maxisorb, NUNC) were coated overnight with 2μg/ml hIFNγ in PBS and control plates were coated with 2 μg/ml BSA inPBS. Plates were then blocked with 3% skimmed milk/PBS at roomtemperature for 1 h. Plates were washed 3 times with PBS 0.05% Tween 20before adding different concentration of purified scFv and incubationfor one hour at room temperature. Plates were then washed 3 times withPBS 0.05% Tween 20. 50 μl of 3% skimmed milk/PBS containing(HRP)-conjugated anti-myc antibody to each well. Following incubation atroom temperature for 1 hr, the plates were washed 5 times with PBS 0.05%Tween 20. The ELISA was then revealed by adding 50 μl TMB substrate and50 μl of 2N H₂SO₄ to stop the reaction. The signal was read on anabsorbance spectrophotometer at 450 nm. The data shows that the selectedclones are binding to hIFNγ in a dose dependent manner and gave a verygood signal when compared to a positive control scFv A6 that has a highaffinity for hIFNγ (FIG. 20).

Example 14 ScFv Inhibition of Interferon Gamma-Induced Reporter GeneExpression

A panel of selected scFv specific for hIFNγ was produced and purified asdescribed above and tested for the capacity to block the biologicalactivity of hIFNγ. A reporter gene (firefly luciferase), driven by theIFNγ-inducible GBP1 promoter, was transfected into the human melanomacell line, Me67.8. Various concentrations of scFv were incubated with 2ng/ml of hIFNγ and then added to the cell culture. Following a 6 hourincubation time, the luciferase reporter assay was performed and theintensity of the luminescence measured. The activity was compared to ascFv isolated from another human scFv antibody library constructed bytraditional capturing of the VH/VL repertoires form human donors (cloneG9). The data shows that scFv isolated either from synthetic or naturalhuman diversity libraries (AE1 and AD1) were capable of neutralizing thebiological activity of hIFNγ in a dose dependent manner (FIG. 21). Theneutralization potential of these scFv was superior to the benchmarkscFv clone G9.

Example 15 scFv Inhibition of Interferon Gamma-Induced MHC Class IIExpression

A flow cytometric assay was implemented to identify fully human IgGantibodies, or fragments thereof, capable of blocking the expression ofIFNγ-induced MHC class II molecules. Following the plating of Me67.8cells, 5 ng/ml recombinant human IFNγ was added to cultures in thepresence of various concentrations of candidate fully human anti-IFNγmonoclonal antibodies. Following 48 h in culture, cells were stainedwith fluorescently labeled anti-human MHC class II antibody (HLA-DR) andanalyzed using a FACSCalibur®. Thus, the IC₅₀ (where 50% of theIFNγ-induced MHC class II expression is inhibited, i.e., 50% inhibitoryconcentration), for each candidate antibody is measured.

Purified fully human scFv were produced as described above. The effectof selected scFv on IFNγ-induced MHC class II expression on melanomacells was evaluated using the flow cytometric cell-based assay describedabove. These scFv inhibited IFNγ-induced MHC II expression on melanomacells (FIG. 22).

Example 16 Reformatting scFv into IgG Format

The V_(H) and V_(L) sequence of selected scFv were amplified withspecific oligonucleotides introducing a leader sequence and a HindIIIrestriction site at the 5′ end. An ApaI site was introduced at the 3′end of the heavy whereas an AvrII and a BsiWI site were introduced atthe 3′ end of the lambda or kappa light chain sequences, respectively.The amplified V_(H) sequences were digested HindIII/ApaI and cloned intothe pCon_gamma1 expression vector (LONZA, Basel, Switzerland). Theamplified V_(L) lambda sequences were digested HindIII/AvrII and clonedinto the pCon_lambda2 expression vector and the amplified V_(L) kappasequences were digested HindIII/BsiWI and cloned into the pCon_kappaexpression vector (LONZA, Basel, Switzerland). The constructions wereverified by sequencing before transfection into mammalian cells.

The V_(H) and V_(L) cDNA sequences in their appropriate expressionvectors were transfected into mammalian cells using the Fugene 6Transfection Reagent (Roche, Basel, Switzerland). Briefly, Peak cellswere cultured in 6-well plates at a concentration of 6×10⁵ cells perwell in 2 ml culture media containing fetal bovine serum. The expressionvectors, encoding the candidate V_(H) and V_(L) sequences, wereco-transfected into the cells using the Fugene 6 Transfection Reagentaccording to manufacturer's instructions. One day followingtransfection, the culture media was aspirated, and 3 ml of freshserum-free media was added to cells and cultured for three days at 37°C. Following three days culture period, the supernatant was harvestedfor IgG purified on protein G-Sepharose 4B fast flow columns (Sigma, St.Louis, Mo.) according to manufacturer's instructions. Briefly,supernatants from transfected cells were incubated overnight at 4° C.with ImmunoPure (G) IgG binding buffer (Pierce, Rockford Ill.). Sampleswere then passed over Protein G-Sepharose 4B fast flow columns and theIgG consequently purified using elution buffer. The eluted IgG fractionwas then dialyzed against PBS and the IgG content quantified byabsorption at 280 nm. Purity and IgG integrity were verified bySDS-PAGE.

Example 17 IgG Inhibition of Interferon Gamma Biological Activity

Two scFv, AE1-4-R3-P2E4 (2E4) and A2-AD1-R4P1A9 (1A9), that hadconfirmed inhibitory activity against hIFNγ in functional assays werereformatted into IgG as described in Example 16 and tested in theinterferon gamma-induced reporter gene assay described in Example 14.The results shown in FIG. 23 indicate that in a IgG format both 1A9 and2E4 could neutralize the activity of hIFNγ with IC₅₀ of 42 nM and 10 nM,respectively whereas a negative control IgG (NI-0701) had no effect inthis assay. Thus these two candidates isolated from both synthetic andnatural diversity libraries could be reformatted into full IgG andfeature neutralizing activity against the selected target.

Example 18 Development of a Pharmacokinetic Assay for the Detection of5E3 in Mouse Serum

Two scFv candidates AD15E3R3P1_A4 and AD25E3R3P1_G11 that bindspecifically to mouse monoclonal antibody 5E3 (FIG. 19) were reformattedinto full human IgG as described in Example 16. The specificity of thecorresponding IgGs DA4 and G11 was confirmed in ELISA against mouse 5E3and a chimeric version of this monoclonal antibody in which the mousevariable regions have been fused to rat constant IgG regions. Theresults shown in FIG. 24 demonstrate that the IgG DA4 and G11 arespecific for the variable region of 5E3 as they bind to both mouse andchimeric rat 5E3 and not to mouse and rat isotype controls. These twomonoclonals antibodies were used to develop an assay for thequantification of 5E3 in mouse serum for pharmacokinetic studies.Several dilutions of mouse serum were spiked with 5 μg/ml of mouse 5E3antibody and serially diluted in such a way that serum concentration wasmaintained constant throughout the dilution series. Maxisorb plates(Nunc, Denmark) were coated overnight with 1 μg/ml of IgG DA4 or IgGG11. After blocking with PBS; 1% BSA dilution series of the spiked serumpreparations were added to the wells. After incubation and washing, thesignal was revealed using an anti-mouse Kappa light chain monoclonalantibody coupled to horse radish peroxydase (HRP) and a fluorescentsubstrate (Amplex red; Invitrogen). The results show that bothantibodies can be used to specifically detect the mouse monoclonal 5E3antibody in mouse serum (FIG. 25). The detection limit of mouse 5E3 inserum was about 200 ng/ml and the assay was not significantly affectedby the serum concentration indicating that IgG DA4 and IgG G11 arehighly specific for mouse 5E3 and do not bind to other mouseimmunoglobulin. These experiments demonstrate that highly specificanti-idiotypic antibodies could be isolated from the natural orsynthetic libraries AE1 and AD1.

Example 19 Phage Selection Using Libraries Containing CDRH3 DiversityCaptured from Naïve and Immunized Mice

The MnA, MiB and MiC libraries described in Examples 8 and 9 were usedin parallel for phage selections against hIFNγ following the proceduredescribed in Example 11. During the selection process a similarenrichment of phage was observed (FIG. 26).

scFv expression in microtiter plate format: Single clones were pickedinto a microtiter plate containing 150 μl of 2×TYAG media (2% glucose)per well and grown at 37° C. (100-120 rpm) for 5-6 h. Plates werecentrifuged at 280 rpm, the medium discarded and the cell pelletsresuspended in 100 μl of 2×TYA medium containing 1 mM IPTG. The plateswere incubated overnight at 30° C. with shaking (100 rpm). Followinggrowth, plates were centrifuged at 3,200 rpm for 10 min and thesupernatant carefully transferred to a plate containing 2× concentratedPBS containing 5% skimmed milk powder for blocking.

scFv ELISA: ELISA plates (Maxisorb, NUNC) were coated overnight with 2μg/ml hIFNγ in PBS. Control plates were coated with 2 μg/ml recombinantBSA (Sigma). Plates were then blocked with 3% skimmed milk/PBS at roomtemperature for 1 h. Plates were washed 3 times with PBS 0.05% Tween 20before transferring the pre-blocked scFv supernatants and incubation forone hour at room temperature. Plates were then washed 3 times with PBS0.05% Tween 20. 50 μl of 3% skimmed milk/PBS containing (HRP)-conjugatedanti-cMyc antibody (diluted 1:5,000) to each well. Following incubationat room temperature for 1 hr, the plates were washed 5 times with PBS0.05% Tween 20. The ELISA was then revealed by adding 50 μl of AmplexRed (Invitrogen). Fluorescence intensity was measured at 590 nm uponexcitation at 530 nm. The frequency of hits giving a signal of half theintensity of the control A6 clone was evaluated after each round ofselection for the three libraries (FIG. 27). The hit rate obtained withthe MiB library was dramatically higher compared to the two otherlibraries and the average level of signal was superior for the clonesderived from the MiB library, indicating that higher affinity scFv wereenriched (FIG. 28). In order to confirm this observation, positiveclones were sequenced, expressed in larger scale and purified to betested in dose response binding experiments according to Example 13. ThescFv derived from the MiB library all had a higher apparent affinity forhIFNγ than those isolated from the naïve MnA library (FIG. 29). Theresults indicate that the CDRH3 repertoire from mice immunized with aprotein could be captured into a human antibody framework context in aproductive way to generate at higher frequency high affinity humanantibody fragments. Libraries generated using the present invention thusrepresent a powerful mean of generating antibodies with therapeuticpotential.

Other Embodiments

While the invention has been described in conjunction with the detaileddescription thereof, the foregoing description is intended to illustrateand not limit the scope of the invention, which is defined by the scopeof the appended claims. Other aspects, advantages, and modifications arewithin the scope of the following claims.

1. A method for producing a collection of nucleic acids, wherein eachnucleic acid encodes a human immunoglobulin variable domain comprising aplurality of complementarity determining region 3 (CDR3) sequencesisolated separately from the immunoglobulin variable domain repertoirefrom a mammalian species.
 2. A method for producing a collection ofnucleic acids, wherein each nucleic acid encodes a human immunoglobulinvariable domain comprising a plurality of complementarity determiningregion 3 (CDR3) sequences isolated separately from the immunoglobulinvariable domain repertoire from a non-human mammalian species.
 3. Amethod for producing a collection of nucleic acids, wherein each nucleicacid encodes a human immunoglobulin variable domain comprising aplurality of complementarity determining region 3 (CDR3) sequencesisolated separately from the immunoglobulin variable domain repertoirefrom a human.
 4. The method of claim 1, the method comprising: (a)providing a plurality of Acceptor Framework nucleic acid sequencesencoding distinct human immunoglobulin variable domains, each AcceptorFramework nucleic acid sequence comprising a first framework region(FR1), a second framework region (FR2), a third framework region (FR3),and a fourth framework region (FR4), wherein the FR1 and FR2 regions areinterspaced by a complementarity determining region 1 (CDR1), the FR2and FR3 regions are interspaced by a complementarity determining region2 (CDR2), and the FR3 and FR4 regions are interspaced by a stuffernucleic acid sequence comprising at least two Type IIs restrictionenzyme recognition sites interspaced by a random nucleic acid sequence;(b) providing a plurality of diversified nucleic acid sequences encodingcomplementarity determining region 3 (CDR3) sequences isolated from themammalian species immunoglobulin repertoire wherein each of theplurality of diversified nucleic acid sequences comprises a Type IIsrestriction enzyme recognition site at each extremity; (c) digestingeach of the plurality of nucleic acid sequences encoding the CDR3regions using a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (b) and digesting thestuffer nucleic acid sequence of step (a) from the Acceptor Frameworkusing a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (a); and (d) ligating thedigested nucleic acid sequences encoding the CDR3 regions or the aminoacid sequences of step (c) into the digested Acceptor Framework of step(c) such that the FR3 and FR4 regions are interspaced by the nucleicacid sequences encoding the CDR3 region or the amino acid sequence thatcan fulfill the role of a CDR3 region and a complete immunoglobulinvariable domain encoding sequences that do not contain the Type IIsrestriction enzyme recognition sites of steps (a) and (b) are restored.5. The method of claim 4, wherein step (b) is performed by amplifyingthe CDR3 sequence from a mammalian species using oligonucleotide primerscontaining a Type IIs restriction site.
 6. The method of claim 5,wherein the oligonucleotide primer is designed to enhance compatibilitybetween the mammalian CDR3 sequence and the Acceptor Framework encodinga human immunoglobulin variable domain.
 7. The method of claim 6,wherein the oligonucleotide primer is designed to modify a nucleic acidsequence at a boundary of the mammalian CDR3 sequence to produce acompatible cohesive nucleotide sequence in the Acceptor Frameworkencoding a human immunoglobulin variable domain.
 8. The method of claim5, wherein step (b) is performed by amplifying the CDR3 sequence from anon human species using oligonucleotide primers containing a FokI IIsrestriction site.
 9. The method of claim 2, wherein the non-humanspecies is non-human primate, rodent, canine, feline, sheep, goat,cattle, horse, a member of the Camelidae family, llama, camel,dromedary, or pig.
 10. The method of claim 4, wherein the Type IIsrestriction enzyme recognition sites of step (a) and step (b) arerecognized by a different Type IIs restriction enzyme.
 11. The method ofclaim 10, wherein the Type IIs restriction enzyme recognition sites areBsmBI recognition sites, BsaI recognition sites, FokI recognition sitesor a combination thereof.
 12. The method of claim 4, wherein thediversified nucleic acid sequences encoding CDR3 sequences encode heavychain CDR3 (CDR H3) sequences.
 13. The method of claim 4, wherein thediversified nucleic acid sequences encoding CDR3 sequences encode lightchain CDR3 (CDR L3) sequences.
 14. The method of claim 4, wherein theAcceptor Framework nucleic acid sequence comprises a human heavy chainvariable gene sequence selected from VH1-2, VH1-69, VH1-18, VH3-30,VH3-48, VH3-23, and VH5-51.
 15. The method of claim 4, wherein theAcceptor Framework nucleic acid sequence comprises a human kappa lightchain variable gene sequence.
 16. The method of claim 15, wherein thehuman kappa light chain variable gene sequence is selected from VK1-33,VK1-39, VK3-11, VK3-15, and VK3-20.
 17. The method of claim 4, whereinthe Acceptor Framework nucleic acid sequence comprises a human lambdalight chain variable gene sequence.
 18. The method of claim 17, whereinthe human lambda light chain variable gene sequence is selected fromVL1-44 and VL1-51.
 19. The method of claim 4, wherein the plurality ofAcceptor Framework nucleic acid sequences comprises a mixture of atleast one variable heavy chain (VH) Acceptor Framework nucleic acidsequence and at least one variable light chain Acceptor Frameworknucleic acid sequence.
 20. The method of claim 4, further comprising thesteps of (e) cloning the library of nucleic acids encodingimmunoglobulin variable domains of step (d) into an expression vectorand (f) transforming the expression vector of step (e) into a host celland culturing the host cell under conditions sufficient to express aplurality of immunoglobulin variable domain encoded by the library. 21.The method of claim 20, wherein the host cell is E. coli.
 22. The methodaccording to claim 20, wherein the expression vector is a phagemid or aphage vector.
 23. A method for producing a collection of nucleic acids,wherein each nucleic acid encodes a human immunoglobulin variable domaincomprising a plurality of complementarity determining region 3 (CDR3)sequences isolated separately from immunoglobulin variable domains froman immunized non-human mammal.
 24. The method of claim 23, the methodcomprising: (a) providing a plurality of Acceptor Framework nucleic acidsequences encoding distinct human immunoglobulin variable domains, eachAcceptor Framework nucleic acid sequence comprising a first frameworkregion (FR1), a second framework region (FR2), a third framework region(FR3), and a fourth framework region (FR4), wherein the FR1 and FR2regions are interspaced by a complementarity determining region 1(CDR1), the FR2 and FR3 regions are interspaced by a complementaritydetermining region 2 (CDR2), and the FR3 and FR4 regions are interspacedby a stuffer nucleic acid sequence comprising at least two Type IIsrestriction enzyme recognition sites interspaced by a random nucleicacid sequence; (b) providing a plurality of diversified nucleic acidsequences encoding complementarity determining region 3 (CDR3) sequencesisolated from the immunized non-human mammal wherein each of theplurality of diversified nucleic acid sequences comprises a Type IIsrestriction enzyme recognition site at each extremity; (c) digestingeach of the plurality of nucleic acid sequences encoding the CDR3regions using a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (b) and digesting thestuffer nucleic acid sequence of step (a) from the Acceptor Frameworkusing a Type IIs restriction enzyme that binds to the Type IIsrestriction enzyme recognition site of step (a); and (d) ligating thedigested nucleic acid sequences encoding the CDR3 regions or the aminoacid sequences of step (c) into the digested Acceptor Framework of step(c) such that the FR3 and FR4 regions are interspaced by the nucleicacid sequences encoding the CDR3 region or the amino acid sequence thatcan fulfill the role of a CDR3 region and a complete immunoglobulinvariable domain encoding sequences that do not contain the Type IIsrestriction enzyme recognition sites of steps (a) and (b) are restored.25. The method of claim 24, wherein step (b) is performed by amplifyingthe CDR3 sequence from the immunized non-human mammal usingoligonucleotide primers containing a Type IIs restriction site.
 26. Themethod of claim 25, wherein the oligonucleotide primer is designed toenhance compatibility between the mammalian CDR3 sequence and theAcceptor Framework encoding a human immunoglobulin variable domain. 27.The method of claim 26, wherein the oligonucleotide primer is designedto modify a nucleic acid sequence at a boundary of the mammalian CDR3sequence to produce a compatible cohesive nucleotide sequence in theAcceptor Framework encoding a human immunoglobulin variable domain. 28.The method of claim 25, wherein step (b) is performed by amplifying theCDR H3 sequence from the non-human mammal using oligonucleotide primerscontaining a FokI IIs restriction site.
 29. The method of claim 24,wherein the non-human mammal is non-human primate, rodent, canine,feline, sheep, goat, cattle, horse, llama, camel, dromedary, or pig. 30.The method of claim 24, wherein the Type IIs restriction enzymerecognition sites of step (a) and step (b) are recognized by a differentType IIs restriction enzyme.
 31. The method of claim 30, wherein theType IIs restriction enzyme recognition sites are BsmBI recognitionsites, BsaI recognition sites, FokI recognition sites or a combinationthereof.
 32. The method of claim 24, wherein the diversified nucleicacid sequences encoding CDR3 sequences encode heavy chain CDR3 (CDR H3)sequences.
 33. The method of claim 24, wherein the diversified nucleicacid sequences encoding CDR3 sequences encode light chain CDR3 (CDR L3)sequences.
 34. The method of claim 24, wherein the Acceptor Frameworknucleic acid sequence comprises a human heavy chain variable genesequence selected from VH1-2, VH1-69, VH1-18, VH3-30, VH3-48, VH3-23,and VH5-51.
 35. The method of claim 24, wherein the Acceptor Frameworknucleic acid sequence comprises a human kappa light chain variable genesequence.
 36. The method of claim 35, wherein the human kappa lightchain variable gene sequence is selected from VK1-33, VK1-39, VK3-11,VK3-15, and VK3-20.
 37. The method of claim 24, wherein the AcceptorFramework nucleic acid sequence comprises a human lambda light chainvariable gene sequence.
 38. The method of claim 37, wherein the humanlambda light chain variable gene sequence is selected from VL1-44 andVL1-51.
 39. The method of claim 24, wherein the plurality of AcceptorFramework nucleic acid sequences comprises a mixture of at least onevariable heavy chain (VH) Acceptor Framework nucleic acid sequence andat least one variable light chain Acceptor Framework nucleic acidsequence.
 40. The method of claim 24, further comprising the steps of(e) cloning the library of nucleic acids encoding immunoglobulinvariable domains of step (d) into an expression vector and (f)transforming the expression vector of step (e) into a host cell andculturing the host cell under conditions sufficient to express aplurality of immunoglobulin variable domain encoded by the library. 41.The method of claim 40, wherein the host cell is E. coli.
 42. The methodaccording to claim 40, wherein the expression vector is a phagemid or aphage vector.